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CHAPTER 1 
INTRODUCTION 
Technetium-99m labeled diphosphonates are radiopharmaceuticals, used 
for imaging of skeletal disorders. The development and clinical application 
of these substances, was a major step forward in nuclear medicine during the 
1970's. 
1.1. HISTORY OF NUCLEAR MEDICINE [1]. 
Nuclear medicine, defined as the application of radioactive tracers to 
medical diagnosis and treatment, started in 1923 with Hevesy, who was the 
first to conceive of using radioisotopes as physiologic tracers. In that time, 
only naturally occurring radioisotopes were available, but these were not of 
great biological importance. The invention of the cyclotron by Lawrence in 
1931 delivered a device for the production of artificial radioisotopes. In 
1935 radiophosphorus was the first artificial radioisotope, used for the 
study of a specific physiological element in an animal system Hevesy 
studied the tissue distribution of P-32 in rats and found strong support for 
the view, that the formation of bone is a dynamic process: bone being 
continuously renewed. 
After 1942 the nuclear reactor could also be used for the production of 
radioisotopes. It took until 1946 before radioactive isotopes became 
available for public distributioa 
For radiation measurements Geiger counters were used, but these have a 
low sensitivity to gamma radiation. In 1947 a scintillation detector was 
introduced by Kallmann. This consisted of a naphthalene crystal attached 
to the face of a photo multiplier tube. The crystal had the ability to absorb 
gamma radiation with relatively high efficiency and to produce a flash of 
fluorescence light, called a scintillation. The photo multiplier tube trans-
duced the scintillations into amplified electrical pulses. With these detec-
tors and the vast list of available radioisotopes it became possible to 
measure noninvasively the regional function in practically every organ. 
Imaging however was not yet possible 
The rectilinear scanner, introduced by Cassen in 1951 was another step 
forward. Cassen used a motorized detector moving in a raster fashion over 
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the area to be imaged. The detector activated a moving pen, which depicted 
with ink dots the relative number of counts emanating from the scanned 
region. 
In 1958 the introduction by Anger of the first scintillation camera meant a 
revolution to the practice of clinical nuclear medicine. A scintillation or 
gamma camera creates an integrated image camera-wise, in contrast to a 
rectilinear scanner, which builds up an image point by point by moving over 
the subject 
A gamma camera consists of a large thallium activated sodium iodide 
scintillation crystal with a set of photo multiplier tubes behind it The output 
of the tubes is electronically interpreted in such a way that a scintillation in 
the crystal causes a flash on a cathode ray tube with the same relative 
position as the original scintillatioa Thus, the image can be displayed or 
photographed. The field of view of the camera is determined by the diameter 
of the sodium iodide crystal. The camera provides a continuous registration 
of the regional time course of a radioactive tracer, during long or short 
periods of time. Noninvasive measurements of regional function combined 
with imaging became possible with one instrument 
The physical characteristics of the gamma camera and the need for 
limitation of the radiation burden to patients favoured the use of pure 
gamma emitting radioisotopes with a gamma energy between 100 and 200 
keV and a short half-life. 
Tc-99m was the best radionuclide to fulfill these requirements. It has a 
single gamma ray emission with an energy of 140 keV and its half-life time 
is 6 hours. 
Technetium-99m is an artificial radioisotope of an element which has no 
stable isotopes. Technetium did not appear on the periodic table until Segré 
produced it in a cyclotron in 1937. Technetium could not, therefore, have 
any application as a natural component of any biological system, but its 
physical properties make this element a first class label. Technetium is 
recovered from waste fission product solutions after removal of uranium 
and plutonium. 
To day compact cyclotrons are commercially available for isotope produc-
tion, but the huge investments needed for hardware, building, trained 
personnel and radiochemical facilities make it hardly feasible or desirable 
for every hospital to have a cyclotron for the production of short living 
radioisotopes. 
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A partial alternative to complete radioisotope production facilities is the 
radioisotope generator also called the nuclear cow. This involves the 
uncomplicated storage of a relatively long living radioisotope that decays 
into a short living radioisotope of an other element When needed, the 
daughter material is separated by a simple procedure, commonly involving 
nothing more than eluting with saline solution. 
To dispose permanently of the short living Tc-99m, a molybde-
num-99/technetium-99m generator was developed. Molybdenum-99 (T
 w 
= 67 h) as molybdate is adsorbed to alumina. Technetium-99m-pertechne-
tate can be milked almost quantitatively from the cow by elution with saline 
solution, without leakage of molybdate. This yields solutions of 10 
-10"8 M/l pertechnetate with an activity of 100-1000 mCi. 
Pertechnetate as collected from the generator, behaves in vivo similar to 
iodide, bromide or Perchlorate. The resemblance to iodide makes it suitable 
for thyroid imaging. Besides, pertechnetate, normally not accumulating in 
brain tissue, can be used to show defects in the blood-brain barrier. 
Pertechnetate on its own has only limited applicability. Its desirable 
physical properties however, have encouraged radiochemists to incorporate 
technetium-99m in medically useful chemical forms. Table 1.1 gives some 
examples of technetium-99m labeled radiopharmaceuticals. 
Table 1.1. Some Tc-99m labeled radiopharmaceuticals in common use in nuclear 
medicine. 
Radiopharmaceutical Target organ/system 
Tc-99m-pertechnetate Thyroid 
Tc-99m-antimony sulphide colloid Liver/spleen 
To-99m-diphosphonate Skeleton 
Tc-99m-HIDA Hepato-biliary system 
Tc-99m-DTPA Kidneys/brain 
Tc-99m-aggregated albumin Lung perfusion 
Tc-99m-erythrocytes Blood pool 
HID A : Ы-(ЬГ-(2,6 dimethylphenyl) carbamoyl methyl iminodiacetic acid. 
DTPA : Diethylene triamine penta-acetic acid 
13 
1.2. TECHNETIUM [2,3,4,5]. 
Technetium is located in group Vllb of the periodic table of elements 
together with manganese and rhenium. From its position in the middle of the 
d-block transition metals, technetium is expected to exhibit multiple 
oxidation states and an extensive redox chemistry. Extrapolation from the 
chemistry of the neighbouring elements Mo, Ru, and Re leads to the 
expectations, that Tc complexes will often contain strongly bonded oxo 
ligands, can contain metal-metal bonds, and will exhibit variable coordina-
tion numbers. 
Technetium is a second row transition element and, as expected, it has a 
much greater similarity to the third row transition element rhenium, than to 
manganese. For manganese the most stable oxidation state is the II state; 
technetium and rhenium form few compounds in the II oxidation state, but 
have extensive chemistry in the IV, V and VII states. 
The Tc04" and Re04" ions are much less oxidizing than Mn04". 
The aqueous chemistry of technetium is dominated by the driving force for 
reduction of pertechnetate to the very stable, insoluble Tc02. In the 
presence of appropriate ligands, the lower oxidation states of technetium 
can be stabilized and Tc02 precipitation prevented. Certain of these lower 
oxidation states, in certain coordination environments, can be expected to 
be inert to ligand substitution; this is a highly desirable property since it 
allows reduced technetium complexes to retain their integrity in vivo. 
Polarographie and coulometric studies of the pertechnetate reduction in 
aqueous solutions show a number of reduction steps. Although for most of 
these steps the number of electrons involved has been determined, because 
of potential reoxidation phenomena the precise nature of the species present 
remains obscure. 
Most of the technetium-based radiopharmaceuticals contain the radio-
nuclide in a reduced form. A large number of reagents has been used for this 
purpose, but stannous salts are the particular choices in the majority of 
clinically used preparations. In recent years, a number of studies has been 
carried out to elucidate the valence state of technetium in these systems. 
From the results of titration experiments for the reaction between pertech-
netate and stannous chloride in the presence of various complexing agents 
the valence state of the resulting technetium species was calculated. It was 
assumed, that the consumption of one mol stannous tin in the titration 
corresponds to a gain of 2 electrons per mol pertechnetate. These 
experiments showed more or less equivocal results. Valence states of V and 
IV were found in the presence of citrate and IV and III in the presence of 
DTPA [6]. 
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The main impurities in technetium labeled radiopharmaceuticals are 
pertechnetate and "hydrolyzed" technetium. The latter term represents 
unbound reduced technetium. The precise nature of this species is unknown, 
but it is removable from a solution by sephadex gel filtration, probably 
through adsorption [21]. 
A question fundamental to the design and development of technetium 
radiopharmaceuticals is, whether or not tin is incorporated into the chemical 
structure of the final radiopharmaceutical [7]. Biodistribution experiments 
using double labeling and reduction of pertechnetate with non-stannous 
reducing agents do not directly answer this point Therefore chemical 
evidence must be used to answer this essentially chemical questioa With 
high performance liquid chromatography it was established that Tc-HIDA 
does not contain tin. Single crystal X-ray structural analysis of Tc-Sn-
dimethylglyoxime demonstrated that this material does contain chemically 
bound tin. 
Thus it appears, that with certain ligands, especially those that are capable 
of simultaneously binding to two metal atoms, tin can and does bind to the 
technetium complex. This is not unexpected, considering that Sn (IV) and 
Тс (Г ) centres have the same size and charge, and therefore should have an 
affinity for the same types of ligands. 
For the elucidation of many problems related to the chemistry of technetium 
labeled radiopharmaceuticals, the application of Tc-99 or another long-
lived technetium isotope is required. Much concern has been voiced about 
the applicability of the results obtained with Tc-99 to radiopharmaceutical 
problems involving Tc-99m. The chemical and biological properties of 
Tc-99 and Tc-99m have been shown to be identical [8] and no example has 
yet been presented where Tc-99 and Tc-99m systems differ significantly. 
Reactions, which are second order in technetium concentration will, of 
course, be very sensitive to the total concentration of technetium, and this 
could cause differences between "carrier" and "carrier-free" systems. 
However, Tc-99m produced from Mo-99 generators is never carrier-free, 
and in fact clinically operated generators can produce eluates that are ca. 
ΙμΜ in total technetium [9]. 
Several techniques, especially electrochemistry, are sensitive and effective 
at this concentration level and even lower. Thus the range of technetium 
concentrations encountered in radiopharmaceutical studies overlaps con­
siderably with the range of concentrations amenable to chemical investiga-
tioa This makes Tc-99 and Tc-99m studies in fact complementary, but the 
concentration difference should always be kept in mind, while interpreting 
the results of these studies. 
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In recent years the joined effort of several inorganic chemistry research 
groups and nuclear medicine practitioners has lead to the application of new 
techniques for the elucidation of the chemistry of technetium complexes, 
relevant to nuclear medicine. One of these techniques is the single crystal X-
ray structural analysis. Several technetium complexes have now been 
characterized by this technique [10]. 
The main results so far obtained can be listed as follows: 
- Reduced technetium complexes exhibit a wide range of coordination 
numbers and geometries. They are certainly not restricted to octahedral 
structures, as is often assumed. 
- Technetium (V) appears to be a prevalent oxidation state for complexes, 
prepared in water under aerobic conditions. 
- Technetium labeled radiopharmaceuticals prepared in aqueous media are 
likely to contain oxo ligands. 
- In nitrosyl technetium complexes the NO ligand stabilizes low oxidation 
states and Tc-NO centres should provide suitable templates for syntheses 
of substitution inert radiopharmaceuticals. 
- The solid state structure of [Tc(OH)MDP"] (prepared by substitution of 
MDP onto TcBr62") is polymeric with technetium centres bridged by 
MDP and OH(or H20) ligands, and MDP ligands in tum bridged by 
technetium centres. 
- X-ray analysis of technetium dimethylglyoxime crystals revealed the 
presence of the binuclear technetium-tin complex (Tc(dmg)3(SnCl,) 
(OH)3H20. 
In this material the Tc and Sn atoms are joined by three bridges: one 
bridge is comprised of a single oxygen atom, while the other two bridges 
consist of N-0 linkages from different dimethylglyoxime (dmg) ligands. 
Tin is undoubtedly present as Sn (IV) and technetium is most likely 
present as Tc (V). 
1.3. TECHNETIUM LABELED DIPHOSPHONATES. 
Diphosphonic acids used in technetium labeled radiopharmaceuticals for 
bone scintigraphy have a general formula as shown in fig 1.1. 
Technetium diphosphonates are the successors of technetium polyphos-
phates and technetium pyrophosphate. Subramanian and coworkers intro-
duced technetium tripolyphosphate in 1971 [11]. 
Labeling of diphosphonates with technetium is performed as follows: a 
stannous salt is added to a diphosphonate solution in a molar ratio of about 
1:10. The pH is brought between 5 and 8. A few minutes later Tc-99m-
pertechnetate is added. 
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но 
Fig. 1.1. General formula of diphosphonic acids. 
The specificity of the preparation is supposed to be conferred by the 
diphosphonate moiety but, to make the radionuclide selectively localize in 
bone, it must first be reduced. Reduction alone is not sufficient : when 
pertechnetate is reduced in the absence of suitable complexing agents, 
hydrolysis of the tin and the reduced technetium species will cause the 
accumulation of technetium activity in liver, spleen, and bone marrow. 
1.3.1. Mechanism of uptake in bone of technetium diphosphonates. 
The most widely accepted view of the mode of action of technetium labeled 
diphosphonates is that they react through the phosphonate groups by 
sorption on to the calcium of hydroxy apatite in bone [12]. Factors affecting 
the sorption of imaging agents on hydroxyapatite are vascularity and the 
rate of modeling and remodeling of bone. The initial phase of the uptake of 
bone seeking radiopharmaceuticals is predominantly dependent on the 
rapidly exchangeable Ca 2 + pool of the skeleton, the amorphous fraction of 
the hydroxyapatite [13] and the large surface area of bone [14]. Blood flow 
is no doubt an important factor, but the closest relationship of bone uptake of 
radiopharmaceuticals exists with the extracellular fluid content of the bone. 
All bone imaging compounds are diffusable and their concentration in the 
extracellular fluid will determine the initial exchange reactions and uptake 
in bone. 
Sites of rapid bone formation such as the epiphyseal plate region of the long 
bones, metastatic bone tumors, and other regions of high bone turnover, as 
seen in Paget's disease, are known to be associated with a large area 
OH 
,4° 
7 R. 
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available for exchange and sorption [15]. Bone areas of low reactivity with 
labeled bone seeking agents are thought to be associated with sites of bone 
resorption and low metabolic activity such as mature cortical bone. 
Deposition of all components of the labeled diphosphonate in bone appears 
to be in the same proportion as in the original mix. This would seem to 
indicate that technetium diphosphonate travels to the bone as a single entity 
[16]. It has not been determined, whether or not this complex stays intact 
after reaching the bone surface. Possibly, after the complex has diffused to 
the bone site, the small quantity of diphosphonate used in scanning agents 
adsorbs at kink and dislocation sites on the surface of the apatite [17], 
releasing both the tin and the technetium. These would then hydrolyze and 
deposit separately or together as hydrated tin oxide and technetium dioxide 
particles. 
1.4. PURPOSE AND SETUP OF THIS STUDY. 
This study has concentrated on the process of binding of technetium and 
diphosphonate onto bone tissue. More in detail: the focal point of this study 
has been the elucidation of the influence of the diphosphonate complex 
stability on the uptake of technetium in bone tissue. 
For this reason adsorption experiments were carried out to simulate the 
binding process in vivo. The results of these experiments are described in 
chapter 3. Further, the stability constants of calcium and tin complexes of a 
series of six diphosphonates were determined. These results are described 
in chapter 5. The determination of a stability constant of a To-diphospho-
nate complex is described in chapter 6. 
The stannous tin complex chemistry was studied partly because of the 
similarity in the adsorption behaviour between reduced technetium and 
stannous tin and because stannous diphosphonate is the main component of 
the bone seeking radiopharmaceutical. We were able to show beyond doubt, 
that the diphosphonate complex stability has a pronounced effect on the 
uptake of technetium by hydroxyapatite. 
As a model for the binding phase of technetium diphosphonate in bone, 
synthetic hydroxyapatite was chosen. 
We believe, that the amorphous fraction of the hydroxyapatite in bone is the 
phase, which binds technetium labeled bone seekers. Although this vision is 
shared by most authors to day [18], some alternatives have been described 
in literature. These will be discussed together with the hydroxyapatite 
model in chapter two. In this chapter also an introduction is given to 
structure and physiology of bone tissue and a review is presented of the 
interactions between diphosphonates and bone. 
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One of the most important steps in the preparation of the technetium labeled 
radiopharmaceutical is the reduction of pertechnetate. Because stannous tin 
is the most commonly used reducing agent, we studied the oxidation 
behaviour of stannous tin in diphosphonate containing media in relation to 
the reduction of pertechnetate. The reduction of pertechnetate and the 
oxidation of stannous tin were studied separately by voltametric techniques 
in order to detect specific influences of the diphosphonate present The 
reaction of pertechnetate with stannous tin was studied in titrations with 
amperometric endpoint detection. The results are presented in chapter 6. 
The results of blood disappearance and tissue distribution experiments in 
rabbits are described in chapter 4 for 27 Tc-99m-(di)phosphonates. These 
data were used to compare with results of adsorption and stability 
measurements. 
To obtain standard values for comparison with the results of chemical 
determinations and in order to get more information on the structure activity 
relationship, the tissue distribution behaviour of 27 technetium labeled 
(di)phosphonates was determined. The results are described in chapter 4. 
1.5. SUMMARY OF THE MAIN RESULTS. 
Because this study deals with such a wide field of experimental investiga-
tions, it is tempting to illustrate the main results by describing the fate of the 
components of the technetium labeled diphosphonate from the moment of 
preparation until the settlement in bony tissue. 
1.5.1. The preparation of the radiopharmaceutical. 
It is known from common practice, that pertechnetate is not taken up in the 
skeleton. In chapter 3 an in vitro adsorption experiment (nr. 20) is 
described, which confirms this well known fact 
Pertechnetate has to be reduced to a lower oxidation state to obtain a 
preparation with affinity for bone. However, the hydrolysis of reduced 
technetium has to be prevented, otherwise, mainly soft tissue uptake will be 
found. 
Thus, reduced technetium has to be coupled in some way to a carrier 
molecule, which prevents the reduced technetium from hydrolyzing. In 
chapter 3 it is demonstrated, that reduced technetium itself has affinity for 
bone tissue ( see experiments 21 and 24), ( provided that it is not hydrolyzed, 
as is well known). In 1974 Cox already mentioned this possibility [22]. 
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As reducing agent for pertechnetate, stannous salts have found the widest 
application. Mostly stannous chloride is used. We however, prefer stannous 
sulphate, mainly because it is nonhygroscopic and therefore less sensitive 
to hydrolysis and air oxidation on the shelf. 
Stannous tin in water hydrolyzes rather rapidly, unless the tin salt is 
dissolved in relatively concentrated mineral acid. Hydrolysis turns the tin 
solution over into a suspension of colloidal and finely divided precipitated 
stannous oxide particles. 
Solutions containing these tin particles should not be used for the reduction 
of pertechnetate, because the reduced pertechnetate would be bound by 
adsorption to or occlusion in the hydrolyzed tin particles. One should also 
prevent the formation of these tin particles in the presence of reduced 
pertechnetate, because that would give the same result 
Thus, there is a need for an agent, which prevents the hydrolysis of reduced 
technetium and the precipitation of stannous tin(the amountof stannous tin, 
which is oxidized by Tc-99m-pertechnetate is negligible). 
One of the results of this study is the demonstration, that the main role of 
MDP in the technetium labeled bone seeking radiopharmaceutical is the 
prevention of the precipitation of stannous tin and the hydrolysis of reduced 
pertechnetate. MDP and other diphosphonates are well suited to fulfill 
these requirements. 
From the foregoing it is clear, that tin has to be added to MDP (or another 
suitable agent), before pertechnetate is added. Best results are obtained, 
when a solution of stannous salt in 0.1 N mineral acid is added to a solution 
of MDP. The pH of the mixture is then usually brought between 5 and 7 be-
fore pertechnetate is added. 
Measurements showed, that stannous diphosphonate complexes are more 
stable than the corresponding calcium complexes, but the tendency of 
stannous tin to hydrolyze causes the dissociation of the diphosphonate 
complexes and the formation of more stannous hydroxide as the pH 
increases. Several tin species may be present in solution, especially in the 
presence ofDCPDP (see chapter 5, Figure5.13). A strong pH influence was 
demonstrated. 
In the series of diphosphonates, described in chapter 5, MDP forms the least 
stable tin complexes and pCPMDP the most stable ones. DCPDP, which 
has recently been introduced as an excellent bone seeker, also forms 
relatively unstable complexes with tin. 
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Diphosphonates were shown to be able to stabilize supersaturated Sn (OH)2 
solutions, probably because they inhibit the growth of crystal nuclei. 
When the risk of tin precipitation has been avoided, pertechnetate may be 
added and then the reduction will proceed. 
We studied the influence of diphosphonates on the reduction of pertechne-
tate with stannous tin and the results are described in chapter 6. 
These results made us believe, that pertechnetate is reduced to Tc (III) by 
stannous tin, no matter whether the pH=2.5 or 6.5. Only for pCPMDP a 
reduction of pertechnetate to Tc(IV) is found, but this diphosphonate can 
not be used for skeletal scintigraphy (see chapter 4, table 4.8), although its 
affinity for hydroxyapatite is about the same as for MDP (see chapter 3, 
table 3.9 and figure 3.23). 
Literature data suggest, that Tc (III) is easily oxidized to Tc (IV) by water 
and that the formed Tc (IV) is reduced by excess stannous tin [19]. In this 
way stannous tin is consumed by the continuing reduction of Tc (IV) and 
hydrogen formation. This might explain, why pertechnetate is found after a 
few hours in a solution of a radiopharmaceutical, even if it is kept under 
nitrogen, while a stannous tin solution without Tc-99m under the same 
conditions is supposed to be stable. 
For the bone seeking diphosphonates no influence was found on the 
reduction process of pertechnetate. The reason for the different result for 
pCPMDP is discussed in chapter6, section 6.4. Tc (IV) is complexed with 
diphosphonate as could be detected for DCMDP in coulometrically 
reduced pertechnetate solutions. ATc(IV)-(E)CMDP)2 complex was 
found. However, no corresponding MDP complex could be identified. No 
information is available concerning the identity of technetium complexes in 
the presence of stannous tia 
In conclusion: 
Pertechnetate is reduced to Tc (III) by stannous tin in the presence of 
diphosphonate, which prevents precipitation of stannous tin and the 
hydrolysis of reduced pertechnetate. Several tin diphosphonate 
species may be formed, depending on the pH. 
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1.5.2. The blood compartment 
After administration of the radiopharmaceutical to the circulating blood 
compartment, several influences on the technetium labeled compound, may 
be exerted 
1. Dilution. 
The result of dilution depends on the stability of the tin diphosphonate 
complex and on the ratio of the (stannous diphosphonate) dose and the 
blood volume. For diphosphonates, which form relatively stable tin 
complexes, like EHDP, the dose-blood volume ratio is not a critical one. 
The same dose as is usually administered to humans gives comparable 
tissue distribution results in rabbits. For diphosphonates which were 
found to form unstable complexes with tin, like MDP and DCPDP (see 
chapter 5 ), the dose-blood volume ratio is of great influence. When a dose 
as is usually administered to humans is given to rabbits, an elevated 
technetium uptake in the RES is found. However, the same dose from the 
same preparation produces normal results in humans. 
If the tin diphosphonate dose is sufficiently reduced, also in rabbits a 
normal tissue distribution pattern is found. 
Apparently diphosphonates which form unstable tin complexes are not 
able to stabilize relatively high tin concentrations in blood for a sufficient 
period of time. 
Hydrolyzed stannous tin forms colloidal particles to which technetium is 
bound by adsorption or occlusioa 
The increased vulnerability to dilution of instable diphosphonate com-
plexes may explain the elevated soft tissue uptake of technetium in 
patients with high plasma calcium concentations. The expelling of 
technetium from the complex with diphosphonate by elevated concentra-
tions of calcium is feasible. It may be expected that this effect is less 
significant with EHDP than with DCPDP. 
2. Binding to erythrocytes. 
It is well known, that after administration of a solution of stannous tin 
(containing pyrophosphate, DTPA or a diphosphonate) to the blood 
circulation, an appreciable part of the tin is fixed to the erythrocytes and 
also to other blood cells. Pertechnetate, injected 30 minutes after the 
administration of tin solution, is coupled for 90% or more to the blood 
cells. This method is currently applied for the labeling of red blood cells 
for blood pool studies. 
The question arises whether in the presence of unstable diphosphonate 
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complexes also an appreciable part of the prereduced Tc-99m activity, 
administered for skeletal scintigraphy, will be bound to the erythrocytes. 
This is however, not confirmed by experiments in rabbits (see chapter 4). 
Only for DCPDP, 1 hr after injection, some concentration of activity on 
the erythrocytes is seen, but at that moment only a few percents of the 
initial activity was left in the circulation (see chapter 4). 
Thus it is concluded, that the interaction between reduced technetium and 
diphosphonate is stronger than the interaction between tin and the 
corresponding diphosphonate. This is also suggested by the results of 
adsorption experiments ( chapter 3 ). If however, pertechnetate is added to 
stannous tin without the presence of sufficient stabilizing agent, after 
hydrolysis the reduced technetium species remains adhered to the 
surface, where reduction took place. 
3. Binding to proteins. 
Only for phenylchloro-MDP and pCPMDP some activity has been found 
in association with plasma proteins (see chapter 4). It is supposed, that 
plasma protein binding may occur in the case of stable diphosphonate 
complexes, where the ligand molecules contain lipophylic groups. For 
technetium diphosphonates, which are commonly used for skeletal 
scintigraphy, no protein binding of any importance was found 
In conclusion: 
Dilution in blood may exert a marked influence on the tissue 
distribution of the best bone seeking technetium diphosphonates, if 
the tin dose is too high. Binding of reduced technetium to any of the 
macromolecular blood components does not seem of much impor-
tance for the commonly used technetium labeled bone seekers. 
1.5.3. The uptake in bone. 
As mentioned in the preceding section, most technetium diphosphonates 
are not fixed to any of the macromolecular components of blood. Provided, 
that the technetium diphosphonate itself is no macromolecular substance, 
(single crystal X-ray analysis suggests that technetium MDP consists of 
polymeric molecules) the technetium diphosphonate may freely diffuse 
from the blood compartment into the extracellular fluid. The extremely low 
concentrations of technetium-99m, which exist in normal radiopharmaceu-
tical preparations, make it very unlikely, that technetium labeled MDP 
consists of polymeric substances of high molecular weight The Tc-
(DCMDP)2 complex could be identified as a monomer. This also throws 
doubt on the suggestion that technetium diphosphonates form polymeric 
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molecules. The fast bone uptake of technetium, which is normally seen, is in 
favour of the idea, that a relatively small molecule easily diffuses from blood 
into the extracellular fluid surrounding the bone tissue. Diffusion into the 
extracellular fluid, surrounding the bone tissue is a prerequisite for uptake in 
bone. 
As stated before, the amorphous fraction of the hydroxyapatite is believed 
to be the phase, where the technetium diphosphonate accumulates. 
Amorphous hydroxyapatite is the first stage of calcium phosphate crystal 
formation and it has a most extended hydration layer, which favours 
interaction with the contents of the extracellular fluid (see chapter 2). 
The radiopharmaceutical which reaches the fluid surrounding the amor-
phous hydroxyapatite, contains a large excess of diphosphonate. This 
excess of diphosphonate is uncomplexed with tin and it will be adsorbed on 
the apatite surface. The extent of adsorption of diphosphonate is determined 
by the available surface and by the amount of diphosphonate present (see 
chapter 3). 
It will be shown in chapter 3, that technetium and tin diphosphonate 
complexes as such are not adsorbed on the apatite surface. Technetium and 
tin show a very similar adsorption pattern, although technetium and tin are 
not taken up on the surface in a fixed molecular ratio. Technetium and tin 
have their own affinity for hydroxyapatite, but they are not adsorbed, unless 
their complex with diphosphonate dissociates. So there is a competition for 
binding of technetium and tin between the diphosphonate and the hydroxy-
apatite surface. Diphosphonate binds to specific sites at the apatite surface. 
Per surface unit cell exposed to the hydration layer, there is only one binding 
site for a diphosphonate molecule. 
The order of increasing tin complex stability: 
MDP<EHDP<pCPMDP (see chapter 5) is in accord with the order of 
decreasing technetium and tin adsorption: 
MDP>EHDP>pCPMDP. (see chapter 3). 
This is the same order as found for the bone uptake of technetium-99m in 
rabbits (see chapter 4). 
So the nature of the diphosphonate especially its complexing ability towards 
tin and technetium plays a rather delicate role. A strong complex forming 
diphosphonate inhibits the detrimentous colloidal precipitation of stannous 
hydroxide but also reduces the uptake of technetium in bone. 
A weak complex forming diphosphonate favours the adsorption of techne-
tium and tin on hydroxyapatite but brings with it the risk of complex 
dissociation in the blood circulation which may cause uptake of technetium 
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in the reticuloendothelial system and other soft tissues. An intermediate 
strength of complexation is required. It is interesting to note, that the 
described mechanism of uptake of technetium in bone is related to the 
mechanism of the uptake of the rare earth elements in bone, where the 
biodistribution is known to depend greatly on the chelation strength of the 
carrier molecule: an intermediate strength of chelation is required [20]. 
The main conclusion of this study is, that the level of technetium uptake is 
primarily determined by the stability of the diphosphonate complex and that 
the affinity of the diphosphonate for hydroxyapatite is only of secondary 
importance. 
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CHAPTER 2 
THE EXPERIMENTAL MODEL 
2.1. STRUCTURE AND PHYSIOLOGY OF BONE [5,6,7,]. 
Bone is a highly specialized form of connective tissue, composed of 
branching cells in an intercellular substance and forming the skeleton of the 
body of most vertebrates. The intercellular substance consists of fibers and 
ground substance and is, unlike the other types of connective tissue, 
mineralized, making it hard and ideally suited for its supportive and 
protective function. The fibers are mainly collagenic and the ground 
substance is characterized in bone by its contents of mucopolysaccharides. 
Bone provides for the internal support of the body and for the attachment of 
the muscles and tendons essential for locomotion. Bone protects the vital 
organs of the cranial and thoracic cavities, and it encloses the blood forming 
elements of the bone marrow. In addition to these mechanical functions, it 
plays an important metabolic role as a mobilizable store of calcium, which 
can be drawn upon as needed in the homeostatic regulation of the 
concentration of calcium in blood and other fluids of the body. 
2.1.1. The macroscopic structure of bone. 
Upon inspection with the naked eye, two forms of bone are distinguishable: 
spongy and compact bone. Spongy bone consists of a three dimensional 
lattice of branching bony spicules delimiting a labyrinthine system of 
intercommunicating spaces that are occupied by bone marrow. Compact 
bone appears as a solid continuous mass. 
In typical long bones, such as the femur, the shaft (diaphysis) consists of a 
thick walled hollow cylinder of compact bone with a voluminous central 
cavity occupied by the bone marrow. 
The ends of long bones consist mainly of spongy bone covered by a thin 
peripheral cortex of compact bone (see fig. 2.1). The intercommunicating 
spaces among the spicules of this spongy bone in the adult, are directly 
continuous with the marrow cavity of the shaft In the growing child, the 
ends of the long bones, called the epiphyses, arise from separate centers of 
ossification, and are separated from the diaphysis by a cartilaginous 
epiphyseal plate which is united to the diaphysis by columns of spongy bone 
in a transitional region called the metaphysis. The epiphyseal cartilage and 
the adjacent spongy bone of the metaphysis constitute a growth zone, in 
which all increment in length of bone occurs. At the ends of long bones, the 
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thin cortical layer of compact bone is covered by a layer of articular 
cartilage. 
With a few exceptions, bones are invested by periosteum. This is a layer of 
specialized connective tissue containing blood vessels, which has the ability 
to form bone. The marrow cavity of the diaphysis and the cavities of spongy 
bone are lined by the endosteum, a thin cellular layer that also possesses 
osteogenic properties. 
Though bones other than long bones, for example the flat bones of the skull, 
may have a different origin, they still are a mixture of compact and spongy 
bone and the behaviour of these bones as a tissue is similar irrespective of 
type. 
Fig. 2.1. 
2.1.2. The microscopic structure of bone. 
If a thin section of the shaft of a long bone is examined with the microscope, 
it is apparent that the contribution of the cellular elements of bone to its total 
mass is small. Compact bone is largely composed of the mineralized 
interstitial substance, the bone matrix, deposited in layers or lamellae of 3-7 
μτη thick. 
Rather uniformly distributed throughout the interstitial substance between 
the lamellae one finds bone cells or osteocytes in small cavities, called 
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lacunae. The lacunae are interconnected by a three dimensional network of 
tubular passages, the canaliculi. The canaliculi penetrate the interstitial 
substance and anastomose with the canaliculi of neighboring lacunae 
forming a continuous system of cavities. These slender passages are 
believed to be essential to the nutrition of the osteocytes. The intercommu-
nicating canaliculi provide avenues for exchange of metabolites between 
cells and the nearest perivascular space. 
The lamellae of compact bone are disposed in two main patterns. 
- Haversian systems or osteons. In osteons the lamellae are arranged 
concentrically around longitudinal vascular channels, to form cylindrical 
units. Osteons are made up of 4-20 lamellae. 
- Outer and inner circumferential lammellae. 
At the external surface of the cortical bone, immediately beneath the 
periosteum, and on the internal surface, subjacent to the endosteum, there 
are several parallel lamellae that extend uninterruptedly around much of 
the circumference of the shaft 
Two categories of vascular channels are distinguished in compact bone. 
- Longitudinal channels in the centers of the osteons: the haversian canals. 
These contain small blood vessels mostly capillaries. 
- Transverse and oblique channels: the Volkmann's canals. These connect 
the haversian canals with one another, with the free surface and with the 
marrow cavity. 
The blood vessels from the endosteum and, to a lesser extent, from the 
periosteum, communicate with those of the haversian systems via the 
Volkmann's canals. 
Spongy bone is also composed of lamellae, but its spicules are relatively 
thin, and are usually not penetrated by blood vessels. The cells in spongy 
bone are nourished by diffusion from the endosteal surface via the minute 
canaliculi that interconnect the lacunae. 
2.1.3. Bone cells. 
The cellular components of bone are associated with specific functions: 
osteoblasts with the formation of bone, osteoclasts with the resorption of 
bone and osteocytes with the maintenance of bone and the calcium 
homeostasis. 
It is generally assumed, that bone cells arise from relatively undifferentiated 
cells, the osteoprogenitor cells, localized on or near all of the free surfaces of 
bone: in the endosteum, the periosteum, lining the haversian canals, and on 
the spicules in the spongy bone. The bone cells, having a common ancestor, 
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are closely interrelated and frequent transformations occur from one to 
another of the morphological different types. In doing so, they retain the 
potencies common to all bone cells. This makes it more reasonable to regard 
the different bone cells as different functional states of the same cell type 
rather than as distinct cell types. Such reversible changes in appearance are 
examples of cell modulation, in contrast to cell differentiation, which is 
irreversible. 
Osteoblasts are responsible for formation of the organic matrix (mucopo-
lysaccharides and collagenic fibers) and are found on the advancing 
surfaces of developing or growing bones. 
During active deposition of new matrix, osteoblasts are arranged in a layer 
of cuboidal cells connected to one another by short slender processes. They 
appear to form a barrier between the surface of the forming bone on one side 
and the connective tissue and blood vessels on the other side. The 
osteoblasts give a strong histochemical reaction for alkaline phosphatase 
and they contain small granules in the cytoplasm that are believed to 
represent precursors of the bone matrix. After termination of its bone 
forming activity, the osteoblast is either incorporated in the mineralizing 
organic matrix becoming an osteocyte, or it returns to the osteoprogenitor 
state. The principal cells of fully formed bone are the osteocytes in the 
lacunae within the calcified interstitial substance. Osteocytes have nume-
rous slender processes which extend into canaliculi in the surrounding 
matrix and are in contact with the processes of neighboring osteocytes. The 
cell junctions between the osteocytes permit flow of ions and possibly of 
small molecules. This may explain how cells deep within the mineralized 
matrix of bone can respond to hormonal stimuli. An osteocyte is essentially 
a modulated osteoblast which has become surrounded by bone matrix. 
Osteocytes play an active role in the process of osteolysis whereby the bone 
matrix immediately surrounding the osteocytes is modified and bone salt is 
resorbed [1]. In this way osteocytes are involved in the release of calcium 
from bone to blood, and hence participate in the homeostatic regulation of 
calcium concentrations in the boay fluids. Besides this metabolic function, 
osteocytes are active in the remodelling of the immediately surrounding 
bone. [2]. The osteocyte is believed to be capable of modulation to other 
bone cell types. 
Bone is resorbed as a whole, both mineral and matrix, by osteoclasts which 
are multinucleated giant cells, closely apposed to the bone surface. 
Osteoclasts are frequently found in shallow concavities in the surface of 
bone formed by an erosive action of the osteoclast They are always most 
abundant in those areas that are known to be undergoing resorption. The 
side of the osteoclast adjacent to bone has a ruffled border with numerous 
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cytoplasmic extensions infiltrating the desintegrating bone surface. Small 
crystals of bone mineral liberated from the bone matrix may be found deep 
in these clefts. The ruffled border of the osteoclast seems to be highly active 
and constantly changing its configuration. Osteoclasts secrete lysosomal 
acid hydrolases together with lactate and citrate. The latter two acidify the 
medium and this solubilizes the bone mineral. The acid hydrolases are 
activated by the local acid production and resorb the organic matrix [3]. The 
surface membrane of osteoclasts around the periphery of the active ruffled 
border is very smooth and closely applied to the underlying bone. This might 
help to seal off the active portion of the cell and enable it to maintain a 
microenvironment conducive to solubilization of mineral and to optimal 
activity of hydrolytic enzymes [4]. Osteoclasts arise by coalescence of 
mononuclear cells. Fusion of osteoprogenitor cells seems to be the principal 
source of osteoclasts, but osteoclasts may also arise by coalescence of 
mononuclear cells emigrating from the blood, presumably monocytes [8]. 
Osteoclasts may be able to divide their cytoplasm into mononuclear units 
which revert to progenitor cells. 
2.1.4. The bone matrix. 
The bone matrix consists for 95% of coUagenic fibers and for 5% of 
mucopolysaccharides such as chondroitin sulphate and hyaluronic acid. 
The collagen molecule consists of three left-handed helically wound 
polypeptide chains, which again are wound around each other and around a 
common axis into a triple-chained right-handed superhelix [9]. These three 
chains are held together by hydrogen bands between the three peptide-
banded backbones. Electron microscope studies have shown that bone 
collagen fibers exhibit a clearly demonstrable 680 Âbanding pattern. This 
680 À periodicity is caused by the axial displacement of each collagen 
molecule relative to its neighboring molecules. Adjacent nonoverlapping 
molecules do not lie end to end but are separated by a space of 
approximately 430 Д giving rise to hole regions [10,11]. 
Collagen is characterized by a high glycine content of about 30 mole % and 
a (hydroxy)proline content of 20-25 mole %. In the three chains of the 
molecule the glycine residues seem to occur rather regularly spaced. 
The amino acid sequence of the triplet gly-X-Y, in which X often is proline 
and only Y can be hydroxyproline, is the predominantly occurring one. 
In mature lamellar bone, the collagen fibers are highly ordered in their 
arrangement Those within each lamella of an haversian system are parallel 
in their orientation and run helically with respect to the axis of the haversian 
canal, but the pitch of the helix changes from one lamella to the next A close 
morphological relationship exists between the collagen fibers and the 
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crystallites of the mineral phase [12]. The crystallographic c-axis of the 
apatite was found to be oriented more or less parallel to the fiber axis of the 
collagen fibrils. This close morphological relationship between collagen 
and apatite led to the suggestion that collagen fibers may be part of the so-
called local factor for tissue mineralization [13]. Collagen fibers are able to 
initiate the precipitation of apatite in metastable calcification buffers in vitro 
[14]. It was shown that the first deposits of apatite crystallites in collagen 
occur in the so-called interband regions of the 680 Â spacings. Several 
investigators tried to explain the observed periodicity of 680 Â and the 
parallel orientation of collagen fibers and apatite crystallites by means of an 
epitactic overgrowth. Epitactic or oriented overgrowth involves the nuclea-
tion and growth of crystals of a second solid phase on a crystalline substrate. 
The phenomenon is caused by similarities in the dimensions of the atomic 
(or ionic) nets of the contacting planes. A clear case of epitaxy requires a 
well-defined crystal growing on a well-defined crystalline substrate. Biolo-
gical apatites are however, poorly crystallized and very impure. The 
catalyzing substrates show a crystallographic structure which is far from 
well-defined. The parallel orientation of apatite crystallites and collagen 
fibers in mineralized tissues was shown very likely to be due rather to steric 
factors than to epitaxy [15]. 
The available spaces between the collagen fiber bundles and fibrils are small 
and elongated, and of the same order of magnitude as the crystallites/This 
could easily result in the parallel orientation of the fibrils and the thin 
elongated apatite crystals. 
It was found that fine-grained apatite or thallous phosphate precipitates can 
be deposited in bundles of collagen or /3-chitin (a mucopolysaccharide) 
fibers so that the crystallographic c-axis of the crystals is parallel with the 
fiber axis. Blocking of the free carboxylic or amino groups of the amino acid 
side-chains of the collagen did not influence its ability to orient precipitating 
apatite or thallous phosphate crystals. Such ionic groups would most likely 
be involved in an epitactic overgrowth. 
Catalysis of apatite nucleation may occur by a variety of organic substances 
in vitro. It is highly unlikely that all these organic substances would have 
catalytic arrays which show considerable similarity to the crystal lattice of 
apatite. Though collagen apparently does not induce apatite crystallization 
by epitactic overgrowth, evidence clearly suggests that collagen and other 
biopolymers can catalyze apatite nucleation. 
A problem that can not be solved to day is the difference in behaviour in vivo 
of collagen in mineralizing and nonmineralizing tissues. Collagen from 
both types of tissues is able to induce crystallization in vitro and shows the 
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familiar 680 Â banding pattern in the electron microscope. To day no 
evidence exists for differences in structure although the possibility can not 
be excluded. The existence of a local factor has been suggested by several 
authors. Fleisch proposed pyrophosphate as an inhibitor of mineralization 
[16,17]. This inhibiting activity is partially destroyed by alkaline phospha-
tase or pyrophosphatase [ 18] reaching maximum activity just as calcium 
begins to be deposited. Sobel stated that sulphated mucopolysaccharides 
like chondroitin sulphate play an important role in tissue mineralization by 
their ability to bind large amounts of calcium [19]. Sulphated mucopolysac-
charides are synthesized in the osteoblasts of bone and secreted into the 
organic matrix. 
Secretion is maximal just prior to the mineralization of the matrix [20]. 
Sulphated mucopolysaccharides are present in the form of mucoproteins, 
so-called protein-polysaccharides (PPL). The calcium chelating properties 
of PPL can be destroyed by removal of the protein part. Histochemical 
studies suggest that calcium in association with organic material is secreted 
by hypertrophic cells in mineralizing epiphyseal cartilage [21]. Formation 
and subsequent removal of PPL seem to be intimately associated with the 
process of cartilage mineralization. There is evidence now that first apatite 
crystals may not be formed in the collagen fibers in all mineralizing 
collagenous tissues, but rather in mucoprotein containing regions. Spherical 
bodies, probably rich in mucopolysaccharides or mucoprotein, seem to act 
as the earliest sites for crystal formation in these tissues. Acid phospholipids 
within the membranes of these bodies could provide sites for initial calcium 
binding and establish an environment in which mineralization can be 
facilitated [22,23]. 
Howell suggested that after secretion of PPL a hydrolytic enzyme may set 
free the bound calcium and phosphate which could result in the spontaneous 
deposition of apatite [ 24]. Despite all support for the role of mucoproteins in 
tissue mineralization much further work will be required because this matter 
has not yet been settled. There are no reasons at the present time to assume 
the presence of specific PPL fractions in mineralizing cartilage although the 
concentration was found to be highest in the ossifying zone. 
The variety of biological environments, both collagenous and noncolla-
genous, in which calcium phosphates can be deposited makes it unlikely that 
there is only one single mechanism of tissue mineralizatioa It seems likely, 
however, that collagen is involved in this mechanism in bone. Any cofactor 
or activator which may be required by the collagen in bone should exert its 
action in conjunction with the fine-structure of the 680 Âbanding pattern of 
the collagen fibrils [25]. 
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2.1.5. The mineral phase of bone. 
As far back as the nineteenth century, the mineral of osseous tissue has been 
known to be a calcium phosphate, but it was not until 1926 when, for the first 
time, de Jong [26] applied the method of X-ray diffraction to bone and 
established the structure of this mineral as hydroxyapatite, Ca10(PO4)6 
(OH)2> Unfortunately this conclusion gives no answer to the question of the 
elementary composition of bone: all basic calcium phosphates with a Ca/P 
ratio of 1.3-2.0 show X-ray diffraction patterns characteristic for hydroxy-
apatite. The unit cell for hydroxyapatite is a right rhombic prism of height 
6.88 Â(c-axis) and length along the basal edge of 9.43 Â(a-axis). When 
stacked together, the unit cells form a simple hexagonal lattice. The three-
dimensional structure of apatite, as revealed by X-ray diffraction, shows 
that all the phosphate tetrahedra are nearly regular and positionally 
equivalent This is not true, however, for the calcium ions. 
Six of the ten calcium ions in the unit cell are associated with the hydroxyl 
ions. These calcium ions have an irregular sevenfold coordination with six 
oxygen atoms from five different phosphate tetrahedra in addition to the 
hydroxyl ioa The other four calcium ions are not coordinated by hydroxyl 
ions but, instead, their ninefold coordination polyhedra are defined entirely 
by oxygen atoms from six different phosphate groups. The hydroxyl ions lie 
along columns perpendicular to the rhombic base of the unit cell. These ions 
are regularly coordinated by a triangular array of three calcium ions 
perpendicular to the hydroxyl column. 
Except for Ca2+, P043" and OH", the mineral fraction of bone consists of 
carbonate and citrate with small amounts of other ions, especially Na+, 
Mg2"1" and P . The hydroxide groups in hydroxyapatite can be replaced by 
halogenide ions like fluoride or chloride without disturbing the apatite 
structure. One of the first detailed reports of the mineral composition of 
bone and teeth was published by Gabriel in 1894 [27]. 
It still compares favorably with the analytical data which Singer and 
Armstrong published 71 years later [28]. See table 2.1. 
Table 2.1. 
Calcium 
Magnesium 
Sodium 
Phosphate 
Carbonate 
Citrate 
Fluoride 
Analytical data on dry, fat-free bovine cortical bone. 
26.70 % 
0.436% 
0.731% 
12.47 % 
3.48 % 
0.863% 
0.072% 
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In 1911 Gassman advanced the idea that the atomic ratios Ca/PO./CO, 
remain constant in bone. For him this was a strong argument to say that the 
three elements or groups are combined into a single molecular complex 
similar to carbonatoapatites, Ca1 0(PO4)6CO3. According to Gassman the 
inorganic phase of bone would be a very stable mineral similar to those that 
are widespread in nature. In particular Marek et al. opposed this concept 
For them, the composition of bone should be able to vary since they believed 
that the skeleton participates in the metabolism of both calcium and 
phosphorus. On the basis of improved analytical data Marek and others 
were eventually able to exclude the hypothesis advanced by Gassman: 
phosphate and carbonate in bone and teeth are biologically a. i chemically 
independent and their ratio is not constant 
These authors were, however, not able to eliminate the possibility of partial 
substitution of various anionic groups in apatite by C0 3
2
". Klement [2S], 
using reliable analytical data for normal bone, tried to compute the 
equivalence between anions and cations. He assumed that Na+, K+ and 
Mg2"1" do not belong to the mineral phase of bone proper but exist as (bi­
carbonates in the extracellular fluids. For the remaining ions he obtained a 
ratio Ca3(P04)2/Ca(OH)2 /CaC0 3= 3/0.99/0.4. Therefrom Klement 
attributed to bone mineral the formula: 3 Ca 3 (P0 4 ) 2 · Ca(OH)2 + 0.4 
CaCOj. This calculation was the basis for the theory, still generally 
accepted, that bone mineral is made of hydroxyapatite, Ca1 0(PO4)6(OH)2, 
associated with calcium carbonate. Dallemagne, in 1942 [30], was the first 
to discover that Klement made an arithmetical error, due to a misplaced 
decimal point Correct calculations with Klement's data led to 
Ca3(P04)2/Ca(OH)2/CaC03 = 3/0.71/0.7. 
Based on this result Dallemagne concluded that the phosphate in minerali­
zed tissues has a lower Ca/P ratio than apatites. By analogy with hydroxy­
apatite, which can be written as Ca^PO^g- Ca(OH)2, he suggested for 
hydrated tricalcium phosphate (a-tricalcium phosphate) the formula: 
C a ^ P O ^ - H ^ O H ^ . According to this theory the bone mineral would 
represent a mixture of hydrated tricalcium phosphate and calcium carbona­
te. How the substitution of one Ca 2 + ion by two H + ions could take place 
without disturbing the X-ray diffraction pattern, was not completely solved. 
As stated before, both hydrated tricalcium phosphate and hydroxyapatite, 
were said to have similar X-ray diffraction patterns, specially difficult to 
distinguish in view of the small crystal size. Thermogravimetric experi­
ments to above 700° С with synthetic hydrated tricalcium phosphate, 
synthetic hydroxyapatite and bone mineral showed that the latter behaves 
different from hydrated tricalcium phosphate [31]. Another disquieting 
finding was the relative instability of hydrated tricalcium phosphate in 
water even at room temperature, delivering hydroxyapatite by hydrolysis. 
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Newman and others at Rochester never accepted hydrated tricalcium 
phosphate, but explained the lower Ca/P ratios of bone mineral, as 
compared to hydroxyapatite, by adsorption of phosphate at the surface of 
the very small crystals [ 13]. In 1950 Arnold described still another calcium 
phosphate characterized by a ratio Ca/P = 8/6 and therefore called 
octocalcium phosphate [32]. He proposed for this compound the formula: 
Cag(P04)6(OH)2*(H30)4. This salt, which is difficult to prepare, was 
found to be even more unstable than hydrated tricalcium phosphate. Thus 
by then, three synthetic calcium phosphates, presumably apatitic in 
structure, had been described, ranging with their Ca/P ratios between 1.33 
and 1.67. It became rapidly apparent that also intermediary compounds 
could be prepared and a new theory was proposed. Hydroxyapatite, 
hydrated TCP and OCP should be considered as belonging to a continuous 
series of apatitic calcium phosphates containing between 8 and 10 calcium 
atoms for every 6 phosphate groups [33]. The apparently identical 
crystalline structure would be explained by the existence of randomly 
distributed defects at the level of positions normally occupied by calcium in 
the apatite crystals. The electroneutrality would be maintained by the 
introduction of H + ions to form hydrogen bands between the oxygens of 
adjacent tetrahedral phosphate groups. The continuous series of calcium 
deficient apatite phosphates was described by: Ca J 0 χ Η 2 (P04)6(OH)2, 
(0<x<2). "" X 
According to the so-called defect theory, bone mineral is made up of a 
mixture of Ca-deficient apatite and CaC03. However, no evidence could be 
found for the presence of acid phosphate groups or hydrogen bands. Further 
work, initiated by Winand, finally led to firm experimental data that allowed 
for a much better understanding of synthetic and biologic apatites. These 
results confirmed that the continuous series of calcium deficient apatites 
could be described by the formula: Ca1Q Η (P0 4) 6(OH) 2 , where 0<x< 
2 [34]. 
For every missing Ca 2 + only one rather than two H + is introduced in the 
structure in the form of a hydrogen band between adjacent orthophosphate 
groups; concomitantly one OH" is also lost At the time when Winand 
introduced his concept, his formula incorporated all chemical data avail­
able, but he had almost no structural data in support of the existence of Ca 2 + 
and OH" vacancies or the existence of hydrogen bands between orthophos­
phate groups. Later, evidence for the existence of calcium and hydroxide 
vacancies was found by others [35,36]. The question of the hydrogen bands 
is still left unresolved. It has become obvious that, to solve this question, 
single crystal stoichiometric and nonstoichiometric apatites must become 
available. Thermogravimetric experiments have shown that the Ca/P ratio 
of the main mineral component of bone is lower than the overall Ca/P ratio 
and also lower than that of hydroxyapatite. HA does not adequately 
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describe the salt present in bone. The main component of bone mineral can 
be usefully compared to the series of calcium deficient apatites, as described 
by Winand. Bone tissue is heterogeneous with regard to the structure and 
composition of its mineral phase. Younger structures appear to contain a 
mineral more deficient in calcium than older structures in which the mineral 
is closer to hydroxyapatite. No firm conclusion could be reached as far as 
the carbonate fraction of bone is concerned beyond the fact that it probably 
exists in more than one form. C032" has been proposed to substitute 
isomorphically for P043". 
Whether carbonate substitutes randomly throughout the crystal or only at 
the surface remains in doubt Engström believes that the carbonate is either 
surface bound or occurs as a separate amorphous phase [37]. The calcium 
deficiency and the presence of carbonate are just two illustrations of the 
abundant experimental evidence suggesting that departures from stoichio-
metry in apatites are the rule and not the exception. These departures are 
apparently strongly influenced by the composition of the reaction milieu 
during the growth process. 
In his pioneering study, de Jong concluded from the poor resolution of the 
X-ray diffraction pattern of bone salt that the apatite crystallites are very 
small. More recent investigations gave a value of 640 Âfor the mean crystal 
length in the c-direction and a value of 42 Âfor the diameter of bone crystals 
[38 ]
-
Although other groups found values of less than 100 Ato 200 Âfor the 
average crystal length in the c-direction and a réévaluation of crystallite size 
in bone apatite may be necessary, it should be emphasized, however, that 
these discrepancies should not overshadow the areas of agreement Bone 
crystals are extremely minute with the smallest dimension less than 50 Â 
and with the largest dimension parallelling the crystallographic c-axis, 
probably much less than 1000 Â 
Studies on the aging of apatite crystals in synthetic aqueous systems showed 
that at the end of the initial nucleation and growth phase, which occurred 
quite rapidly, the crystallinity of the synthetic material was less than for 
apatite in mature bone. After the initial growth phase a slow, time dependent 
increase in the crystallinity of the precipitated particles followed. This 
consolidation process is known as Ostwald ripening. This ripening is the 
result of the dissolution of smaller, more soluble particles in the system and 
the deposition of dissolved material on the larger, more stable particles. A 
minimum amount of water is required, however, to support this process. 
The submicroscopical small size of bone crystals results in a very large 
mineral surface. For adult human bone values up to 180 m2/g have been 
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found [39]. The physiological importance of this interface may not be as 
great, however, as the magnitude of its area would suggest Much of the bone 
mineral may not have access to sufficient water to support the transport of 
ions to and from its surface. Rowland deduced from autoradiographic 
studies that less than 1 % of the bone calcium in humans is part of an 
exchangeable pool [40]. 
As was mentioned before, the c-axis parallels the length of the apatite 
crystals in bone and this latter dimension is coincident with the direction of 
the collagen fiber axis. The crystals are arranged in chains of indeterminate 
length. 
The X-ray diffraction patterns of osseous tissue clearly demonstrate that 
apatite is the principal if not sole crystalline component of bone mineral. 
The absence of diffraction lines of other inorganic crystalline phases in bone 
patterns, however, does not preclude the existence of mineral components 
in bone tissue of such low crystallinity that their diffraction maxima would 
be completely obscured by the poor resolution of the apatite pattern and by 
the diffuse scatter from the matrix components. The existence of an 
amorphous phase was demonstrated indirectly by showing that the X-ray 
peak intensities from the apatitic portion of the bone pattern were 
considerably less than the values expected if one had assumed that bone 
mineral is composed entirely of this crystalline phase [41]. Quantitations of 
this difference between observed and expected intensity values revealed 
that the weight fraction of apatite in whole bone was frequently 60% or less 
of the weight fraction of the total mineral content of whole bone. Since the 
discrepancy between the two weight fractions could not be ascribed to the 
presence of other crystalline phases, it was concluded that the remaining 
40% of this mineral was amorphous to X-rays. Highest levels of this X-ray 
amorphous mineral component are found in young bone (approximately 
70%), but these levels steadily decline as bone matures [42]. From the 
results of chemical analyses, it can be concluded that this X-ray amorphous 
bone mineral phase is a calcium phosphate, most likely a tricalcium 
phosphate. Synthetic amorphous calcium phosphate is metastable, and if 
allowed to remain in contact with basic aqueous solutions, it will convert in 
to crystalline apatite [43]. 
As much as 1% of the fresh weight of bone may be accounted for as citrate 
and 90% or more of the citric acid of the body is in the skeleton. The 
occurrence of citrate in the mineral portion of the skeleton forms one of the 
strongest arguments for the belief that such substances are held on the 
surfaces of apatite crystals, since the size of the citrate molecule clearly 
excludes it from the apatite structure itself. Whether citrate is present in 
bone as an ion or whether it is combined in a complex form with calcium is 
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still unclear. Probably the citrate exists in more than one form in bone. 
Citrate seems to play a role in the solubilization of the bone mineral and the 
transfer of calcium from bone to blood. 
Because the crystals of bone mineral are only 2 -4 unit cells thick, only one 
third to one half of the crystal is comprised of normal unit cells. The other 
unit cells are located in the surface and possess one or more unshared sides. 
On the surface Ca2+, P043~, OH", and C032" ions are exposed to the 
hydration shell and to the surrounding body fluids. Ion exchange takes place 
readily, especially in the more accessible and more reactive portions of the 
bone, the new bone in the partially mineralized osteons. The crystals are 
subject to constant ion exchange, as well as to other surface phenomena, and 
must be considered as participants in a very dynamic system. It was shown 
by Falkenheim that ionic exchange rather than adsorption is responsible for 
the fixation of radiophosphate in vitro [44]. Hodge reported similar 
findings for radiocalcium [45]. Some specificity is associated with substitu-
tions involving the ions in the surfaces of hydroxyapatite crystals. For 
example, at least two monovalent ions (Na+, H ,0 + ) whose ionic radii 
(0.95 Â and ca 1.0 Â) are similar to that of calcium (0.99 A) are able to 
displace calcium mole for mole. This results in a lowered positive charge on 
the crystals and, as expected, a reduced number of boundary anions 
associated with the crystal surfaces [46]. The potassium ion( 1.33 A), on the 
other hand, exhibits an ionic radius one third greater than that of calcium 
and does not undergo appreciable heteroionic exchange. The strontium ion 
(1.13 Ä) behaves normally, and undergoes exchange with the calcium ion 
on an equivalent basis. The dynamics of the behaviour of ions at the crystal 
surfaces are best expressed in terms of ion exchange without, however, 
eliminating the possibility of chemisorption occurring concurrently. 
There are recurring suggestions that the blood plasma and even the bulk of 
extravascular fluids are not in direct equilibrium with the crystals of the 
bone mineral. Instead, a gradient is postulated, or even a physical barrier, 
which maintains a gradient between the pH at the crystal surfaces and that 
in the circulating fluids [47]; the nature of such a hypothetical barrier has not 
been elucidated Nordin [48] postulated a pH = 6.8 at the surfaces of the 
crystals; Terepka et al. stated that the pH in the immediate environment of 
the crystals must be lower than pH 6.8 and believed that the gradient be-
tween this pH and the pH in the circulating fluids in the body is maintained 
by the production of acid by the cells of bone. Borie et al. [49] also supported 
the concept that the concentrations of calcium and phosphate, found in the 
extracellular fluid, are the result of local pH changes at the bone mineral 
surface determined by lactate formation. McLean and Budy do not accept 
the idea of apoolof fluid at pH= 6.8 or below, surrounding the crystals in 
the process of dissolution [50]. 
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Neuman believes that the hydrolytic transition of amorphous CaHPO. into 
hydroxyapatite causes a precipitous fall in pH [13]. The possibility of a 
gradient in H-*" ion concentration between the fluids surrounding the crystal 
surfaces and the circulating body fluids, though difficult to imagine, can not 
be excluded. The sequence of events in mineralization can be summarized 
as follows: 
- The mineral phase of bone is deposited first as an amorphous material. 
- The amorphous material changes into an initial crystalline precipitate, 
which is an apatite with a composition close to that of octocalcium 
phosphate. 
The initial crystalline precipitate is progressively transformed into a final 
crystalline product, which is an apatite similar to hydroxyapatite. 
- The apparent crystal size does not vary much with time; the increase in 
the mineral load is mainly due to an increase in the number of crystals 
present 
2.7.6. Bone turnover. 
The term, "bone turnover", refers to the formation and resorption of bone. 
In a normal adult animal or human being, generally less than 5% of the bone 
surfaces are being formed or resorbed at any time. 
Bone formation is carried out by osteoblasts which form a sheet of cells on a 
bone surface and produce collagen and mucopolysaccharide; together these 
form the organic matrix or osteoid The collagen is secreted by the 
osteoblasts in the form of fibrils, which are the building blocks of collagen 
fibers and which aggregate to produce a periodic banding of 640 Â. Initially 
the organic matrix is unmineralized and remains so for approximately 15 
days. Since the osteoblasts produce osteoid at a rate of about 1 jum/day, a 
border of unmineralized bone about 15 μτη wide exists on surfaces where 
normal bone formation is taking place. After 15 days a histologically 
demonstrable change occurs in the osteoid and it becomes mineralizable. 
Amorphous calcium phosphate, which is later converted to crystalline 
hydroxyapatite, is deposited at the mineralization front The mineral is 
deposited rapidly at first so that only a narrow border of bone of low mineral 
density is found in areas of bone formation. After the density is about 85% 
of the final mineral density, further mineral is added slowly and may take 
months to reach the full density of mature bone. However, once deposition 
of new tissue has stopped, mineralization continues up to the surface of the 
bone, producing an inactive calcified surface. A border of osteoid, therefore, 
generally indicates bone fonmatioa However, if there is a failure of 
mineralization during the formation of new bone, then an increase in width 
of osteoid tissue is seen. As osteoid is laid down, osteoblasts become 
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included in the matrix at regular intervals in lacunae and are buried 
subsequently in the mineralized bone. The cell is then called an osteocyte. 
Bone resorption is accomplished by osteoclasts, which appear to secrete 
proteolytic and demineralizing substances which remove the matrix and the 
mineral at the same time. Formation and resorption take place along tunnels 
which are formed in an approximately vertical direction through the bones. 
Osteoclasts resorb bone at the end of the tunnel; a region of inactive surface 
follows, and finally osteoblasts lay down unmineralized osteoid. 
Bone turnover in an adult skeleton, therefore, consists of a continuous 
process of forming tunnels and filling them in with new bone. 
2.2. INTERACTIONS BETWEEN DIPHOSPHONATE AND BONE. 
In 1966 Fleisch et al. suggested that pyrophosphate might be one of the 
physiological regulators of calcification, with calcium phosphate deposi­
tion only taking place after the destruction of the pyrophosphate by 
pyrophosphatase, an enzyme present in large concentrations in minerali­
zing tissues [51]. 
This proposal was based on findings of small quantities of pyrophosphate 
both in plasma and urine and on experiments with calcium phosphate 
precipitation in vitro. Pyrophosphate strongly inhibits calcium phosphate 
precipitation in vitro even at the small concentrations (2-4 μ.Μ/1) found in 
urine and plasma. The inhibition of mineralization by pyrophosphate was 
explained as a blockade of crystal growth centres by adsorption of the 
compound on to the apatite crystals at growth sites. Hydroxyapatite coated 
with pyrophosphate is unable to act as a seed for the precipitation from 
supersaturated solutions. 
This type of phenomenon is well known for other substances. The growth of 
strontium sulphate crystals and calcium carbonate crystals for instance, can 
be blocked by surface adsorption of small amounts of polyphosphates, 
including pyrophosphate. 
Pyrophosphate was present mainly in the hydration shell and the surface 
layer of the crystals. Coating of apatite inhibits the growth as well as the 
dissolution of crystals. Pyrophosphate seems to act as some sort of a buffer 
around apatite crystals, impeding their formation as well as their dissolu­
tion. In later work [17] Fleisch et al. showed that pyrophosphate inhibits the 
transition of amorphous to crystalline calcium phosphate. 
The results from the in vitro experiments with pyrophosphate suggested, that 
pyrophosphate might be used for the treatment of several bone diseases for 
instance Paget's disease, dermatomyositis ossificans, senile osteoporosis 
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and others. Unfortunately, in vivo trials were not very successful due to the 
hydrolytic instability of pyrophosphate. 
In 1969 Francis used two pyrophosphate analogues: ethane-1-hydroxy-1, 
1- diphosphonate and dichloromethane diphosphonate and showed that 
these geminai diphosphonates, like pyrophosphate, inhibit the hydroxyapa-
tite crystal growth [52]. The general formula of geminai diphosphonates is 
shown in fig. 1.1. Geminai diphosphonates are characterized by a P-C-P 
link, while pyrophosphate has a P-O-P chain. Geminai diphosphonates are 
resistant to enzymatic hydrolysis in vitro as well as in vivo and can be 
administered by mouth without loosing their biological and chemical 
properties. Geminai diphosphonates inhibit hydroxyapatite crystal growth 
by strong adsorption on the microcrystallites of HA (possibly at screw 
dislocation sites) thus preventing the rapid addition of ions into the apatite 
lattice. 
Despite their relative simple structure, geminai diphosphonates have rather 
divers (bio)chemical properties which make them useful in a wide field of 
applications. 
By adsorption diphosphonates can act as crystal poisons in the same way as 
described for pyrophosphate. Based on this property diphosphonates are 
used as anticorrosives in industrial cooling water systems and as water 
softeners in clothes washing machines. 
Diphosphonates are excellent complexing agents, but generally their 
complex stability constants are smaller than the corresponding constants 
for EDTA. 
Diphosphonates can also act as surfactants [53,54]. This property explains 
their influence on phospholipid complexes as well as their peptizing effect 
on solid calcium phosphates [55]. 
The similarity between diphosphonates and pyrophosphates can cause a 
competitive blockade of pyrophosphatase enzymes [56]. 
2.2.1. Physicochemical aspects of diphosphonates. 
2.2.1.1. Adsorption. 
Originally the influence of diphosphonates on hydroxyapatite systems in 
vitro and in vivo have been attributed to their physicochemical properties. 
Interactions between diphosphonates and bone were explained in terms of 
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adsorption on the hydroxyapatite crystal. A lot of physicochemical work 
has been done to evaluate the diphosphonate-hydroxyapatite system. 
Neuman and Neuman [57] showed that hydroxyapatite crystals are able to 
bind at the surface a volume of water nearly twice that of the crystal itself. 
This bound water or hydration layer contains high concentrations of single-
and multicharged ions including calcium and phosphate. The ions in the 
hydration layer are freely exchangeable with isoions in the bulk solutioa 
Robertson et al. [55] showed that under the influence of diphosphonates, Ca 
ions from the incubation medium enter the hydration layer around the 
crystals. At the same time phosphate is lost from the hydration layer into the 
bulk solutioa The disappearance of calcium from the bulk solution was not 
caused by formation of an insoluble Ca-diphosphonate complex [58]. The 
order of potency of the tested diphosphonates and pyrophosphate was: 
Pyrophosphate > MDP > EHDP > DCMDP. 
Pak and Diller demonstrated that the multivalent ions magnesium and 
citrate also change the distribution of exchangeable calcium and phosphate 
[59]. 
Francis and Briner initially supposed that diphosphonates just as SnF2 
interfere with crystal growth by formation of an insoluble film on the crystal 
surface, which reduces dissolution of the crystal and also provides a surface 
which calcifies poorly [60]. In a later paper these authors stated that 
complex formation is not the mechanism of action, since neither citrate nor 
ethylenediaminetetraacetate produced a significant crystal growth inhibi-
tion effect [61]. Taves and Reedy proposed a different mechanism for 
polyphosphate binding [62] to hydroxyapatite, but this could also apply to 
diphosphonates. It was demonstrated that tripolyphosphate and pyrophos-
phate are adsorbed with their long axes parallel to the c-axis of the 
hydroxyapatite crystal in grooves, which are generally filled by HP042" and 
H20. By adsorption HP042" and H.O are displaced and growth of the 
crystal will be blocked at this plane. Diphosphonates do not have to cover 
the whole hydroxyapatite crystal surface in order to block effectively growth 
and dissolutioa Meyer and Nancollas showed that only 15% of the total 
surface area of the crystals was covered when the crystal growth was 
completely inhibited [63]. Prevention of crystal growth by monolayer 
coverage of the crystal surfaces by diphosphonate was impossible. The only 
mechanism whereby complete inhibition can be achieved by a relatively 
small concentration of additive is the adsorption at active growth sites on the 
crystal faces. 
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Jung et al. compared the binding of pyrophosphate and two diphosphonates 
by hydroxyapatite [64]. The binding is greatest for pyrophosphate, less for 
EHDP and least for DCMDP. These authors suggest that more than one 
type of binding sites exists for pyrophosphate and that the affinity of the first 
class of binding sites is in the order : EHDP > pyrophosphate > DCMDP. 
A separate class of binding sites is preferential for pyrophosphate. The 
common binding site is probably the one described by Taves and Reedy 
[62]. The inhibitory effect on the crystallization of calcium phosphate 
follows the same order as the affinity of the first class of binding sites: 
EHDP > pyrophosphate > DCMDP [65]. The inhibition of apatite 
dissolution follows the same order as the total binding capacity of apatite: 
pyrophosphate > EHDP > DCMDP [66]. 
2.2.1.2. Crystal growth inhibition. 
Eanes and Posner suggested that calcium phosphate precipitates in an 
amorphous form without any fixed stoichiometry and that a gradual 
recrystallization takes place to hydroxyapatite, which is thermodynamical-
ly the most stable form under physiological conditions [67]. Robertson 
defined the formation product of spontaneous precipitation as the activity 
product of octocalcium phosphate at the onset of spontaneous precipitation 
[68]. Above the formation product spontaneous precipitation of calcium 
phosphate will occur. This is the point at which homogeneous nucleation 
commences in the system Between the formation product and solubility 
product lies the metastable zone where nucleation is predominantly 
heterogeneous. Pyrophosphate and diphosphonates show no inhibiting 
effect above the formation product of spontaneous precipitation, but they do 
inhibit all the processes of crystallization in the metastable zone i.e. 
heterogeneous nucleation (collagen) and crystal growth. The amount of 
inhibition produced by each inhibitor increased according to the concentra-
tion of inhibitor added but there appears to be a concentration of inhibitor 
above which no further increase in activity is observed. In the case of 
heterogeneous nucleation, maximum inhibition is reached when the super-
saturation is close to the formation product of spontaneous precipitation. 
Pyrophosphate and diphosphonates markedly inhibit the conversion of 
amorphous calcium phosphate to crystalline hydroxyapatite. The mecha-
nism by which these inhibitors block the process of maturation probably 
involves adsorption of the inhibitor on the surface of the microcrystalline 
calcium phosphate. Similarly adsorption of the inhibitor on to active 
nucleation and growth sites is probably the important first stage in 
preventing heterogeneous nuHeation. 
Meyer and Nancollas [63] suggested that phosphonates inhibit crystal growth 
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by formation of strong, substitution inert chelate bonds with calcium ions 
present at kinks and dislocations on the crystal surface of hydroxyapatite. 
Hansen et al. studied the aggregation of hydroxyapatite crystals under 
several influences [69]. Mg2"1" had only a small effect, citrate inhibited 
aggregation, pyrophosphate was a strong inhibitor, while EHDP and 
DCMDP were even more potent Growth and aggregation seem to be 
governed by different factors, as is suggested by the fact that substances 
such as heparin, which have no influence on the crystal growth of apatite at 
the concentration tested, strongly inhibit aggregation. The inhibiting effect 
of citrate and diphosphonate was apparently not due to chelation of calcium 
since EDTA at similar concentrations had no effect on aggregatioa 
Meyer et al. demonstrated that the inhibition of calcium oxalate crystal 
growth by multidentate phosphonates is stronger at pH = 7 than at pH = 5 
[71]. At pH=5 EHDP is a much less active inhibitor than Ν,Ν,Ν,Ν -
ethylenediaminetetra(methylene-phosphonic acid), but at pH =7 the diffe­
rence in activity is much smaller. 
2.2.1.3. Peptization. 
Robertson and coworkers demonstrated that diphosphonates have a, so 
called, peptizing effect on the microcrystals of hydroxyapatite [55]. This 
means that crystalline calcium phosphate is dispersed, but not dissolved in 
the bulk solution, under the influence of diphosphonates. The dispersed 
particles are colloidal in nature. The order of peptizing ability is: 
DCMDP > EHDP > MDP. Pyrophosphate showed no peptizing ability. 
Bisaz et al. studied the disaggregation of hydroxyapatite crystals [70]. 
Disaggregation was induced by pyrophosphate, EHDP, DCMDP, heparin 
and citrate. Lactate had no effect The effect of pyrophosphate and the two 
diphosphonates might be caused by their strong binding to hydroxyapatite. 
DCMDP is the most active, EHDP less, and pyrophosphate the least The 
phenomenon of peptization showed the same order of activity. However, 
the binding on to hydroxyapatite is greatest for pyrophosphate, less for 
EHDP and least for DCMDP. Therefore, the difference in disaggregation is 
not explained only by the relative binding, but also by the activity of the 
compound itself. 
2.2.2. Diphosphonates in biosystems. 
Based on this physicochemical evidence a lot of work has been done to 
confirm these findings in biosystems. 
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Cabanela and Jowsey showed in rats that EHDP is able to prevent local 
immobilization osteoporosis, but is ineffective in preventing the systemic 
bone loss produced by cortisone administration [72]. These authors 
suggested that the most prevalent action of EHDP is the production of large 
amounts of osteoid and that EHDP has little effect on bone resorption, in 
contrast with what was expected from in vitro experiments [73]. These 
findings were not confirmed by others. 
In a study of the mechanism of biological calcification Luben et aL found, 
that during the early stage of calcification in a collagen containing matrix, 
intrafibrillar electron dense particles are formed [74]. During later stages, 
these particles appear to coalesce and serve as centers for the growth of 
hydroxyapatite crystals. MDP allows the formation of the noncrystalline 
electron dense particles but prevents subsequent growth of hydroxyapatite. 
MDP probably functions as a crystal poisoa During the period of dense 
particle formation the molar ratio of calcium to phosphate uptake is 1.0 -
1.3; the second stage of the process is characterized by H+ production and 
a gradual increase of the Ca/P ratio which approaches a value of 1.6 - 1.7. It 
seems that the electron dense particles are deposits of CaHPO.. The initial 
matrix bound product is induced from a soluble phase at an ion product 
which is 15 - 100 times smaller than is required for spontaneous precipita-
tioa 
Russell et al. found that at low doses (0.01 - 1 mg P/kg/day s.c.) EHDP and 
DCMDP similarly reduce both resorption and mineralization rates [75]. 
EHDP and DCMDP reduce bone turnover without significantly changing 
the amount of calcium retained by the bone. At higher doses (10 - 30 mg 
P/kg/day S.C.) EHDP impaired bone growth and inhibited mineralization of 
new cartilage and osteoid. DCMDP did not impair mineralization at 
equivalent doses. No evidence was found that EHDP causes osteoid to 
appear by increasing the rate of synthesis of bone matrix. The appearance of 
osteoid at the higher doses of EHDP is due to a relatively greater 
suppression of matrix mineralization compared with matrix synthesis. 
Different diphosphonates appear to differ in their effects on bone. 
Schenk et al. [76] confirmed these findings but also showed that DCMDP at 
high doses (10-30 mg P/kg/day s.c.) produces a marked impairment of 
normal metaphyseal remodelling, with persistence of columns of calcified 
cartilage. This impairment of remodelling is due to reduced resorption. At 
high doses of DCMDP bone resorption was also shown to be inhibited at the 
periosteal surface in the metaphysis. While EHDP is stronger than 
DCMDP as an inhibitor of crystalline dissolution in vitro, in vivo DCMDP 
is stronger against bone resorption. This reversed order suggested that 
diphosphonates in vivo might work by other than just physicochemical 
mechanisms e.g. by effects on cell metabolism. 
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Minkin et al. demonstrated in tissue culture that DCMDP causes a 50% 
reduction of hydroxyapatite turnover while EHDP causes only a 20% 
reduction at a concentration of 10 jug P/ml culture medium [77]. The 
hydroxyproline turnover was a measure of degradation of collagea The 
50% decrease of hydroxyproline turnover under the influence of DCMDP 
suggests a profound effect on the activity of the osteoclasts in the system 
under consideration. 
Each diphosphonate level which inhibits resorption also decreases hydro-
xyproline turnover and formation. This was most evident for DCMDP at a 
concentration of 10 ju.g P/ml. It is likely that DCMDP at this concentration 
is toxic to the bones in the culture medium. The difference in effectivity 
between EHDP and DCMDP could possibly be explained by the fact that 
EHDP is more tightly bound to hydroxyapatite than is DCMDP. This 
might account for a difference in free concentration in the extracellular fluid 
of the bone and hence for a difference in effects on cellular metabolism. 
Rosenblum confirmed the conclusions on EHDP [78]. Low doses of EHDP 
(0.01 - 1 mg P/kg/day) reduce bone turnover by inhibition of resorption. At 
high doses (10-30 mg P/kg/day) no dramatic effect on the content or 
composition of collagen was found. EHDP exerts both inhibition of 
mineralization and resorption simultaneously, but to varying degrees. The 
propensity for these two effects appears to be dose dependent, as well as 
dependent upon the duration of treatment and the growth state of bone. No 
evidence was found for an EHDP-induced stimulation of bone matrix 
formation. 
Rosenblum, McCuskey et al. used a metallic chamber implanted in bone for 
microscopic examination of living bone in situ [79]. Following low doses of 
EHDP (smaller than 0.1 mg P/kg/day) no toxic effect on the bone in the 
chambers was seen, but there appeared to be an increase in bone formation 
as compared to controls. Higher doses (2.5 mg P/kg/day) were not toxic to 
bone cells but thick osteoid seams formed on the bone in the chambers. No 
osteoclasts were found associated with the bone, apparently due to the 
coverage of bone surfaces by osteoid. These results confirm the conclusion 
that EHDP at relatively large doses inhibits the mineralization process. The 
fact that no osteoclasts could be found in structurally organized osteoid 
suggests that the deposition of mineral is a prerequisite, or perhaps a signal, 
for appearance of osteoclasts. 
Plasmans studied the influence of EHDP on ectopic bone tissue. For this 
purpose he used a bone induction model evolved by Urist. EHDP was 
shown not to influence the induction process itself, but the tissues obtained 
differed fundamentally from those in untreated animals. Under the influen-
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ce of EHDP large areas of chondroid structures are found and the osteoid 
formed shows qualitative differences from those in untreated implants. 
EHDP blocks the mineralization and remodelling of formed tissues and an 
interference with the cellular metabolism is among the real possibilities 
[102]. 
Weisbrode et al. [80] studied the effect of DCMDP in thyroparathyroidec-
tomized rats. As expected, a decrease in remodelling of metaphyseal bone 
was found at doses of 1 - 2.5 mgP/kg/day. Bone magnesium concentration 
and alkaline phosphatase activity were significantly increased. Calcium and 
phosphorus concentrations were decreased. No change in bone cell 
morphology was seea The effect of DCMDP on metaphyseal remodelling 
appears independent of calcitonine or PTH (parathyroid hormone). 
Morgan et al. reported on the effect of PTH, calcitonine and DCMDP on 
bone resorption, lactate production and phosphatase content in mouse 
calvaría in culture [81]. PTH increased the rate of bone destruction and the 
production of lactate, citrate and phosphatase enzymes. DCMDP dimi-
nishes the effect of PTH on bone resorption and lactate production, but has 
no effect on alkaline phosphatase and pyrophosphatase. Instead, DCMDP 
prevented the rise of acid phosphatase under the influence of PTH. 
It is possible that these effects of DCMDP on cell metabolism could be a 
consequence of the effect of DCMDP on mineral dissolution, perhaps 
through local changes in calcium concentration. Another possibility is that 
DCMDP produces some of its effects by direct actions on cell metabolism. 
A direct influence on cellular metabolism could not be provea 
In an interesting paper Hill et al. reported on the indirect inhibition of the 
biosynthesis of 1,25-dihydroxycholecalciferol by EHDP in rats [82]. 
Inhibition by EHDP of mineral deposition in the skeleton conditions the 
development of hypercalcemia and hyperphosphataemia, provided that the 
intestinal uptake of calcium and phosphate is not diminished. Hypercal-
ciemia may inhibit the 1-hydroxylation of 25-hydroxycholecalciferol in the 
kidneys either by suppressing PTH secretion or through increasing the 
calcium concentration within the renal cell. Lack of 1,25-dihydroxychole-
calciferol impairs the active intestinal calcium uptake. 
The results described by Hill et al. suggest that also other biological effects 
of diphosphonates could be attributed indirectly to their physicochemical 
properties. 
Influence of physicochemical properties of diphosphonates on the activity 
of alkaline pyrophosphatase was demonstrated by Wöltgens, Bonting and 
Bijvoet [56]. Wöltgens and Bonting found that Zn 2 + and possibly Co 2 + can 
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act as a cofactor of an alkaline pyrophosphatase enzyme (pH optimum 
= 8.7) from the molars of 3-day old hamsters [83]. Mg24" increased the 
pyrophosphatase activity of this enzyme, probably because magnesium 
pyrophosphate is the true substrate for the enzyme. MDP, EHDP, and 
DCMDP inhibit the enzyme activity primarily due to their complexation 
with the cofactor for the enzyme. For EHDP the inhibition is, moreover, in 
part due to a competition between magnesium pyrophosphate and Mg-
EHDP. It was suggested that diphosphonates, in addition to inhibiting 
hydroxyapatite crystallization directly, may also inhibit mineralization in 
vivo through their effect on the pyrophosphatase activity. 
Felix et al. confirmed this conclusion for lysosomal enzymes [84]. These 
authors compared the effects of DCMDP and EHDP on some lysosomal 
hydrolases derived from rat liver and bone. EHDP showed no inhibition of 
the enzymes under investigation, except at high concentrations. DCMDP 
strongly inhibited most of the enzymes. There is some degree of correlation 
between the ability of an individual diphosphonate to inhibit acid hydrolases 
and bone resorption, suggesting that at least part of their effect in vivo may 
be explained by a direct effect on acid hydrolases. 
2.2.3. Cellular effects of diphosphonates. 
Most of the effects of diphosphonates described in the preceding sections 
could be explained at least in part by the physicochemical properties of 
diphosphonates. During the first few years following their introduction, all 
biological effects of diphosphonates were explained in terms of physico-
chemical reactions. More recently an increasing number of papers is 
devoted to direct influences of diphosphonates on cellular metabolism. 
Guilland et al. [85] reported on the delayed release of calcium from rat 
kidney mitochondria under the influence of diphosphonates. EHDP 
showed a greater activity than DCMDP. The authors suggested that 
diphosphonates can influence the transport of calcium through a membrane 
in vitro. This could not be proven by the results of their experiments. A 
physicochemical explanation seems to fit better with the experimental 
outcome. 
More convincing evidence of a possible influence of diphosphonates on 
membrane transport has been presented in an interesting paper by Boskey et 
aL [86]. These authors demonstrated that diphosphonates not only act as 
hydroxyapatite crystal poisons but also as surfactants which probably 
change the nature of the lipid micelle and the charge and conformational 
properties of the lipid molecules. It was shown that EHDP and DCMDP 
are able to block lipid induced hydroxyapatite formation in calcium 
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phosphate solutions. The diphosphonates prevent the acid phospholipids 
from forming Ca-phospholipid-P04 complexes, the intermediates in lipid 
induced calcification processes [87]. These findings suggest that the in vivo 
action of diphosphonates may be, in part, lipid related. This is confirmed, 
for example, by the fact that diphosphonates prevent cholesterol induced 
atherosclerotic plaque formation in experimental animals [88]. Boskey and 
coworkers showed that more lipid was dispersed in the presence of 
diphosphonates than in controls. EHDP was more effective than DCMDP. 
EHDP and DCMDP had the same general effect on formation of 
hydroxyapatite as commercial surfactants in the presence of phospholipids. 
These authors also suggested that the peptization effect of EHDP on solid 
calcium phosphate should be attributed to its surface activity. The effects of 
diphosphonates on complexed phospholipids explain the postulated in-
fluence of EHDP on the membrane transport of cells involved in minerali-
zation complexed phospholipids are components of both the membranes of 
chondrocytes and extracellular matrix vesicles, isolated from epiphyseal 
cartilage. 
Larsson reported a general inhibitory effect of EHDP on the syntheses of 
mucopolysaccharides [89]. 
Most striking indications of direct cellular effect of diphosphonates have 
recently been reported by the group of Fleisch [90,91]. Experiments were 
done on connective tissue cells in culture. Diphosphonates show only minor 
effects on cellular growth. The potassium content in the cells was 
diminished only by the highest concentration of DCMDP (Ü.25 mM). The 
diphosphonate uptake in the cells is slow, linear with time, and dependent on 
the concentration in the medium Both EHDP and DCMDP, in a dose 
dependent fashion, markedly inhibited glycolysis and lactate production, 
DCMDP being more potent than EHDP. An increase in the glycogen 
content in the cultured cells was found. This was not due to the glucose 
concentration of the medium. The site of action of the diphosphonates 
remained unknown. It was concluded that the effectiveness of the diphos-
phonates could be attributed to the combination of two properties: 1 ) their 
physicochemical propensity to localize selectively in bone; 2) their ability 
to inhibit lactate production in cells. 
2.2.4. Conclusion [92]. 
Diphosphonates inhibit both the formation and dissolution of calcium 
phosphate crystals in vitro by binding to the crystal surface. In several 
experimental models the diphosphonates proved to be effective in preven-
ting both ectopic and normal calcification in vivo. This latter effect was 
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much less marked for DCMDP than for EHDP. It was also noted that many 
diphosphonates inhibit bone resorption in vivo. In this respect DCMDP 
was much more effective than EHDP. Today the impairment by diphos-
phonates of mineralization is attributed for the main part to the physico-
chemical properties of the diphosphonates. 
When various diphosphonates were compared, no correlation was found 
between the actions on crystal dissolution in vitro and those on bone 
resorption in vivo. 
Although this might be due to differences in the pharmacokinetics of the 
compounds, it seems likely that other mechanisms, especially cellular ones, 
come into play. Indeed, recent studies demonstrate that the diphosphonates 
have profound effects on cellular metabolism. The reason why diphospho-
nates do not effect tissues other than bone and teeth is probably their rapid 
elimination from the blood pool and their attachment to the mineral of bone 
and teeth. 
2.3. MODELS FOR THE UPTAKE OF TECHNETIUM 
DIPHOSPHONATES. 
Three models have been described to explain the uptake of technetium 
labeled diphosphonates in bone: 
- The hydroxyapatite model; 
- The collagen model; 
- The enzyme model. 
2.3.1. The hydroxyapatite model. 
In this model hydroxyapatite is the agent which binds the technetium 
activity after administration of technetium diphosphonate. Some aspects of 
this model have already been described in section 1.3. The data described in 
section 2 of this chapter make it indisputable that diphosphonates are able to 
bind to hydroxyapatite. Despite the work of Cox [93], it is still believed that 
the specificity of the technetium labeled bone seeking preparation is 
conferred by the phosphonate moiety. Technetium as pertechnetate even 
when mixed with diphosphonate localizes mainly in the thyroid and gastric 
mucosa and not in bone, so a reduction step is required. It is supposed that 
the reduced pertechnetate has some kind of interaction with the diphospho-
nate so that this can act as a carrier. For reduction of pertechnetate, 
preferably stannous salts are used. In the absence of suitable ligands or 
when an excess of stannous salt is added, the reduced pertechnetate is 
brought into a colloidal form, probably as a result of stannous hydrolysis, 
and after injection all activity will be found in liver, spleen and bone marrow. 
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In the presence of both the reducing agent and the suitable diphosphonate 
however, the radioactivity either localizes in the bone or is rapidly cleared 
from nonosseous tissues via the kidneys. As was described in section 1.3, 
the labeled diphosphonate seems to move to the bone as a single entity. 
V. Langevelde et al. [94] used hydroxyapatite suspensions to evaluate the 
binding of technetium diphosphonate. The results were compared with 
scintigraphical data in rats. Pretreatment with EHDP diminishes the uptake 
of Tc-EHDP in hydroxyapatite (vitro) and bone (vivo experiments). 
Microautoradiography showed that technetium is only taken up in the bone 
matrix. More than 90% of the added technetium in Tc-EHDP was taken up 
by the hydroxyapatite crystals within 10 mia incubation time. The authors 
suggest that technetium binds to hydroxyapatite separately from the 
diphosphonate. From the results of pretreatment with EHDP it might be 
concluded that EHDP and Tc-EHDP compete for the same binding sites. 
For diphosphonates the target is definitely the hydroxyapatite. 
Tofe and Francis [95] also demonstrated some kind of competition between 
technetium and EHDP for hydroxyapatite binding sites. 
An independent behaviour of technetium and diphosphonate in bone is also 
supported by McRae et al. [96] who showed that EHDP is expelled from its 
complex with technetium by sodium gluconate. 
It is undeniable that hydroxyapatite is able at least in vitro to bind 
technetium from a technetium labeled diphosphonate. 
2.3.2. The collagen model 
This model was introduced by Rosenthall et al. [97]. These authors 
observed that blood flow did not always correlate with bone uptake. The 
experiments designed to evaluate the biochemical basis for the uptake of 
technetium diphosphonates suggested that pertechnetate as well as techne­
tium diphosphonate has a great affinity for immature collagea Immature 
collagen is supposed to be present in zones of elevated bone turnover. 
Similar results from similar experiments have been reported by de Jonge 
and Oldenburg [98]. De Jonge and Rosenthall both used sagitally dissected 
bone halves which were either demineralized by treatment with hydrochlo­
ric acid or heated at 400° С to remove the organic matrix. The pieces of 
bone were incubated for 30 mia with the preparations under investigatioa 
It is interesting to note that EDTA treatment for demineralization causes 
much less uptake of To-pyrophosphate than treatment with hydrochloric 
acid. It was claimed that partial dissolution of the collagen molecule 
liberated reactive groups. The severe treatment of the bone pieces makes it 
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difficult to believe in the validity of this experimental system. The finding 
that pertechnetate in this system follows the same trend as technetium 
pyrophosphate makes it even less likely. Moreover, a direct interaction 
between diphosphonate and collagen has never been described. 
2.3.3. The enzyme model 
Sites of active bone formation are characterized by high levels of alkaline 
phosphatase. This fact and the knowledge that diphosphonates are able to 
interfere with phosphatase enzymes encouraged Zimmer et aL [99] to 
propose that technetium diphosphonates localize in bone through interac-
tion with phosphatase enzymes. 
Bone is not the only site with high levels of phosphatase in the human body. 
High levels of alkaline phosphatase are also found in the liver and the 
prostate containes high levels of acid phosphatase. Nevertheless, techne-
tium diphosphonates are not significantly taken up by either of these organs. 
Many bone diseases are characterized by high serum levels of phosphatase 
enzymes. This would cause a delayed clearance of technetium diphospho-
nate if the specificity was primarily a reaction with the enzyme. This has not 
been observed. 
Wöltgens showed (see section 2.2) that the inhibition of phosphatase by 
diphosphonates is primarily through complexation with the enzyme's 
metal cofactor and not with the enzyme itself. 
2.3.4. Discussion. 
The uptake of diphosphonate by the mineral phase of bone is undeniable, as 
it has been proven in vivo ( autoradiography) [ 100] and in vitro ( see section 
2.2). This is also confirmed by Rosenthall et al. (section 2.3.2). Technetium, 
when used to label diphosphonates, localizes in the same region as the 
diphosphonate: at the interface of osteoid and the mineralized bone [101]. 
No activity is seen in the osteoid. Technetium from the labeled bone seeking 
radiopharmaceutical is also taken up by hydroxyapatite in vitro. 
It seems very unlikely that the diphosphonate would bind to the mineral 
phase of bone, while technetium would couple to collagen; this would 
require a désintégration of the technetium diphosphonate entity and a 
migration of reactive reduced technetium to another bone compartment In 
the light of the fact that hydroxyapatite is able to bind reduced technetium, 
this migration seems very unlikely. 
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Some objections have already been raised against the enzyme model. 
Another argument against interaction of technetium diphosphonate with 
phosphatase enzymes is its relative small concentration ( 10"9 -10~'1 M) in 
the presence of substrate concentrations of 10"3 - 10"6 M. The interaction of 
diphosphonates and the substrate with the phosphatase enzymes have been 
shown to be comparable in strength. So the substrate will effectively 
overwhelm the interaction of enzyme with technetium diphosphonate. 
In conclusion: 
Hydroxyapatite is the only species in bone that has been definitely 
shown to be able to bind technetium diphosphonate in vivo and in 
vitro. The other models have been developed because of a lack of 
understanding of the interaction of technetium diphosphonate with 
bone and soft tissue. Many objections can be raised against the 
collagen as well as the enzyme model 
For better understanding of the interaction between technetium 
diphosphonate and bone it was thought more appropriate to in-
vestigate the apatite model further, rather than to develop a new 
model. 
This is the main objective of the work that will be described in the 
next chapters. 
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CHAPTER 3 
ADSORPTION EXPERIMENTS 
3.1. INTRODUCTION 
In the preceding chapter it was concluded, that the young amorphous 
hydroxyapatite is the target species for technetium diphosphonates in bone. 
To simulate the uptake process of technetium diphosphonates in vivo, it was 
decided to carry out adsorption experiments with synthetic amorphous 
hydroxyapatite. The adsorbent in these experiments should closely resem-
ble the apatite in bone. 
Neuman and Neuman [ 1 ] mentioned some of the characteristics of the 
mineral phase of bone: spec, surface area 60 - 65 m2/g; Ca/P ratio 1.5 - 1.8; 
young hydroxyapatite is amorphous. We used a finely divided synthetic 
calcium phosphate preparation, which meets these criteria. The incubation 
medium in the adsorption expriments should resemble the extracellular 
fluid surrounding the bone tissue. To meet biological conditions in some 
adsorption experiments human serum albumin (15-30 mg/ml) in 0.9% 
NaCl was used as incubation medium. It was thereby assumed that the 
albumin concentration in the extracellular fluid in bone is half the 
concentration in blood plasma. The NaCl concentration and the pH also 
met in vivo conditions. 
Adsorption affinity of organic molecules for hydroxyapatite is not unknown. 
Hydroxyapatite is, for example, used in chromatographic separations of 
complex compounds such as serum proteins. 
Adsorption studies of amino and carboxylic acids have been reported 
[2,3,4]. The binding of pyrophosphate and diphosphonates by hydroxyapati 
te crystals has also been described [5]. 
Calcium hydroxyapatite is a good adsorbent for a wide range of ions, small 
molecules, and macromolecules. 
Several literature references concerning adsorption experiments of diphos-
phonates in suspensions of hydroxyapatite have already been mentioned in 
chapter 2 (see section 2.2.1.1.). 
Van Langevelde et al. described adsorption experiments with Tc-99m-
EHDP, designed to evaluate the role of Ca2+ in the binding mechanism of 
technetium-99m-diphosphonates to bone [6]. The conclusion was drawn 
that technetium is not dissociated from EHDP in binding to hydroxyapatite. 
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It was postulated that calcium plays an important role in bone labeling with 
technetium EHDP and that in fact the EHDP-Ca-Tc complex is the binding 
agent This hypothesis could not be supported by in vivo experiments. 
It is the purpose of the study, described in this chapter, to elucidate the 
adsorption behaviour to hydroxyapatite of technetium, tin and diphospho-
nates in relation to each other. 
Three diphosphonates were selected for the adsorption experiments: MDP, 
EHDP, and pCPMDP (nrs. 1,6, and 4 in table 4.1.; cf. figure 1.1.: MDP: 
ІЦ = ¿2 = H; EHDP: R, = CH3, R^ = OH; pCPMDP: Rj = H, 1^ = 
p-chloro-phenyl). 
These diphosphonates were chosen because of their markedly distinguished 
biological and complexing properties (see chapters 4 and 5). Because it has 
to be expected that the charge of the diphosphonate molecules (see chapter 
5) and the apatite surface (pH of zero charge 7.1 - 7.6) varies with the pH, 
corresponding adsorption experiments were carried out at pH = 6.5 andpH 
= 7.5. 
Separate adsorption isotherms were obtained by direct measurements for 
the three labeled components of the Tc-( Sn)-diphosphonate complex. An 
interpretation of the results, however, is best achieved by the use of a 
theoretical adsorption model. Within the limited aim of this study we have 
not tried to interprete the adsorption data in terms of the many theoretical 
adsorption models available. Some of our results however, fit nearly into the 
simple Langmuir adsorption equatioa 
3.2. THE LANGMUIR THEORY 
Though an extensive treatise on this subject can be found in every handbook 
on surface chemistry, a short compilation, will be given here. 
The Langmuir theory is based on the assumption, that molecules are 
adsorbed on fixed equivalent sites and are subjected to negligible forces of 
attraction or repulsion in directions parallel to the surface of the adsorbent 
The heat of adsorption is assumed to be independent of the fraction of the 
surface covered. Langmuir postulated, that adsorption occurs as a mono-
molecular layer. The equilibrium set up between adsorbent and adsórbate is 
regarded as a dynamic one, such that the rate of adsorption equals the rate of 
desorptioa 
If at concentration с the fraction of sites occupied is Sj and the fraction of 
sites empty is SQ (so that S j + S 0 = 1), then the rate of adsorption is KjcS0, 
and the rate of desorption is K-S,. 
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Then at equilibrium: 
K,cS0 = K2S1 (3.1) 
Kjcil-S,) = K2SL (3.2) 
K,c (3.3) 
s = 1 
K l C + K 2 
If now X is the adsorption in moles per gram of adsorbent at concentration c, 
then S, = X/X . 
1 m 
χ (Viyc (3.4) 
X (K./K-)c + 1 
IfK,/K2 = K, 
X
 =
 Kc 
X
m
 Kc + 1 
Kc + 1 _ с 
K-X X 
m 
(3.5) 
(3.6) 
+ = -S- (3.7) 
X K-X X 
m m 
The graph of с/X against с should give a straight line. 
X is the maximum adsorption capacity per gram of adsorbent The 
parameter К reflects the affinity of the adsórbate molecules for the 
adsorption sites. 
Although К (eq. 3.7), as an affinity parameter, has no theoretical 
significance, when applied to adsorption from solutions, we used the value 
of К to compare the affinities of the three diphosphonates in corresponding 
experiments. 
From the values of the slope and the intercept of the graph of c/X against с 
(equation 3.7) the parameters X and К can be calculated. 
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If the adsorption data plotted according to the Langmuir equation (3.7) 
render a straight line, these data fit into the Langmuir equatioa Frequently, 
the experimental data deviate considerably from equation 3.7 and this has 
been attributed to the nonuniformity of the surface, multilayer adsorption 
and other phenomena. 
The Langmuir theory was in fact developed for the explanation of 
adsorption in solid-gas systems, where the concentration of the gas at the 
surface of the solid is large, compared with the concentration in the free gas 
and thus the adsorption measurement is relatively easy. 
When a pure liquid is placed in contact with a solid, the concentration of the 
liquid at the surface will be less obvious than in gas-solid systems, 
essentially because the concentration is already so high in the free liquid. 
Very accurate measurements are required, unless the specific surface of the 
solid is large. 
The problem is quite different, when the liquid phase contains two 
components, e.g., if it is made of two miscible liquids or if it is a solution of a 
solid in a liquid. Both components will be adsorbed by the solid to different 
extents so that the mole fraction in the bulk of the solution will change. 
Kipling [7] has emphasized the necessity for distinguishing the term 
"adsorption" as applied in studies with gases and with solutions. The 
adsorption isotherm of a gas refers to the actual amount of a substance 
adsorbed by the unit mass of a solid 
However, the adsorption isotherm for a solution refers to a change in 
concentration in the solution and is a measure of the difference in the 
amount of solute and solvent adsorbed It is a composite isotherm and a 
great deal more can be learned about the system if the isotherm can be 
resolved to show the separate adsorption of each component In such a 
composite isotherm the ordinate represents the apparent adsorption of a 
particular component, uncorrected for the adsorption of the other, and is 
calculated from the change in the concentration ofthat component brought 
about by adsorption. This isotherm is called an isotherm of concentration 
change and represents the combined adsorption of the two components. 
IIQ· Δ Ν , / m is plotted against Nj , where nQ is the total number of moles 
originally present, Nj is the mole fraction of component 1, and m is the 
weight of adsorbent in grams. From an isotherm of concentration change the 
individual adsorption isotherms of each component (n s against Ν , where 
η
s
 is the number of moles of component i adsorbed on one gram of solid and 
N ( is the mole fraction of that component) can be calculated 
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In dilute solutions of one component the isotherm of concentration change 
often resembles the low pressure region of the adsorption isotherm of a gas 
on a solid. 
The data are often found to fit, over restricted ranges an equation of the 
Langmuir type (3.7). The apparent adsorption X is equal to the experimen­
tally determined quantity iu · ANj/ra An isotherm, which approximates to 
the Langmuir equation, is often taken to denote the formation of a completed 
monolayer. This conclusion is sound if, the solute happens to be adsorbed to 
the nearly complete or complete exclusion of the solvent, but this is an 
unusual case, because for a dilute solution one would in general expect the 
adsorption of the solvent to be large. 
It is perhaps surprising that, if the isotherms of both solute and solvent are of 
the Langmuir type and are comparable in scale, the isotherm of concentra­
tion change for dilute solutions is almost identical with the individual 
isotherm of the solute itself, despite the extensive adsorption of the solvent 
The next equation can be derived [8]: 
η Δ Ν , 
ο 1 
m V - N 2 + n^-Nj (3.9) 
η Δ Ν , 
ο 1 
m— 
= ( η , 5 + η^) N j N 2 (3.10) 
Ν 2 =0 
Fig. 3.1. Two Langmuir adsorption isotherms of a solvent and a solute. 
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From figure 3.1. it can be seen that at small concentrations of the solute 
(N2—1 ) njVNj is much greater than n^/Nj, for the former is equal to the 
slope of the isotherm of component 1 near its origin, whereas the latter is the 
slope of the chord from the point N 2 = 0 to a point near N, = 1. 
Thus: 
η ΔΝ, n, s 
о 1 1 
m 
or, since N2— 1 
N Ν , · Ν 2 О · " ) 
'1 
η ΔΝ, 
-2. 1 ^ n , s (3.12) 
m ' 
so that the apparent adsorption calculated from the concentration change is 
nearly equal to the true adsorptioa 
If the solute has a limited solubility (c0) in a solvent, it is best for 
comparative purposes to plot the isotherm with c/cQ rather than with с or 
N., as abscissa. 
3.3. EXPERIMENTAL ASPECTS 
The adsorption experiments can be divided into five groups: 
1. experiments to estimate the equilibration time. 
2. adsorption experiments with EHDP. 
3. adsorption experiments with EHDP and stannous tía 
4. adsorption experiments with EHDP and technetium with and without 
tia 
5.adsorption experiments with MDP or pCPMDP with and without 
technetium and tia 
Hydroxyapatite. 
Most of the experiments were conducted using a calcium phosphate 
preparation (Merck nr. 2148) showing an amorphous X-ray diffraction 
pattern. Chemical analysis yielded a Ca/P ratio of 1.76. The specific 
surface area, determined by gas adsorption, was 65 m2/g. 
For one reference experiment (exp. nr. 8) another hydroxyapatite prepara-
tion was used (Merck nr. 11490). This preparation also showed an 
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amorphous X-ray diffraction pattern. Chemical analysis yielded a Ca/P 
ratio of 1.54. The specific surface area was less than 0.5 m2/g. 
Solutions. 
Most experiments were carried out with EHDP-Na^^HjO as the 
disphosphonate. As a tracer C-14-EHDP (0.0958 jnCi/jnM) was added A 
stock solution of C-14-EHDP in water was prepared (24.8 μΜ/ml, 2.38 
juCi/ml). EHDP and C-14-EHDP were kindly supplied by Henkel & Cie, 
Düsseldorf, FRG. MDP as free acid was purchased from Sigma Chemical 
Company, SL Louis, USA (Sigma nr. M 9508). P-32-MDP was prepared 
by irradiating MDP with neutrons in a nuclear reactor. The dry product was 
dissolved in water and a small amount of dihydrogen phosphate was added. 
The solution was fractionated on a Biogel P2 column (30X1 cm). Elution 
was performed with 0.1 M acetate buffer (pH=4.8). MDP fractions were 
identified by paperchromatography, using an heptamolybdate solution and 
autoradiography as indicators. 
The precise concentration of MDP in the collected fractions was not known, 
but the amount of MDP in the tracer solution was small compared to the 
total amount of MDP used in an adsorption experiment 
pCPMDP as acid was kindly supplied by Henkel & Cie., Düsseldorf, FRG. 
Concentration measurements of this diphosphonate were performed by 
means of a spectrophotometer, the UV absorbance was determined at 264 
nm. 
As tin source stannous sulphate (Merck nr. 7823 p.a.) was used. Sn-119m-
stannous chloride in 4 M HCl (75-400 mCi/g tin, NEN NEZ-099B) was 
added as a tracer. The original solution was diluted with 0.1 N HCl to a 
volume of 2 ml/250 μΏ. 
Tc-99m-pertechnetate was freshly eluted from a Mo-99/Tc-99m generator, 
purchased from New England Nuclear, Boston, USA. Тс-99-pertechnetate 
was purchased from the radiochemical centre Amersham, UK (TCS.l, 
NH 4 Tc0 4 in 0.1 M NH4OH, 616 mCi/ml, 36 mgTc/ml). 8.2 ml of the 
pertechnetate solution was made up to a volume of 100 ml with distilled 
water. 
In some experiments human serum albumin (HSA, Institut Mèrieux S. A, 
Lyon, France) was added to simulate biological conditions and to maintain 
the pH of the incubation medium. In media containing HS A saline (0.9% 
NaCl solution) was used as solvent instead of water to prevent the 
precipitation of protein. The influence was studied of the presence of 
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albumin on the adsorption of diphosphonate (EHDP) (experiments 7,9, and 
10). The albumin adsorption on hydroxyapatite in diphosphonate solutions 
was studied in experiment 19. 
In some experiments instead of albumin, 0.1 M tris buffer (tris-(hydroxy-
methyl)aminomethane, Fluka nr. 93350) was added to maintain the pH. 
Equilibrations. 
For each adsorption experiment a stock solution of adsórbate was prepared 
Seven different concentrations were made with the same solvent as the one 
used for the stock preparation, according to the following scheme: 
a 5 ml stock solution 
b 4 Vi ml stock solution-l- Vi ml solvent 
с 4 ml stock solution-l- 1 ml solvent 
d 3 ml stock solution+ 2 ml solvent 
e 2 ml stock solution+ 3 ml solvent 
f 1 ml stock solution+ 4 ml solvent 
g Vi ml stock solution-b AVi ml solvent 
Of every sample the pH was determined. 
Three milliliter of each sample was incubated under nitrogen gas with 100 
mg of hydroxyapatite. The precise amount was determined by weighing. 
The temperature wss kept at 37°, unless otherwise indicated. Of each 
sample Vi ml was used as reference solution in the concentration measure­
ments. 
During the incubation period the vials were mounted on an end-over-end 
shaker to achieve good mixing, but preventing foam formation. 
After the incubation time the contents of the penicilline vials were filtered 
over a millipore filter (Millex, 0.22 μ, The Millipore corporation). The pH 
of the filtrate was measured. Half a milliliter of the filtrate was acidified with 
Vi ml 0.5 N HCl in order to prevent the precipitation of diphosphonate in 
liquid scintillator containing solutions. When C-14 or P-32 had to be 
measured, 10 ml of a liquid scintillator (Instagel, Packard) was added. 
The standards were treated and counted in the same way as the filtrate 
samples. 
Concentration measurements. 
EHDP concentrations were measured by C-14 counting in a liquid 
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scintillation counter (Packard Tri-carb spectrometer) with a standard C-14 
channel. 
No efficiency corrections were made. No quenching could be observed in 
the C-14 measurements. 
MDP concentrations were measured by P-32 counting in a liquid scintilla­
tion counter, as well as in a sodium iodide scintillation counter (Packard 
5220 gamma spectrometer). The results of the two different counting 
techniques were comparable. 
pCPMDP concentrations were measured with a spectrophotometer (Pye-
Unicam SP8-500) at 264 nm. 
Tin concentrations were measured by Sn-119m counting with a sodium 
iodide scintillation counter at26 keV. Sn- 119m causes a large contribution 
to the counting result in the C-14 channel. This contribution was estimated 
for each adsorption experiment with two Sn-119m standard samples. The 
correction factors were averaged. With help of these factors it was possible 
to obtain correct results for the EHDP and tin concentrations in the same 
sample. 
Technetium concentrations were measured by counting Tc-9 9 m at 140 ke V 
with a sodium iodide scintillation counter. Tc-99 was not counted directly, 
but instead Tc-99 m was added as a tracer to facilitate the measurements. 
Because of its short half-life time (6 hrs), Tc-99m should be measured 
immediately after finishing the experiment A few days later the other 
radioisotopes in the sample can be counted without contributions of Tc-
99m. 
Calculations. 
The post-incubation concentration (c) was calculated by multiplying the 
pre-incubation concentration (c ) with the ratio of the counting results of 
e^ual amounts of incubated and nonincubated solutions: 
R 
posi 
С 
Ρ
0 5
' (3.13) 
R p r e 
pre 
The adsorbed amount of EHDP (q) is calculated by multiplying the 
incubated volume (V) with the difference in concentration, caused by 
adsorption. 
q = V - ( c p r e - c ) (3.14) 
Because 100 mg of hydroxyapatite was used as adsorbent, X=10q. 
X = 10V· ( c p r e - c ) (3.15) 
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Stock solutions and incubation times. 
Group 1. Estimation of the equilibration time for EHDP. 
No dilution series were made. 
Each sample in an experiment had the same pre-incubation concentration. 
The incubation times differed The concentration range for EHDP was 
between 0.1 and 0.0001 M. 
Experiment 1. 
To 20 ml 0.0444 M EHDP solution 0.66 ml 1 N NaOH was added to 
adjust thepHto7.4 and0.05 ml C-14-EHDP solution was added as tracer. 
Six samples (3 ml) were incubated between 0.25 and 116 hr. 
Experiment 2. 
To 20 ml 0.0089 M EHDP solution 0.05 ml C-14-EHDP solution was 
added The pH was adjusted to 7.4 with 0.15 ml 1 N NaOH. Incubation 
times for six samples varied between 1 and 118 hr. 
Experiment 3. 
To 20 ml 0.0889 M EHDP solution 0.91 ml 1 N NaOH was added to 
adjust the pH to 7.4 and0.05 ml C-14-EHDP solution was added as tracer. 
Incubation times for five samples varied between 18 and 137 hr. 
Experiment 4. 
To 40 ml distilled water 0.1 ml C-14-EHDP was added and with 0.06 ml 1 
N NaOH the pH was adjusted to 7.65. Incubation time: 0.5-144 hr (12 
samples). 
Experiments. 
To 25 ml 0.0009 M EHDP solution 0.05 ml C-l 4-EHDP solution was 
added as tracer, and 0.11 ml NaOH solution was used to adjust the pH to 
7.1. Incubation time: W- 24 hr(7 samples). 
Experimentó. 
To 25 ml 0.0032 M EHDP solution 0.05 ml C-l 4-EHDP solution was 
added as tracer. With 0.07 ml 1 N NaOH the pH was adjusted to 7.5. 
Incubation time: V* - 30 hr (7 samples). 
Group 2. Adsorption of EHDP. 
Based on the results from group 1 experiments, the incubation time was set 
to 72 hr. A standard set of dilutions was made for each experiment The 
67 
concentration range for EHDP was between 0.01 and 0.001 M. To each of 
the seven samples0.01 ml C-14-EHDP solution(8 mg/ml, 0.0248 M ) was 
added as tracer. 
Experiment?. 
To25 mlO.0095 M EHDP solution 0.16 mil NNaOHwas added to adjust 
the pH to 7.43. The standard set of dilutions was prepared by addition of 
water to the stock solution. No buffer was added. 
Experiment 8. 
To 25 ml 0.0095 M EHDP solution 0.16 ml 1 N NaOH was added to 
adjust the pH to 7.35. A different hydroxyapatite preparation (Merck nr. 
11490) was used as adsorbent Dilutions were prepared by addition of 
water to the stock solution. No buffer was added. 
Experiment 9 
100 ml of a stock solution was prepared containingO.9474 mM EHDP, 15 
ml of a 20% HSA solution ( Inst Mérieux), and 900.8 mg NaCl. The pH of 
25 ml of this solution was adjusted to 7.65 with 0.3 ml 1 N NaOH. The pH 
of another 25 ml portion of the stock solution was adjusted to 6.40 with 0.05 
ml 1 N NaOH. 
The resulting concentrations were: 
EHDP : 0.0094 M ; HSA : 30 mg/ml ; NaCl : 0.15 M ; pH = 7.65 
EHDP : 0.0095 M ; HSA : 30 mg/ml ; NaCl : 0.15 M ; pH = 6.40. 
Dilutions were prepared with aO. 15 M NaCl solution containing 30 mg/ml 
HSA; 
pH = 7.60 resp. 6.41. 
Experiment 10. 
The stock solution was prepared as described for experiment 9. The 
resulting concentrations were : 
EHDP: 0.0094 M; HSA: 15 mg/ml; NaCl: 0.15 M; pH = 7.75. 
EHDP: 0.0095 M; HSA: 15 mg/ml; NaCl: 0.15 M; pH= 6.32. 
Dilutions were prepared with a 0.15 M NaCl solution containing 15 mg/ml 
HSA; 
pH = 7.70 resp. 6.31. 
Group 3. Adsorption of EHDP and stannous tin. 
Tin was added to the EHDP solution in the same ratio as is common 
practice in radiopharmaceuticals. This mol ratio (1:13) was thus initially 
present in the standard dilution series. In experiment 16 however, a series of 
solutions was used with constant EHDP concentration, but with varying 
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concentrations of tin. In experiment 17 an equimolar ratio of EHDP and tin 
was incubated to discriminate between the adsorption behaviour of free 
EHDP and EHDP-tia Incubations continued for 72 hr (equilibrium) or 1 
hr (the same period as chosen for the animal experiments). In some 
experiments human serum albumine (HSA) was added to test its influence 
on the adsorpion of EHDP and tia HSA is expected to be present in the 
fluids surrounding the bone tissue. In those experiments where HSA was 
used, no extra buffei was added The HSA concentration was set to 15 
mg/ml; the HSA solutions contained NaCl (0.15 M) to imitate biological 
conditions. When no HSA was used, tris buffer (0.1 M) was added to main­
tain the pH. The solutions were prepared under nitrogen to prevent stannous 
tin oxidation. The incubator was flushed with nitrogen during the incubation 
period. 
Experiment 11. 
75.8 mg EHDP (0.235 mM) was dissolved in a few milliliters of distilled 
water-,0.1 ml C-14-EHDPsolution(8 mg/ml) was added. 101.1 mgSnS04 
(0.453 mM) was dissolved in 25 ml 0.1 N HCl. 
One milliliter of this solution was mixed under nitrogen with the diphospho-
nate solutioa After five minutes a solution was added, containing 375 mg 
HSA and 225 mg NaCl. The volume was brought up to 25 ml with distilled 
water. To 24 ml of this solution0.28 ml 1 N NaOH was added to adjust the 
pH to 6.55. The final concentrations were: 
EHDP: 9.3 X 10"3 M; Sn: 0.71 X 10"3 M; HSA: 15 mg/ml; NaCl: 
0.15 M; pH= 6.55. A second solution was prepared in the same way, but 
with a higher pH. The concentrations of the second solution were: 
EHDP : 9.2 X 10"3 M ; Sn : 0.71 X 10"3M ; HSA : 15 mg/ml ; NaCl : 0.15 
M ; pH= 7.85. Dilutions were prepared with HSA solutions in saline of the 
corresponding pH (6.55 resp. 7.85). The incubation continued for 72 hr. 
Experiment 12. 
110.4 mg EHDP (0.343 mM) was dissolved in 1 ml of distilled water. This 
solution was mixed with a solution of 6.0 mg SnS04 (0.027 mM) ini ml 0.1 
N H-SO^ which contained 10 μ\ of a Sn-119m-SnS04 solution in 2 N 
FL SO, and which was kept under nitrogea After five minutes 25 ml was 
added of a solution, containing 15 mg/ml HSA and 9 mg/ml NaCL The pH 
was adjusted to 6.44 with NaOH. The final concentrations were: 
EHDP: 13.1 X 10"3M; Sn: 1.03 Χ 10"3 M ; HSA: 14.4 mg/ml; NaCl: 
0.15 M ; p H = 6 . 4 4 . 
A second solution was prepared in the same way, but with a higher pH. The 
final concentrations of the second solution were : 
EHDP: 13.1 X 10" 3M;Sn: 1.05 Χ ΙΟ"3 M ; HSA : 14.4 mg/ml; NaCl: 
0.15 M; p H = 7.65. 
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Dilutions were prepared with HSA solutions in saline (0.15 M NaCl) of the 
corresponding pH (6.44 resp. 7.65). The incubation temperature was 21°. 
The incubation continued for 72 hr. 
Experiment 13. 
114.4 mg EHDP (0.355 mM) was dissolved in 1 ml 0.1 M tris buffer (pH 
= 7.47). 0.2 ml C-14-EHDP solution(8 mg/ml) was added 6.3 mg SnS04 
(0.028 mM) was dissolved in 1 ml 0.1 N H 2 S0 4 under nitrogea 10 /il of a 
solution of Sn-119m-SnS04 in2 N HjSC^ was added. The EHDP solution 
was mixed with the stannous tin solutioa After five minutes, 24 ml 0.1 M 
tris buffer (pH = 7.47) was added. The pH was adjusted to 7.5 with 
NaOH. The final concentrations were : 
EHDP : 13.5 X 10"3 M ; Sn : 1.06 Χ ΙΟ"3 M ; tris : 0.09 M ; pH = 7.5. 
Dilutions were prepared withO.l M tris buffer pH = 7.47. The incubation 
temperature was 21°. The incubation continued for 72 hr. 
Experiment 14. 
According to the prescription for experiment 11a solution was prepared of 
EHDP-Sn in saline. The final concentrations were : 
EHDP: 0.0094 M ; Sn: 0.76 X IO"3 M: HSA: 15 mg/ml ; NaCl : 0.15 
M; p H = 6.43. 
A second solution was prepared. The concentrations were : 
EHDP : 0.0093 M ; Sn : 0.75 X IO"3 M ; HSA : 15 mg/ml ; NaCl : 0.15 
M ; pH = 7.80. 
Dilutions and tin standards were prepared in the usual way. The incubation 
continued for 1 hr. 
Experiment 15. 
110.0 mg EHDP (0.342 mM) was dissolved in 1 ml 0.1 M tris buffer (pH 
= 6.82). 
6.1 mg SnS04 (0.027 mM) was dissolved in 1 ml 0.1 N I^SC^ under 
nitrogen. 
10 μ\ of a solution of Sn-119m-SnS04 in 2 N l^SC^ was added. The 
EHDP solution was mixed with the stannous tin solutioa After five minutes 
24 ml 0.1 M tris buffer (pH = 6.82) was added. The pH was adjusted to 
6.8 with NaOH. The final concentrations were : 
EHDP: 13.1 X 10"3 M; Sn: 1.05 X 10" 3M; tris: 0.1 M; pH = 6.8. 
A second solution was prepared in a similar way but at a higher pH. The 
concentrations of the second solution were : 
EHDP: 13.1 X 10"3M; Sn: 1.05 X 10"3 M; tris: 0.1 M ; p H = 7.2. 
Dilutions were prepared with 0.1 M tris buffer of the corresponding pH 
(6.82 resp. 7.24). The incubation temperature was 21°. The incubation 
continued for 1 hr. 
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Experiment 16. 
58.9 mgEHDP(0.1829 mM) was dissolved in TA ml water; 0.2 ml C-14-
EHDP solution(8.1 mg/ml) was added. 7.8 mg S n S 0 4 (0.0350 mM) was 
dissolved in 2Vi ml 0.1 N l·^ S 0 4 under nitrogen; 10 μλ of a solution of Sn-
119m-SnS04 in 2 N HjSO,^ was added To each of seven penicilline vials, 
containing 100 mg hydroxy apatite, 1 ml of the EHDP solution was given. 
Varying amounts of the stannous tin solution, 0.1 M tris buffer, and 0.1 M 
TMA- OH were added to the seven vials, according to the following scheme: 
a 0.5 mlSnS0 4 soL + 3 ml 0.1 M tris + 0.85 mlO. lMT-OH. 
b 0.45 mlSnS0 4 soL + 3.1 ml0.1 M tris + 0.75 ml0.1MT-OH. 
с 0.4 ml S n S 0 4 soL + 3.2 ml0.1 M tris + 0.65 m l 0 . 1 M T - O H 
d 0.3 ml S n S 0 4 soL + 3.4 ml 0.1 M tris + 0.50 ml0.1MT-OH. 
e 0.2 ml S n S 0 4 soL + 3.6 ml 0.1 M tris + 0.375 ml 0.1 M T-OH. 
f 0.1 ml S n S 0 4 soL + 3.8 ml 0.1 M tris + 0.225 ml 0.1 M T-OH. 
g 0.05 ml S n S 0 4 sol. + 3.9 ml 0.1 M tris + 0.125 ml 0.1 M T-OH. 
T-OH represents TMA-hydroxide. 
The pH of the mixtures was 7.2. By this way of sample preparation a 
constant EHDP concentration was achieved with varying concentrations of 
tia The E H D P concentration was 4.7 mM/1; the tin concentration varied 
between 0.1378 and 1.308 mM/1. The tris concentration varied between 
0.08 and 0.06 M/1. The incubation temperature was 21°. The incubation 
continued for 1 hr. 
Experiment 17. 
110.6 EHDP (0.344 mM) was dissolved in 1 ml 0.1 M tris buffer (pH = 
6.8) 0.2 ml C-14-EHDP solution(8.1 mg/ml) was added 70.5 mg SnS0 4 
(0.316 mM) was dissolved in 5 ml 1 N H 2 S 0 4 under nitrogen. 
10 μ\ of a solution of Sn-119m-SnS04 in 2 N HjSO^, was added The 
EHDP solution was mixed with the stannous tin solutioa After five minutes 
24 mlO.l M tris buffer(pH= 6.8) was added The pH was adjustedto6.8 
with N a O H The final concentrations were : 
E H D P : 10.8 X 10"3 M ; Sn: 9.8 X 10"3 m; tris: 0.08 M; pH = 6.8 
A second solution was prepared in a similar way, but at a higher pH. 
The concentrations of the second solution were : 
E H D P : 10.8 X 1 0 3 M ; Sn: 9.7 X IO"3 M; tris: 0.08 M ; pH = 7.4. 
Dilutions were prepared with 0.1 M tris buffer of the corresponding pH 
(6.8 resp. 7.4). The incubation temperature was 2 Γ . The incubation 
continued for 72 hr. No human serum albumin was added to prevent the 
formation of a gelatinous precipitate of hydrolyzed tin and albumin. This 
precipitate could otherwise block the millipore filter. 
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Group 4. Adsorption of technetium and tin with EHDP. 
Tc-99m-pertechnetate was added. Other conditions were the same as for 
group 3. Incubations continued for 1 hr. Immediately after the end of 
incubation samples and standards were counted for Tc-99m in a gamma 
counter. Three days later no technetium-99m activity of importance was 
left Then, Sn-119m could be counted without disturbance by Tc-99m. 
Experiment 18. 
According to the description of experiment 15 an EHDP-tin solution was 
prepared Before diluting this solution with 24 ml 0.1 M tris buffer, 10 μ.1 
Tc-99m pertechnetate was added. The final concentrations were : 
E H D P : 13.1 X 10"3 M ; Sn: 1.05 X 10"3 M ; tris : 0.1 M ; pH = 6.8. 
A second solution was prepared in a similar way, but at a higher pH. 
The final concentrations of the second solution were : 
E H D P : 13.1 X 1 0 " 3 M ; Sn: 1.05 X 10"3 M ; tris: 0.1 M; pH = 7.2. 
Dilutions were prepared with 0.1 M tris buffer of the corresponding pH 
(6.82 resp. 7.24). The incubation temperature was 21°. 
Experiment 19 
Neither C-14-EHDP, nor Sn-119m-SnS04 were added. 
74.9 mg EHDP (0.233 mM) was dissolved in 1 ml distilled water. 4.3 mg 
SnS0 4 (0.019 mM) was dissolved in 1 ml 0.1 N H 2 S 0 4 under nitrogen. 
The diphosphonate solution was mixed with the stannous tin solution. A 
solution was prepared of 375 mg HSA, 3 μϋί I-131-HSA, and 225 mg 
NaCl in 10 ml distilled water. 10 μΐ of a Tc-99m- pertechnetate solution was 
added to the diphosphonate solution. After five minutes the HSA solution 
was added. The volume was made up to 25 ml with distilled water and the 
pH was adjusted to 6.38 with NaOH. The final concentrations were : 
EHDP : 9.3 Χ ΙΟ"3 M ; Sn : 0.79 Χ ΙΟ"3 M ; HSA : 15 mg/ml ; NaCl : 0.15 
M ; p H = 6 . 3 8 . 
A second solution was prepared in a similar way, but at a higher pH. The 
final concentrations in this solution were : 
EHDP : 9.3 Χ ΙΟ"3 M ; Sn : 0.79 Χ ΙΟ'3 M ; HSA : 15 mg/ml ; NaCl : 0.15 
M ; p H = 7.45. 
Dilutions were prepared with HSA solutions in saline of the corresponding 
pH (6.41 resp. 7.44). 
Experiment 20. 
To establish that pertechnetate is not bound by hydroxyapatite, an 
experiment was performed analogous to experiment 19, but with the 
difference, that no SnSO. was added to the solution. 
74.3 mg EHDP (0.231 mM) was dissolved in 1 ml distilled water, 0.2 ml 
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C-14-EHDP(8 mg/ml) and0.3 ml Tc-99m-pertechnetate were added. The 
volume was made up to 25 ml by adding a solution, containing 375 mg HSA 
and 225 mg NaCl. The final concentrations were : 
EHDP: 9.4 X 10"3 M; HSA: 15 mg/ml; NaCl: 0.15 M; p H = 6.47. 
A second solution was prepared in a similar way, but at a higher pH. The 
concentrations of this solution were : 
EHDP: 9.4 X 10"3M; HSA: 15 mg/ml; NaCl : 0.15 M; p H = 7.83. 
Dilutions were prepared with HSA solutions (15 mg/ml) in saline of the 
corresponding pH (6.5 resp. 7.8). 
Experiment 21. 
Equivalent amounts of technetium and tin (molar ratio 1:2) were used 
110.0 mg EHDP (0.342 mM) was dissolved in 1 ml distilled water, 0.2 ml 
of a C-14-EHDP solution (8.1 mg/ml) was added. 6.5 mg SnS04 (0.029 
mM) was dissolved in 1 ml 0.1 N HjSO ,^ under nitrogen; 10 μΐ of a solution 
of Sn-119m-SnS04 in 2 N HjSC^ was added. The EHDP solution was 
mixed with the stannous tin solutioa 
After five minutes 0.15 ml was added of a Tc-99m-pertechnetate solution 
and 0.5 ml of a Тс-99-pertechnetate solution (0.0298 M). 25 ml was added 
of a solution containing 375 mg HSA and 225 mg NaCl (pH = 7.42). 
The final concentrations were : 
EHDP : 12.2 X 10"3 M ; Sn : 1.04 X IO"3 M ; Tc : 0.53 X IO"3 M ; HSA : 
13.4 mg/ml; NaCl: 0.13 M ; p H = 7 . 4 4 . 
The added amount of pertechnetate was supposed to be equivalent to the 
amount of stannous tin present 
Dilutions were prepared with an HSA solution in saline (pH = 7.42). The 
incubation temperature was 21°. 
Group 5. Adsorption of MDP and pCPMDP with and without 
technetium and tin. 
Adsorption experiments were performed with MDP and pCPMDP. MDP 
concentrations were measured with liquid scintillation counting by addition 
of P-32-MDP as tracer. pCPMDP concentrations were measured with a 
spectrophotometer at264 run. The incubation temperature in this group was 
21°. 
Experiment 22. 
60.0 mg MDP (0.341 mM) was dissolved in 5 ml of a solution of P-32 MDP 
in 0.1 M sodium acetate (pH = 5.6). 6.0 mg SnS04 (0.027 mM) was 
dissolved in 1 ml 0.1 N HjSC^ under nitrogen; 10 μΐ was added of a 
solution of Sn-119m-SnS04 in2 N H 2 S0 4 . The MDP solution was mixed 
with the tin solution. Twenty five milliliters of a 0.1 M tris buffer (pH = 
7.4) were added; the pH was adjusted to 7.42 with NaOH. The final 
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concentrations were : 
MDP: 11.9 X IO"3 M; Sn: 0.86 X IO"3 M ; tris : 0.08 M; pH =7.42. 
Dilutions were prepared with 0.1 M tris buffer (pH = 7.4). The incubation 
continued for 72 hr. 
Experiment 23. 
Experiment 22 was repeated with the exception, that 50 μ\ Tc-99m-
pertechnetate was added to the mixture of the MDP and tin solution before 
addition of tris buffer. The final concentrations were : 
MDP: 13.1 X 10-3M; Sn: 1.0 X 10"3 M; tris : 0.09 M; pH = 7.6. 
Dilutions were prepared with 0.1 M tris buffer (pH = 7.5). The incubation 
continued for 1 hr. 
Experiment 24. 
Experiment 23 was repeated with two exceptions: together with Tc-99m-
pertechnetate also 0.45 ml Тс-99-peitechnetate (0.013 mM) was added, 
and no P-32-MDP was used The final concentrations were : 
MDP: 12.8 X 10"3M; Sn: 1.01 X 10"3 M; Tc: 0.51 X 10' 3 M;Tris: 
0.09 M ; p H = 7.6. 
Dilutions were prepared with 0.1 M tris buffer (pH = 7.6). The 
incubation continued for 1 hr. 
Experiment 25. 
100.0 mg pCPMDP (0.349 mM) was dissolved in 1 ml 0.1 M tris buffer 
(pH = 6.96). 6.0 mg SnS04 (0.027 mM) was dissolved in 1 ml 0.1 N 
H 2 S0 4 under nitrogen; 10 ju.1 was added of a solution of Sn-119m-SnS04 in 
2 N H-SO.. The diphosphonate solution was mixed with the tin solution. 
After five minutes 24 ml of a 0.1 M tris buffer (pH = 6.96) was added. The 
pH was adjusted to 6.96. The final concentrations were : 
pCPMDP : 12.0 Χ ΙΟ"3 M ; Sn : 0.93 Χ ΙΟ"3 M ; tris : 0.09 M ; pH = 6.96. 
Dilutions were prepared with 0.1 M tris buffer (pH = 6/96). The 
incubation continued for 72 hr. 
Experiment 26. 
Experiment 25 was repeated with the exception, that 10 μΐ Tc-99m-per-
technetate was added to the mixture of the pCPMDP and tin solution be­
fore addition of tris buffer. The final concentrations were : 
pCPMDP : 13.4 X 10'3 M ; Sn : 1.03 X 10 3 M ; tris : 0.09 M ; pH= 7.71. 
Dilutions were prepared with 0.1 M tris buffer (pH = 7.71). The 
incubation continued for 1 hr. 
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Table 3.1. Summary of the conditions of the adsorption experiments of three 
diphosphonates(E-=EHDP. M=MDP. P^pCPMDP) with hydroxyapa-
tite, HSA solutions always contained NaCI (0. IS M/l). Radioactive tra­
cers are indicated with an asterisk. 
pCPMDP concentrations were measured with a spectrophotometer at 264 
nm. Tc-99m is carrier-free, so no concentrations can be indicated 
Exp. nr 
Temp. 
1 37s 
2 37° 
3 37° 
4 37° 
J 37° 
6 37° 
7 37° 
8 37° 
9 37° 
10 37° 
11 37° 
12 21° 
13 21° 
14 37° 
15 21° 
16 21" 
17 21° 
18 21° 
19 37° 
20 37° 
21 21° 
22 21° 
23 21° 
24 21° 
25 21° 
26 21° 
E* 
E* 
E· 
E· 
E· 
E* 
E* 
E· 
E· 
E· 
E* 
E 
E· 
E· 
E 
E· 
E· 
E 
E 
E» 
E· 
M· 
M· 
M· 
Ρ 
Ρ 
Initial 
DP cone. 
(mM/1) 
43 
8.8 
84.6 
0.062 
0.92 
3.22 
0.9-9 
0.9-9 
0.9-9 
0.9-9 
0.9-9 
1.3-13 
1.3-13 
0.9-9 
1.3-13 
4.7 
1.1-11 
1.3-13 
0.9-9 
0.9-9 
1.2-12 
1.2-12 
1.3-13 
1.3-13 
1.2-12 
1.3-13 
Initial 
Tin cone. 
(mM/1) 
-
-
-
-
— 
_ 
-
-
— 
0.07 - 0.7 
0.1-1 · 
0.1 -1 · 
0.07-0.7 
0.1 - 1 · 
0.14-1.31 
1.0-10· 
0.1-1 · 
0.08 -0.8 
-
0.1-1* 
0.09-0.9 · 
0.1-1 * 
0.1-1 * 
0.09-0.9 · 
0.1-1 · 
Initial 
Tc cone. 
(mM/1) 
-
-
-
-
— 
_ 
-
-
— 
_ 
-
-
-
-
-
— 
To-99m * 
Tc-99m · 
Tc-99m * 
0.05-0.5· 
_ 
Tc-99m · 
0.05-0.5· 
-
Tc-99m* 
Incub. time 
(hr) 
0.25-116 
1-118 
18-137 
0.5 -144 
0.25 - 24 
0.25 - 30 
72 
72 
72 
72 
72 
72 
72 
1 
1 
1 
72 
1 
1 
1 
1 
72 
1 
1 
72 
1 
T(ris)/H(SA) 
(M/l) (mg/ml) 
-
-
-
-
— 
_ 
-
Η 30 
H15 
Η 15 
Η 15 
Τ 0.09 
Η15 
TO.l 
Τ 0.06-0.08 
Τ 0.08 
Τ0.1 
Η15 
Η 15 
Η13 
Τ 0.08 
Τ 0.09 
Τ 0.09 
Τ 0.09 
Τ 0.09 
Initial 
рн 
ι 
7.4 
7.4 
7.4 
7.65 
7.1 
7.5 
7.43 
7.35 
6.40/7.65 
6.32/7.75 
6.55/7.85 
6.44/7.65 
7.5 
6.43 / 7.80 
6.8 / 7.2 
7.2 
6.8/7.4 
6.8/7.2 
6.38/7.45 
6.47 / 7.83 
7.44 
7.42 
7.6 
7.6 
6.96 
7.71 
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3.4. RESULTS 
Group 1. Estimation of the equilibration time for EHDP. 
EHDP solutions of concentrations between 0.06 and 85 mM/1 were 
incubated with hydroxyapatite for a period between 0.25 and 144 hr. 
Figure 3.2 shows the results from the experiments of group 1. The adsorbed 
amount of EHDP per gram of hydroxyapatite is plotted against the 
equilibration time. 
X m M / g 
0.6-1 
0 . 5 -
0 . 4 -
0.3· 
0 . 2 -
0 . 1 -£»> 
2 0 A0 
— I — α - D -
60 8 0 
• • π 
100 120 1A0hr 
Figure 3.2. Adsorbed amounts of EHDP as function of the equilibration time 
The results from experiment 1 (43 mM) are plotted by -•-, the 
results from experiment! (8.8 mM) are plotted by-+-, the results 
from experiment 3 (84.6 mM) are plotted by -X-, the results from 
experiment 4 (0.062 mM) are plotted by -D-, the results from 
experiment 5 (0.92 mM) are plotted by-A-, and the results from 
experiment 6 (3.22 mM) are plotted by -0-. 
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Figure 3.2 shows, that at the lowest concentrations the maximum adsorp-
tion level is reached within 30 minutes. At the highest concentrations 
equilibrium seems to be reached within 2-4 hours. After 110-120 hours of 
incubation however, for these solutions significantly higher adsorbed 
amounts of EHDP are found than after 2-50 hr. These adsorbed amounts 
are much larger, than what could be expected based on the model of Taves 
and Reedy (0.16 mM/g hydroxyapatite) [9,11]. Possibly the peptizing 
effect of higher concentrations of EHDP on hydroxyapatite caused an 
increase in the specific surface area [10]. 
At intermediate EHDP concentrations about 48 hr is needed to reach 
equilibrium. This was also found by Jung et al. [5]. 
EHDP adsorption proceeds rather rapidly: at a pre-incubation concentra-
tion of 3.22 mM/1 within two hours more than 98% of the available EHDP 
is adsorbed. Figure 3.2 shows a plateau level between 0.17 and 0.2 mM/g 
for pre-incubation concentrations of EHDP of 8.8 mM/1 or higher. This 
result agrees reasonably well with the value predicted by the Taves and 
Reedy model. This item will further be discussed together with the results of 
the experiments from group 2. 
Based on these results, for further adsorption experiments a concentration 
range of 1-10 mM/1 EHDP was chosen and an incubation time of 72 hr for 
equilibrium experiments. This range is appropriate to produce a complete 
adsorption isotherm and 72 hours of incubation are certainly sufficient to 
reach equilibrium. 
Group 2. Adsorption isotherms of EHDP. 
Sets of seven samples of EHDP solutions with concentrations between 1 
and 10 mM/1 were incubated for 72 hr. 
Figure 3.3 shows the results of experiment?. The pH before incubation was 
7.4; neither albumin nor buffer was added. 
Figure 3.4 shows the results of experiment 9; the HSA concentration was 
30 mg/ml. Two isotherms were measured: at pH=6.40 and pH=7.65. 
Figure 3.5 shows the results of experiment 10; the HSA concentration was 
15 mg/ml. Two isotherms were measured: at pH=6.32 and at pH=7.75. 
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XmM 
0.2 -
0.15-
0.1 -
0.05-1 
1 1 1 1 ' 
1 2 3 4 mM/l 
с EHDP 
Fig. 3.3. Adsorption isotherm of EHDP on hydroxyapatite Neither albu­
min nor buffer added ρΗ=ΊΑ. 
XmM/g 1 
0 . 2 -
0.15-
0.1 -
0.05-
• 1 1 1 ι 
1 2 3 4 mM /I 
с EHDP 
Fig. 3.4. Adsorption isotherms ofEHDP on hydroxyapatite at pH=6.40 
(-X-) and at pH=7.65(9). HS A concentration 30 mg/mL 
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'9 
' У 
0.15 
0 . 0 5 -
4 mM/l 
с EHDP 
Fig. 3.5. Adsorption isotherms of EHDP on hydroxyapatite at pH=6.32 
(-X-) and atpH=7.75(-9-). HSA concentration 75 mg/ml. 
In experiment 8 apatite was used with an available surface smaller than 
Vi m2/g. The adsorbed amount of EHDP was about the detection limit (2 · 
10"3 mM/g for the lowest initial concentrations used). This shows that the 
adsorbed amount of EHDP is indeed related to the surface area of the 
apatite and that EHDP is not consumed by any process other than 
adsorptioa Because of this result no further adsorption experiments were 
done with the type of apatite used in experiment 8. 
Figure 3.6 shows two isotherms plotted according to the Langmuir 
equation (3.7) for EHDP adsorption on hydroxyapatite at two pH's (6.7-
6.9 and 7.2-7.3). HSA 15 mg/ml (experiment 10). 
The results of group 2 show maximum adsorption levels of EHDP of about 
0.17-0.20 mM/g apatite. At lower pH values somewhat higher adsorption 
levels are reached than at higher pH values. A small but significant 
influence of the pH is found(cf. figures 3.4 and 3.5). A possible explanation 
for this feature might be, that the charge of the apatite surface is more 
positive at lower pH, while the point of zero charge is about 7 [ 12]. This may 
influence the adsorption of diphosphonate. 
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2 0 
16 
12 
8 -
4 
1 2 3 4 m M / l 
с EHDP 
Fig. 3.6. Adsorption isotherms for EHDP on hydroxy apatite plotted accor­
ding to the Langmuir equation. HSA: 15 mg/ml. 
Table 3.2 summarizes the X and К values derived from slopes and Y-
m
 r 
intercepts of the adsorption isotherms from experiments 7,9, and 10, when 
plotted according to the Langmuir equation (3.7), с vs. c/X. 
The presence of human serum albumin (HSA) in the diphosphonate 
solution does not seem of much importance. If at all, HSA has a greater 
influence on the EHDP adsorption at pH=6.3 than at pH=7.6. This is in 
agreement with the results of Hlady, who found, that HSA adsorption on 
hydroxy apatite decreases with increasing pH [ 12]. Despite the presence of 
HSA the pH was not constant during the incubation period. An initial pH of 
about 6.5 increased during the incubation, but never above pH=6.9. An 
initial pH of about 7.5 decreased during the incubation, but never below 
pH=7.1. The pH shift was more pronounced at lower diphosphonate 
concentrations. 
The adsorption results fit within the Langmuir equation (cf. table 3.2). The 
calculated values of the maximum number of binding sites correspond well 
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a ' ' 
pH = 6.7-6.9 
Table 3.2. Maximum adsorption capacities (X) and affinity constants (К) for 
EHDP on hydroxyapatite. 
Exp. pH after ¡ncub. Xm К Corr. coeff. 
nr. (mM/g) (1/mM) lin. regr. 
EHDP; no HSA 
EHDP 
HSA 30 mg/ml 
EHDP 
HSA 15 mg/ml 
pH = 7.7-8.0 
pH = 6.7-6.8 
pH = 7.2-7.5 
pH = 6.7-6.9 
pH = 7.2-7.3 
0.174 
0.186 
0.171 
0.204 
0.185 
40 
20 
30 
30 
30 
0.999 
0.999 
0.999 
0.999 
0.999 
with the plateau levels from figures 3.3-3.5. These results agree reasonably 
well with the number which would be predicted, based on the model of 
Taves and Reedy (0.16 mM/g hydroxyapatite) [9]. According to these 
authors there occur structural grooves on all faces of the apatite micro-
crystal, which run parallel with the c-axis of the crystal. Normally, in 
aqueous solutions, these grooves are filled with H P 0 4
2
" and either OHions 
or water molecules. The filling of the grooves varies with the composition of 
the solution. Pyrophosphate and linear polyphosphate groups fit almost 
exactly into these grooves. A pyrophosphate molecule adsorbed from the 
solution is oriented in the groove with its long axis parallel to the c-axis of the 
crystal. It displaces the H P 0 4
2
" ion and the water molecule. According to 
the model of Taves and Reedy there is one groove per surface unit cell, 
which can accomodate one diphosphonate molecule. The dimensions of the 
surface of a unit cell of hydroxyapatite are: 6.88 Â in the direction of the c-
axis and 9.42 Â along the a-axis [1]. So one unit cell contributes 64.81 Â2 
to the surface area. The apatite, which was used in experiments 7„ 9, and 10 
had a surface area of 65 m2pergram(see section 3.3). The number of expo-
sed unit cells is thus 9 X 10 ' 9 per gram hydroxyapatite. This means, that per 
gram 0.16 mM diphosphonate can be bound to the surface, if only the 
grooves are occupied. This is in good agreement with the results presented in 
table 3.2. The surplus of adsorbed EHDP molecules, which can not be 
accounted for by the Taves and Reedy model, is possibly due to a small 
dispersing effect of the diphophonate solution on the hydroxyapatite. 
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The Taves and Reedy model explains, that the surface of the apatite may be 
saturated with diphosphonate, although only a minor part of it is really 
covered. 
The affinity constants presented in table 3.2 are a great deal smaller than the 
affinity constant, which can be calculated from the results of Jung et al.[5] 
(K — 200). The affinity constants can be calculated from the Y-intercepts 
of the Langmuir isotherms (cf. figure 3.6 and equation 3.7). These Y-
intercepts are very small in adsorption experiments of diphosphonates with 
hydroxyapatite and so these are difficult to determine accurately. 
In the experiments by Jung et al. relatively many adsorption measurements 
were done at small concentrations. In our experiments more points at higher 
concentrations were measured. This makes the extrapolation less reliable. 
The difference between the experimental designs probably explains the 
difference between the resulting K-values. Apart from the difference 
between the K-values, the results of the experiments by Jung were 
comparable with our results. 
From the results of Jung et al. a K-value was calculated for DCMDP 
(K ^ 100). So the affinity of DCMDP for hydroxyapatite turns out to be 
approximately half the affinity of EHDP. This result will be used in the 
discussion section of this chapter in a comparison with MDP and 
pCPMDP. 
Group 3. Adsorption of EHDP and stannous tin. 
Sets of seven samples of solutions of EHDP and stannous tin (molar ratio 
13:1) were incubated with hydroxyapatite for 72 or 1 hr with addition of 
either HSA or tris buffer.The 1 hr incubation period should simulate the in 
vivo conditions. The tissue distributions (see chapter 4) were measured also 
1 hr after injection. In one experiment (nr. 16) the EHDP concentration was 
kept constant with varying concentrations of tin. In the last experiment of 
this group equimolar amounts of EHDP and tin were used. 
Figure 3.7 shows the results of experiment 11. Only EHDP concentrations 
were measured. The adsorption isotherm measured at pH=6.9 is represen-
ted by- X -signs; the isotherm measured at pH=7.5 is represented by - · -
signs (pH after incub.). 
Figure 3.8 shows the results of experiment 12. Only the tin concentrations 
were measured. The incubation temperature was 21°; the other conditions 
were the same as for experiment 11. 
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Fig. 3.7. Adsorption isotherm for EHDP (0.9-9 mM/l) incubated for 72 
hr in the presence of stannous tin (0.07-0.7 mM/l); HSA: 15 
mg/ml NaCl: 0.15 M, temperature: 37°. 
X mM/g 
0.012 
0.010 
0.00Θ 
0.006-* 
0.004 
0.002 -
0.1 0.3 
— ι — 
0.5 
— ι — 
0.7 0.9 
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с S n ( I I ) 
Fig. 3.8. Adsorption isotherms of stannous tin (0.1-1 mM/l) incubated for 
72 hr in the presence of EHDP (1.3 -13 mM/l) with hydroxyapa-
tite at pH=6A4{- X -) and pH=7.65(- · -). HSA: 14 mg/ml; 
NaCL· 0.15 M; temperature: 21°. 
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Figures 3.9 and 3.10 show the results of experiment 13. Both the EHDP 
and the tin concentrations were measured. The incubation temperature was 
21°. Tris buffer was used instead of albumin. 
X mM 
0.20 -
0.16 
0.12 
o.oe 
0.04 -* 
Ί 1 1 1 
2 4 6 8 m M / l 
с EHDP 
Fig. 3.9. Adsorption isotherms of EHDP (1.3 -13 mM/l) incubated for 72 
hr with hydroxyapatite in the presence of stannous tin (0.1-1 
mM/l). Tris: 0.09 M; pH=7.5; temperature: 21°. 
The adsorption results for EHDP are comparable with the results from 
experiment 10 (cf. figure 3.5): a small amount of stannous tin does not 
disturb the adsorption behaviour of EHDP on hydroxyapatite. This is also 
confirmed У ν the data in table 3.3 (cf. table 3.2). Note however the small 
affinity constant for EHDP from experiment 13. This result probably has to 
be attributed to the lower incubation temperature of experiment 13: for 
experiment 11 the incubation temperature was 37°, but because of technical 
problems for experiment 13 the incubation temperature was only 21 °. The 
difference in temperature seems to have no influence on the adsorption 
capacity, as could be expected. 
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Fig. 3.10. Adsorption isotherm of stannous tin (0.1-1 mM/l) incubated for 
72 hr with hydroxyapatite in the presence of EHDP (1.3 -13 
mM/l). Tris: 0.09 M; pH=7.5; temperature: 21°. 
Table 3.3. gives the values for X
m
 and K, calculated from the adsorption 
isotherms of EHDP, plotted according to the Langmuirequation(3.7): с vs. 
c/X. 
Table 3.3. Maximum adsorption capacities (X) and affinity constants (K) for 
EHDP adsorption on hydroxyapatite in the presence of stannous tin. 
pH after incub. 
EHDP pH = 6.9 HSA (exp. 11 ) 
EHDP pH = 7.6 HSA (exp. 11) 
EHDP pH = 7.3 Tris (exp. 13) 
x
m (mM/g) 
0.206 
0.189 
0.189 
К 
(1/mM) 
30 
20 
3 
Corr. coeff. 
lin. regr. 
0.997 
0.999 
0.983 
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The tin adsorption isotherms look entirely different from the EHDP 
isotherms. This might suggest, that EHDP and tin are separately adsorbed 
on the hydroxyapatite surface. The results described so far do not provide 
however, evidence for this suggestioa The maximum in the tin adsorption 
isotherms is remarkable. This probably has to be attributed to the stability of 
the EHDP-tin complex. A more extensive discussion on this item will be 
given later on in this chapter. 
In the presence of tris buffer the tin adsorption seems to be smaller, than in 
media containing HS A (cf. figures 3.8 and 3.10). 
Figure 3.11 shows the results of experiment 14. The incubation time was 1 
hr. Only EHDP concentrations were measured. These isotherms confirm, 
that one hour incubation time is too short for a 10"2 M EHDP solution to 
reach equilibrium. The maximum adsorption levels are about 25% lower 
than in equilibrium state. 
Fig. 3.11. Adsorption isotherms of EHDP (0.9 - 9 mM/l) in the presence of 
tin (0.07 - 7 mM/l). One hour incubation. HSA: 15 mg/mU NaCl: 
0.15 MpH=6.43(X) resp. 7.80(·). 
Figure 3.12 shows the results of experiment 15. The incubation time was 1 
hr. The incubation temperature was 21°. Only tin concentrations were 
measured. 
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0.004 
0.002 
Fig. 3.12. Adsorption isotherms of stannous tin (0.1-1 mM/l) incubated for 
1 hr in the presence of EHDP (1.3 -13 mM/l) with hydroxy­
apatite at pH=6.8 (-X-) and at pH=7.2 (- -) in 0.10 M tris. 
X т М /g 
0.12 
0.10 -
0.08 -
0.06 
l J
 I 
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I 
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Fig. 3.13. Adsorption isotherm of EHDP (4.7 mM/l) after incubation for 1 
hr with hydroxyapatite in the presence of stannous tin (0.14-1.3 
mM/l); pH=7.2; tris: 0.07 M. 
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This isotherm shows, that in contrast with EHDP, the tin adsorption after 1 
hr is alsmost equal to the adsorption after 72 hr (cf. figure 3.10). 
Figures 3.13 and 3.14 show the results of experiment 16. The initial EHDP 
concentration was constant (4.7 mM/1). The tin concentration varied 
between 0.14 and 1.3 mM/1. The incubation time was 1 hr. The incubation 
temperature was 21°. 
X m M / 
0 . 0 2 0 -
0.016 
0.012 
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Ί Τ Τ 
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Fig. 3.14. Adsorption isotherm of stannous tin (0.14-1.3 mM/1) after 
incubation for 1 hr with hydroxyapatite in the presence of a 
constant concentration of EHDP (4.7 mM/l); pH=7.2; tris: 0.07 
M. 
Figures 3.15 and 3.16 show the adsorption isotherms for EHDP and 
stannous tin after equimolar incubation with hydroxyapatite for 72 hr 
(experiment 17). The incubation temperature was 21°. 
Table 3.4 gives the values for X
m
 and K, calculated from the adsorption 
isotherms of EHDP, plotted according to the Langmuirequation(3.7): с vs. 
c/X. 
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Fig. 3.15. Adsorption isotherms for EHDP (1.1-11 mM/l) (-9-) and 
stannous tin (1-10 mM/l) (-X-) on hydroxyapatite after incuba­
tion for 72 hr, 0.08 M tris buffer, pH=6.8 before incubation. 
The results of experiment 16 (constant EHDP concentration) suggest, that 
the maximum found in the tin isotherms (cf. figures 3.8,3.10,3.12,3.15, and 
3.16) can not be attributed to tin itself and that its appearance has something 
to do with the presence of high concentrations of EHDP. At the highest tin 
concentrations the EHDP adsorption seems to be somewhat reduced as 
well (see figure 3.13). High concentrations of EHDP seem to reduce the tin 
adsorption and vice versa. It is possible, that EHDP and tin compete for the 
same binding sites. A more extensive discussion on the maximum in the tin 
isotherms will be given at the end of this chapter. 
The results of experiment 17 (equimolar amounts of EHDP and tin) 
demonstrate, that EHDP and tin are adsorbed separately. Before incuba­
tion 85% of the available tin was bound in a 1:1 complex with EHDP(see 
chapter 5). So the EHDP-tin complex has to dissociate, before adsorption 
can proceed. 
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Fig. 3.16. Adsorption isotherms for EHDP (1.1-11 mM/l) (-·-) and 
stannous tin (1 -10 mM/l) (-X-) on hydroxyapatite after incuba­
tion for 72 hr, 0.08 M tris buffer, pH=7.4 before incubation. 
Table 3.4. Maximum adsorption capacities (XJ and affinity constants (K) for 
EHDP adsorption on hydroxyapatite in the presence of equimolar 
amounts of stannous tin with tris buffer. 
pH before incub. 
EHDP (pH = 6.8) 
EHDP (pH = 7.4) 
x
m 
(mM/g) 
0.128 
0.113 
К 
(1/mM) 
10 
20 
Corr. coeff. 
Iin. regress. 
0.9981 
0.9998 
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The EHDP adsorption isotherms from experiment 17 (equimolar ratio) 
show the same pattern as the isotherms from experiments 11-13 (molar ratio 
13:1) (cf. figures 3.9 and 3.16). However the maximum adsorption levels 
for EHDP in experiment 17 are 40% lower than in experiments 11 and 13. 
The pH effect seen in experiments 11 and 13 also shows up in experiment 
17, despite the lower adsorption levels of EHDP. 
The tin adsorption isotherms from experiment 17 also show the same 
pattern as the isotherms from experiment 12 and 13. The adsorption levels 
in experiment 17 are ten times as high as in experiment 13 (cf. figures 3.10 
and 3.16). This might be expected in view of the tin concentrations before 
incubation, which were also ten times as high as in experiment 13. The tin 
adsorption isotherms show no pH effect 
Two factors may be responsible for the lower EHDP adsorption in 
experiment 17 (compared with experiments 11-13): 
- The higher tin concentrations in solution might cause the formation of 
more EHDP-tin complex, which is supposed not to be adsorbed by 
hydroxyapatite. 
- Adsorbed tin might occupy some of the EHDP binding sites. 
It is remarkable, that the sum of the adsorbed amounts of tin and EHDP in 
experiment 17 (figures 3.15 and3.16)neverexceedstheX value found for 
adsorption of EHDP without tin (0.17-0.20 mM/g apatite). This suggests, 
that EHDP and tin compete for the same binding sites with a preference for 
EHDP. 
In conclusion: 
- EHDP and tin are not adsorbed in a chemical combination, as a 
fixed molecular ratio on the surface is not found. Instead, it looks 
as if they adsorb as seperate species. So the tin-EHDP complexes 
present in solution ( see chapter 5 ) are dissociated before adsorp-
tion occurs. 
- EHDP and tin influence each others binding to hydroxyapatite, 
possibly through competition for the same binding site and by 
forming chemical compounds in solution (see chapter 5). 
Group 4. Adsorption of technetium and tin with EHDP. 
Sets of seven samples of EHDP, tin (molar ratio 13:1) and Tc-99m-
pertechnetate were incubated with hydroxyapatite for 1 hr with addition of 
either HSA or tris buffer. In one experiment (nr.19) the albumin was 
radiolabeled to estimate its adsorption on hydroxyapatite in the presence of 
EHDP and tia In experiment nr. 20 no tin was added to estimate the 
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adsorption of pertechnetate on hydroxyapatite. In experiment 21 equivalent 
amounts of technetium (Tc-99) and tin were incubated with hydroxyapatite 
together with EHDP to see, whether tin and technetium are adsorbed as 
separate species or in a combination with a fixed molecular ratio. 
Table 3.5 gives the results of experiment 18. The EHDP concentrations 
were not measured in this experiment, but the EHDP isotherms may be 
expected to look like the isotherm shown in figure 3.11. The incubation 
temperature was 21°. 
Table 3.5. Ratios of the technetium and tin activities afierand before incubation and 
tin adsorption data. Incubation of EHDP (1.3 -13 mM/l) and stannous 
tin (0.1 -1 mM/l) plus Tc-99m-pertechnetate with hydroxyapatite in 0.1 
M tris buffer at pH =6.5 resp. 7.2. 
a 
b 
с 
d 
e 
f 
g 
Tc 
R/R 
а Ь 
0.962 
0.941 
0.947 
0.911 
0.802 
0.107 
0.075 
с 
(mM/l) 
0.93 
0.82 
0.70 
0.46 
0.21 
0.008 
0.0 
pH = 6.8 
Sn 
χ 
(mM/g) 
0.004 
0.004 
0.004 
0.005 
0.006 
0.006 
0.003 
ч 
0.887 
0.865 
0.839 
0.743 
0.479 
0.022 
0.0 
Tc 
У\ 
0.958 
0.962 
0.945 
0.923 
0.800 
0.100 
0.085 
рН = 
с 
(mM/l) 
0.93 
0.82 
0.70 
0.47 
0.20 
0.005 
0.0 
= 7.2 
Sn 
χ 
(mM/g) 
0.003 
0.004 
0.004 
0.005 
0.006 
0.006 
0.003 
\ι\ 
0.883 
0.869 
0.827 
0.734 
0.490 
0.040 
0.0 
The tin adsorption isotherms are shown in figure 3.12 (experiment 15). 
For technetium-99m no adsorption isotherms can be calculated, because 
the technetium concentration is extremely small and unknown. 
The tin and technetium adsorption patterns are not identical, but show the 
same trend at higher concentrations of EHDP, when the surface is almost 
saturated, less of technetium and tin is adsorbed. EHDP almost excludes 
technetium and tin from the hydroxyapatite surface. The percentage of 
technetium bound by hydroxyapatite is always smaller than the percentage 
of tin bound 
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Table 3.6 gives the results of experiment 19. I-131-HSA was used to 
measure the albumin adsorption. EHDP and tin concentrations were not 
measured, but as references figures 3.11 and 3.12 may serve. 
Table 3.6. Concentrations and adsorbed amounts of HSA (15 mg/ml) and activity-
ratios for Tc-99m after incubation with hydroxyapatile for I hr in an 
EHDP(0.9-9mM/l). stannoustin(0.08 - 0.8mM/1), andNaCl(0.15M) 
containing solution; pH before incubation is 6.38 resp. 7.45. 
Tc HSA Tc HSA 
KJ\ 
a 0.81 
b 0.78 
с 0.73 
d 0.52 
e 0.06 
f 0.06 
g 0.05 
с 
(mg/ml) 
14.6 
14.6 
15.0 
15.0 
13.8 
12.7 
12.5 
Χ 
(mg/ml) 
small 
small 
0 
0 
37 
69 
77 
pH 
postincut 
6.6 
6.6 
6.6 
6.6 
6.6 
6.7 
6.7 
*J\ 
1. 
0.91 
0.77 
0.72 
0.51 
0.14 
0.06 
0.06 
с 
(mg/ml) 
16.7 
15.0 
14.8 
15.1 
14.8 
13.5 
12.6 
X 
(mg/ml) 
0 
0 
small 
0 
small 
45 
74 
рн 
posLincub. 
7.3 
7.3 
7.2 
7.2 
7.2 
7.1 
7.1 
Only at the smallest concentrations of EHDP and tin some albumin is 
adsorbed on the hydroxyapatite surface. Apparently, the higher affinity of 
EHDP excludes the albumin from a nearly saturated surface. 
The adsorption levels of technetium in HSA solutions are slightly higher 
than in tris buffer (cf. table 3.5). 
Table 3.7 gives the results of experiment 20. There was no tin added to 
measure the adsorption on hydroxyapatite of pertechnetate in the presence 
of EHDP. 
Even at the smallest concentrations of EHDP no significant technetium 
adsorption could be detected. 
The presence of an agent like stannous tin appears to be a prerequisite to 
achieve technetium uptake by hydroxyapatite. This conclusion has also 
been confirmed by animal experiments. 
Figure 3.17 shows the results of experiment 21. Equivalent amounts of 
technetium and tin (molar ratio 1:2, see chapter 6) were added to the EHDP 
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Table 3.7 Concentrations and adsorbed amounts of EHDP (0.9-9 mM/l) and 
activity ratios for Tc-99m-pertechnetate after incubation with hydroxy­
apatite. No tin added Incubation time: 1 hr, HSA: 15 mg/ml NaCL· 0.15 
M. pH before incubation 6.4-6.5 resp. 7.83. 
pH = 6.4-6.5 
EHDP 
(mM/l) 
4.38 
3.51 
2.54 
1.10 
0.089 
0.014 
0.007 
Tc 
X 
(mM/g) 
0.158 
0.158 
0.153 
0.142 
0.115 
0.059 
0.029 
y\ 
0.99 
0.99 
0.99 
0.99 
0.97 
0.97 
с 
(mM/l) 
4.75 
3.81 
2.83 
1.25 
0.197 
0.010 
0.007 
pH = 7.83 
EHDP 
X 
(mM/g) 
0.145 
0.146 
0.145 
0.136 
0.112 
0.056 
0.028 
Tc 
y\ 
0.99 
0.99 
1.00 
0.97 
1.00 
0.98 
0.94 
0.010-1 
0 . 0 0 8 -
0.006 -' 
0.004 -
1 
0 . 0 0 2 -
Í ^ ' 
> 
I 
' o < 
I 1 
ж — — 
*~ Sn 
Tc 
ι I 
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m M / l 
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Fig. 3.17. Adsorption isotherms for technetium and tin after incubation for 1 
hr of equivalent amounts (Tc and Sn) with hydroxyapatite in the 
presence of EHDP. Tc: 0.05-0.5 mM/l; Srv 0.1-1 mM/l; EHDP: 
1.2 -12 mM/l; HSA: 13.4 mg/ml; NaCL· 0.13 M; pH = 7.44. 
94 
solution to test, whether technetium and tin are adsorbed separately or not 
The EHDP/tin ratio was 13:1, the incubation temperature was 21°. 
The ratios of the adsorbed amounts per gram hydroxyapatite for tin and 
technetium (XS n /XT c) vary between 2 (at low concentrations) and 5 (at 
high concentrations). 
The concentration ratio before incubation was 2. Apparently tin and 
technetium are separately adsorbed on hydroxyapatite and tin is preferred 
over technetium. 
The adsorption level of tin is high compared with the results of experiment 
15 (figure 3.12). This is probably caused by the fact that stannous tin is 
completely oxidized by the pertechnetate to stannic tin. The higher ionic 
charge causes the formation of more stable complexes with EHDP and it 
promotes the affinity for hydroxyapatite. The equilibrium is apparently in 
favour of the adsorption. 
The adsorption isotherm of technetium shows a maximum, just as the tin 
isotherm does. At higher concentrations (also of EHDP) the technetium 
and tin adsorptions decrease, but not to the same extent 
In conclusion: 
- Reduction of pertechnetate is a prerequisite for adsorption on 
hydroxyapatite. 
- Reduced pertechnetate and tin are adsorbed separately. 
- At high concentrations of EHDP the adsorptions of tin, techne-
tium, and HSA decrease. 
Group 5. Adsorption of MDP and pCPMDP with and without 
technetium and tin. 
Adsorption experiments were performed with each of the two diphopho-
nates and tin (molar ratio 13:1) for 72 hr. Further, for each of these 
diphosphonates an adsorption experiment was performed with tin and 
technetium-99m for 1 hr. For MDP an experiment was carried out with 
equivalent amounts of technetium and tin analogous to experiment 21. The 
incubation temperature for this group of experiments was 21°. Tris buffer 
was used instead of HSA. 
Figures 3.18 and 3.19 show the results of experiment 22. Both the MDP 
and the tin concentrations were measured. The incubation continued for 72 
hr. 
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Fig. 3.18. Adsorption isotherm for MDP (1.2 -12 mM/l) incubated for 72 hr 
with hydroxyapatite in the presence of stannous tin (0.09-09 
mM/l); 0.08 Mtns; pH = 7.42. 
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0 012 -
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Fig. 3.19. Adsorption isotherm for stannous tin (0.09-0 9 mM/l) incubated 
for 72 hr with hydroxyapatite in the presence of MDP (1.2- 12 
mM/l), 0.08 M tris; pH = 7.42. 
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Table 3.8 gives the maximum adsorption capacity (X ) and the affinity 
constant (K) for MDP. These values were calculated by plotting the results 
of experiment 22 according to the Langmuir equation (eq. 3.7) (c vs. c/X). 
Table 3.8 Maximum adsorption capacity (XJ and affinity constant (K) for the 
adsorption of MDP on hydroxyapatite(MDP: Sn = J 3:1) in 0.08 M tris; 
pH= 7.42. 
Χ Κ Согт.соеіГ. 
m 
(mM/g) (1/mM) Lin. regress. 
MDP 0.163 0.7 0.997 
MDP adsorption fits within the Langmuir equation The affinity of MDP for 
hydroxyapatite is much smaller than the affinity of EHDP, but the 
maximum number of binding sites is only slightly smaller (cf. table 3.3). 
Note that the tin isotherm shows no sharp maximum in the concentration 
range studied. It is remarkable that the maximum adsorption of tin in the 
presence of MDP is twice as high as in EHDP containing solutions (cf. 
figure 3.10). Possibly this difference originates from the difference between 
the stabilities of the MDP-tin and the EHDP-tin complexes, but this item 
will be further discussed at the end of this chapter. 
Figures 3.20 and 3.21 show the adsorption isotherms of MDP and tin 
respectively, from experiment 23. MDP and tin (13:1) and Tc-99m-
pertechnetate were incubated for 1 hr with hydroxyapatite. 
Table 3.9 gives the same data as shown in figures 3.20 and 3.21, together 
with the activity ratios for technetium. 
At the highest concentrations of MDP more technetium is adsorbed, than at 
the highest concentrations of EHDP in a corresponding experiment (cf. 
table 3.5). As in experiment 22, the tin adsorption isotherm shows no sharp 
maximum. The maximum adsorption of MDP after 1 hris about50% of the 
maximum level after 72 hr incubation (cf. figure 3.18). The maximum 
adsorption of tin is only slightly smaller (cf. figure 3.19). 
The same time effect was seen for tin in the presence of EHDP. 
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Fig. 3.20 Adsorption isotherm of MDP (1.3 -13 mM/l) after incubation for 
1 hr with hydroxyapatite in the presence of stannous tin (0.1-1 
mM/l) in 0.09 M tris buffer, pH = 7.6. 
0.004 -
π 1 г 
0.1 0.3 0.5 0.7 mM/l 
с Sn(II) 
Fig. 3.21. Adsorption isotherm of stannous tin (0.1-1 mM/l) after incuba­
tion for 1 hr with hydroxyapatite in the presence of MDP (1.3 -13 
mM/l) in 0.09 M tris buffer, pH = 7.6. 
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Table 3.9. Equilibrium concentrations and adsorbed amounts of MDP (1.3 -13 
mM/l) and stannous tin (O.I -1 mM/l) and activity ratios for technetium 
after incubation for 1 hr with hydroxyapatite in 0.09 M tris buffer; 
pH=7.6. 
Tc 
\i\ 
a 0.779 
b 0.726 
с 0.675 
d 0.544 
e 0.354 
f 0.208 
g 0.183 
с 
(mM/l) 
10.54 
9.41 
8.19 
5.91 
3.69 
1.36 
0.35 
MDP 
Χ 
(mM/g) 
0.075 
0.069 
0.067 
0.057 
0.045 
0.037 
0.028 
Sn 
с 
(mM/l) 
0.57 
0.47 
0.37 
0.17 
0.043 
0.001 
0.0 
Χ 
(mM/g) 
0.013 
0.013 
0.013 
0.013 
0.011 
0.006 
0.003 
Χ mM /g 
0 . 0 1 2 η 
0.010-
0.008-
0.006 -* 
0.004 
-к—» Sn ПС 
•—· Tc 
ι 
о.з 0.5 0.7mM/l 
с Тс and Sn(nZ) 
Fig. 3.22. Adsorption isotherms for stannic tin (0.1-1 mM/l) and reduced 
pertechnetate(0.05 - 0.5 mM/l) after incubation for 1 hr with 
hydroxyapatite in the presence of MOP (1.3 - 13 mM/l) in 0.09 M 
tris buffer, pH = 7.6. 
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Figure 3.22 shows the results of experiment 24. Equivalent amounts of tin 
and technetium were incubated for 1 hr in a MDP solution. The MDP-tin 
ratio was 13:1. 
Both the tin and the technetium isotherm show a plateau. Stannic tin has a 
greater affinity for hydroxyapatite than reduced pertechnetate. The maxi­
mum adsorption level for stannic tin with MDP is about the same as for 
stannous tin under comparable conditions (cf. fig. 3.21). It seems that the 
increased stability of the stannic tin-MDP complex balances the increased 
affinity for hydroxyapatite. This is in contrast with EHDP-tin, where the 
oxidation to stannic tin caused an increase in the tin adsorption (cf. figure 
3.17). At higher concentrations of diphosphonate the technetium adsorp­
tion with MDP is about twice the adsorption with EHDP (cf. figure 3.17). 
Figures3.23 and3.24 show the results of experiment 25. pCPMDPandtin 
(molar ratio 13:1) were incubated for 72 hr with hydroxyapatite. Both the 
diphosphonate and the tin concentrations were measured. 
XmM/g 1 
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Fig. 3.23. Adsorption isotherm ofpCPMDP (1.2 -12 mM/l) after incuba­
tion for 72 hr with hydroxyapatite in the presence of stannous tin 
(0.09 - 0.9 mM/l) in 0.09 M tris buffer, pH = 6.96. 
The adsorption data for pCPMDP were plotted according to the Langmuir 
equation (eq. 3.7,с vs. c/X). 
From this plot the maximum adsorption capacity (X ) and the affinity 
constant (K) were calculated 
X = 0.120 mM/g 
m ° 
К = 1.0 1/mM 
100 
XmM/g 
6.10"3 
4.10° 
2.10" 3-
0.1 0.3 0.5 0.7 0.9 
mM/l 
с Sn(II) 
Fig. 3.24. Adsorption isotherm of stannous tin (0.09-0.9 mM/l) after 
incubation for 72 hr with hydroxyapatite in the presence of 
pCPMDP (1.2 - 12 mM/l) in 0.09 M tris buffer, pH = 6.96. 
The correlation coefficient for linear regression was 0.996. 
So the adsorption of pCPMDP fits within the Langmuir equation. The 
maximum number of binding sites for pCPMDP is smaller than for MDP; 
the affinity constant for pCPMDP is about the same as for MDP (cf. table 
3.8). 
The tin adsorption isotherm shows the same aspect as the tin isotherm after 
incubation of an EHDP-tin solution (cf. figure 3.10): beyond a maximum 
the adsorbed amount of tin decreases with increasing amounts of 
pCPMDP in solution. The tin adsorption level is however, 30% lower than 
after a comparable experiment with EHDP. 
Figures 3.25 and 3.26 show the results of experiment26. pCPMDP and tin 
(13:1) and Tc-99m-pertechnetate were incubated for 1 hr with hydroxy­
apatite. 
Table 3.10 gives the same data as shown in figures 3.25 and 3.26 together 
with the activity ratios for technetium. 
The tin isotherm again shows a maximum, as could be expected based on 
the results of experiment 25 (cf. figure 3.23). 
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Fig. 3.25. Adsorption isotherm for pCPMDP (1.3 - 13 mM/l) after incuba­
tion for Ihr with hydroxyapatite in a stannous tin (0.1-1 mM/l), 
Tc-99m and tris (0.09 M) containing solution; pH=7.71. 
X mM/g 
6.10-3-
4.10- 3 -
2.ΙΟ­
Ι 
0.1 0.3 0.5 0.7 0.9 mM/l 
с Sn(ll) 
Fig. 3.26. Adsorption isotherm for stannous tin(0.1 - 1 mM/l) after incuba­
tion for 1 hr with hydroxyapatite in apCPMDP(1.3 - 13 mM/l), 
Tc-99m and tris (0.09M) containing solution; pH=7.71. 
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The tin adsorption on hydroxyapatite is smaller after 1 than after 72 hr 
incubation (cf. figures 3.24 and 3.26). For pCPMDP however, there is 
almost no difference between the isotherms after 1 and after 72 hr 
incubation (cf. figures 3.23 and 3.25). Over the whole concentration range 
studied, the technetium uptake with pCPMDP is 50-75% smaller than with 
MDP(cf. table 3.10). 
Table 3.10 Concentrations and adsorbed amounts of pCPMDP (1.3-13 mM/l) and 
stannous tin (0.1-1 mM/l) and activity ratios for technetium after 
incubation with hydroxyapatite for 1 hr in 0.09 M tris buffer, pH = 7.71. 
гСГМОР Tin 
RJ\ 
a 0.965 
b 0.985 
с 0.959 
d 0.949 
e 0.910 
f 0.778 
g 0.558 
с 
(mM/l) 
9.28 
8.16 
7.07 
4.91 
2.73 
0.77 
0.31 
Χ 
(mM/g) 
0.118 
0.111 
0.104 
0.091 
0.075 
0.055 
0.030 
с 
(mM/l) 
1.00 
0.87 
0.76 
0.54 
0.30 
0.10 
0.02 
Χ 
(mM/g) 
0.0010 
0.0016 
0.0019 
0.0022 
0.0031 
0.0030 
0.0025 
3.5. DISCUSSION AND CONCLUSIONS 
Most items have already been discussed in the results section. Two however 
have been left, which will be dealt with in this paragraph. 
In order to evaluate the origin of the intriguing maxima found in the 
isotherms of tin in EHDP and pCPMDP solutions, several trials using 
different models were undertaken to reconstruct these isotherms arithmati-
cally. In each of these trials it was assumed, that the diphosphonate tin 
complex is not adsorbed to the apatite surface, but that only the dissociation 
products of the tin complex (stannous hydroxide and diphosphonate, see 
chapter 5) adsorb. The stability constants presented in chapter 5 were used 
to calculate the concentration ratios of free and bound tin and diphospho­
nate. It was further assumed, that all adsorption processes can be described 
by the Langmuir equation. The differences between the models used, 
concerned with assumptions on the interactions of tin and diphosphonate at 
the apatite surface. In one model, independent adsorption of tin and 
diphosphonate was assumed and in another model competition of tin and 
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diphosphonate for the same binding site was assumed. Best reconstruction 
results were obtained by assuming an inhibiting influence on the tin 
adsorption by diphosphonate, while adsorbed tin does not inhibit the 
diphosphonate adsorption. Each of the three models correctly predicts the 
sharp maximum in the tin isotherm from experiment 13 (EHDP : tin = 
13:1, 72 hr incubation), as illustrated in figure 3.27. Reconstruction using 
these models does not produce a sharp maximum in the tin isotherm of 
experiment 22 (MDP : tin = 13:1,72 hr incubation), which is in agreement 
with experimental data (see figure 3.19). 
X mM/g 
0.010-1 
0.008 
0.006-« 
0 . 0 0 4 -
M 
I 
a 
0 . 0 0 2 -
Fig. 3.27. Adsorption isotherm for stannous tin (exp. 13). EHDP and tin 
(13:1) were incubated for 72 hr at 21°. Experimental (-X) and 
calculated curve (-Ш-). 
These simulation results suggest, that the appearance of the maximum in the 
tin isotherms in experiments with excess EHDP is due to the relatively great 
stability of EHDP-tin complexes and that the absence of a sharp maximum 
in tin isotherms in experiments with excess MDP is due to the instability of 
MDP-tin complexes (see chapter 5). pCPMDP forms very stable comple­
xes with tin (see chapter 5), so the maximum in the tin isotherm from 
experiment 25 (pCPMDP : tin = 13:1,72 hr incubation) is not unexpected 
anymore. 
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The maximum in the tin adsorption isotherms in cases, where a diphospho-
nate is present that forms stable tin complexes, can thus be ascribed to the 
decreasing concentrations of tin in solution available for adsorption, under 
the influence of increasing diphosphonate concentrations in solution, as the 
apatite surface approaches saturation with diphosphonate. 
As the exploring of the adsorption models and the fitting of the parameters 
for optimal simulation of the measured isotherms have not been completed 
yet, full details of this work will be published later. 
The main objective of this study was the elucidation of the mechanism of 
uptake of technetium-99m in bone. 
In experiments 21 and 24 carrier technetium was used with EHDP and 
MDP respectively. It was shown, that the technetium adsorption with MDP 
was higher than with EHDP, especially in the presence of an almost 
saturated apatite surface. The technetium isotherms from these experi-
ments (see figures 3.17 and 3.22) show a remarkable similarity with those of 
tin (see figures 3.10 and 3.19). With EHDP a sharp maximum is found, 
which is absent with MDP. 
The results of the experiments with carrier technetium were supported by 
the results of experiments with tracer technetium, which give a more 
realistic simulation of the clinical application. 
True isotherms can not be calculated from the results of experiments with 
Tc-99m, because the absolute concentration of Tc-99m in the stock 
solution is unknown. However, isotherms can be calculated on an arbitrary 
scale, using a fictive technetium concentration (c) for the stock solution and 
equations 3.13 - 3.15. Results are shown in figures 3.28, 3.29, and 3.30. 
For EHDP a sharp maximum, for MDP a broad maximum and for 
pCPMDP an almost constant level of technetium adsorption is found. 
The similarity between the technetium and tin isotherms suggests, that the 
dominant influence of the complex stability on the adsorption behaviour of 
tin might be operative for technetium adsorption as well. 
Figures 3.28-3.30 show the remarkable similarity between the aspects of 
corresponding tin and technetium adsorption isotherms (cf. figures 3.12, 
3.21, and 3.26). 
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(.с) 
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Тс М/І 
Fig. 3.28. Adsorption isotherm for technetium-99m in a solution with 
EHDP-tin(13:l). Incubation for 1 hrat21°. A fictive technetium 
concentration is assumed in the undiluted stock solution of с M/l. 
(cf. table 3.5). 
X mM/g 
8 η 
— ι ' 1 1 1 
0.1 0.3 0 5 0.7 0.9 (,C) 
Tc M/l 
Fig. 3.29. Adsorption isotherm for technetium-99 m in a solution with MDP-
tin (13:1). Incubation for 1 hr at 2Γ. A fictive technetium 
concentration is assumed in the undiluted stock solution of с M/L 
(cf. table 3.9). 
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(.с") 
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Fig. 3.30. Adsorption isotherm for technetium-99m in a solution with 
pCPMDP-tin (13:1). Incubation for 1 hr at 2Г. A fictive 
technetium concentration is assumed in the undiluted stock 
solution ofc" M/l(cf. table 3.10). 
In conclusion: 
Adsorption experiments with hydroxyapatite are able to explain the 
bone uptake values, as found in biological experiments (chapter 4). 
The stability of the diphosphonate complex and the affinity of 
diphosphonate for hydroxyapatite determine the .extent of the 
technetium adsorption on the apatite surface. The complex stability 
seems thereby of decisive importance for the extent of the technetium 
uptake. Among the three diphosphonates studied in this chapter, 
MDP gives the highest technetium uptake on hydroxyapatite. This is 
in agreement with results of biological experiments. 
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CHAPTER 4 
ANIMAL EXPERIMENTS 
4.1. INTRODUCTION 
Since the introduction of technetium-99m labeled phosphate compounds 
for skeletal scintigraphy by Subramanian in 1972 [1], several polyphos-
phates, diphosphonates and imidophosphates have been labeled with 
technetium and tested for their potential capacity as skeletal imaging agents. 
The main purpose was to find a superior bone seeking radiopharmaceutical 
As a result of extensive testing, Tc-99m-MDP became the mostly used 
agent for bone scintigraphy. 
In this chapter an evaluation of 28 technetium-99m labeled phosphorus 
compounds as bone seekers will be described. Most of these compounds 
were not reported in the literature before. These phosphorus compounds 
were kindly supplied by Henkel & Cie., Düsseldorf, G.F.R. The composi-
tion of this set of compounds was determined by the availability of these 
substances in the Henkel laboratories. The main objective of this work was 
to evaluate the biological behaviour of several diphosphonates in relation to 
their molecular structure and physicochemical properties (affinity for 
hydroxyapatite and complexing ability). From this set of phosphorus 
compounds six diphosphonates were selected for further investigation. 
Molecular structures and bone to soft tissue ratios for the labeled 
compounds acted as criteria for selection. 
The second part of this chapter presents a comparative macroscopic 
autoradiographical survey of the uptake of P-32 and Tc-99m labeled 
phosphorus compounds and strontium in the femoral bone of rabbits. This 
serves to illustrate that all bone seekers mainly concentrate in the same bone 
compartments, though differences are found in affinity for bone and in 
stability against hydrolytic activities. 
4.2. EXPERIMENTAL ASPECTS 
4.2.1. Tissue distribution experiments. 
In a first series, twenty seven different phosphonates, diphosphonates and 
pyrophosphate were labeled with technetium-99m and injected intrave-
nously in rabbits. These diphosphonates are listed in table 4.1. Labeling 
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with technetium-99m was standardized [2]. 
Of each phosphorus compound 0.06 - 0.07 mM was dissolved in 1 ml 
water. Of this solution Yi ml was mixed with Vi ml of a solution of stannous 
chloride in 0.1 M hydrochloric acid ( 1 mg/ml). Tc-99m-pertechnetate was 
added (2 mCi in Vi ml). After mixing, the volume of the solution was made 
up to 2 ml by addition of Vi ml 0.1 M sodium acetate buffer (pH = 5.6). The 
final solution was filtered over a sterile millipore filter (Millex 0.22 micron) 
into a sterile penicilline vial. For hydroxymethane diphosphonate a com­
mercially available kit (produced by Procter and Gamble and kindly sup­
plied by Byk-Mallinckrodt) was used. Three milliliters, containing 3 mCi 
Tc-99m-pertechnetate were added to a vial, containing 2 mg HMDP and 
0.16 mg stannous chloride sterile and lyophilized. 
Paperchromatography on Whatman nr. 1 chromatography paper with 
methanol (85 %) as mobile phase was done for quality control. The Rf-
value for unreduced pertechnetate was 0.6 -0.7 ; the labeled product had an 
Rf-valueofO.0-0.2. 
Usually less than 1% pertechnetate was found. 
Each labeled phosphonate or diphosphonate and labeled pyrophosphate 
was tested in two young adult rabbits (New Zealand white albino) with a 
weight of approximately 2200 g (age ± 3 month). 
The dose of technetium-99m was 500 μΟί in Vi ml. The dose of each 
phosphorus compound was approximately 0.01 mM per rabbit and the tin 
dose 0.17 mg (0.76 X 10"3 mM) stannous chloride for each rabbit For 
hydroxymethane diphosphonate a dose of 0.0017 mM diphosphonate was 
given with 0.027 mg (0.12 X IO"3 mM) stannous chloride. 
One hour after administration of the labeled compounds, the rabbits were 
sacrificed. Blood and tissue samples were taken, weighed, and counted in a 
Packard 5220 gammacounter. The results were expressed as percentage of 
dose per gram tissue. The shafts of femoral and tibia bones, freed from 
bonemarrow, were taken as bone samples. Besides full blood, also blood-
plasma was counted for radioactivity. 
Bone to soft tissue uptake ratios (B/S) were calculated for each experiment 
The soft tissue uptake value was calculated by averaging the resulting 
percentages of dose per gram for muscles, blood and myocardium. These 
tissues were not expected to have any specific interaction with the labeled 
diphosphonate. The uptake of each technetium-99m labeled phosphorus 
compound in the reticuloendothelial system (R.E.S.) was calculated by 
averaging the uptake values for liver, spleen and bonemarrow. High R.E.S. 
uptake values would be expected after administration of colloidal techne­
tium labeled material. 
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For several labeled diphosphonates blood disappearance curves were 
estimated by taking blood samples at 5, 15, 30, and 60 minutes after 
administration. 
Table 4 1 Phosphorus compounds tested in rabbits after labeling with technetium-
99m. 
Group 1 Noncyclic phosphonates and diphosphonates 
1 Methanediphosphonic acid (MDP) 
1A Hydroxymethanediphosphomc acid(HMDP) 
2 Dichloromethanediphosphonic acid (DCMDP) 
3 Phenylchloromethanediphosphonic acid 
4 p-Chlorophenylmethanediphosphonic acid (p-CPMDP) 
5 Aminomethane-l-(l,4-diazacyclohexane)-diphosphonic acid 
6 1 Hydroxyethane-l.l-diphosphonic acid (EHDP) 
7 l-Amino-2-carboxyethane-l,l-diphosphonic acid 
8 l-Hydroxy-3-aminopropane-l,l-diphosphonic acid (APD) 
9 2,3-Dicarboxypropane-l,l-diphosphonic acid(DCPDP) 
10 l-Methylamino-3-carboxypropene-2,l,l diphosphonic acid 
11 2-Phosphonobutane-l,2,4-tncarboxylic acid 
12 l,6-Bis-methylaminohexane-l,l,6,6-tetraphosphonic acid 
Group 2 Ν,Ρ-heterocyclic diphosphonates 
13 2,5-Dioxo-2-hydroxy-3-amino-3-phosphono-l ,2-azaphosphacyclopentane 
14 1 Ethyl-2,5-dioxo-2-hydroxy-3-ethylamino-3-phosphono-l,2 azaphosphacyclo-
pentane 
15 2,6-Dioxo-2 hydroxy-3-amino-3-phosphono-l,2-azaphosphacyclohexane 
16 l-Methyl-2,6-dioxo-2-hydroxy-3-methylamino-3-phosphono-l,2-azaphosphacy-
clohexane 
17 l-Methyl-2,6 dioxo-2-hydroxy-3-methylamino-3-phosphono-l,2-azaphosphacy-
clohexene-4 
18 1 Ethyl-2,6-dioxo-2-hydoxy-3-ethylamino-3-phosphono-l ,2-azaphosphacyclo-
hexane 
19 2,7-Dioxc-2-hydroxy-3-amino-3-phosphono-1,2-azaphosphacycloheptane 
20 l-Methyl-2,7-dioxo-2-hydroxy-3-methylamino-3-phosphono-l,2-azaphosphacy-
cloheptane 
Group 3 N-heterocyclic diphosphonates 
21 Pyrrolidine-2,2-diphosphomc acid 
22 Pyrrohdone-5,5-diphosphonic acid (PDP) 
23 N Methylpyrrolidenone-5,5-diphosphonic acid 
24 N ethylpyrrohdone-5,5-diphosphonic acid 
25 Pipendine-2,2-diphosphonic acid 
26 Pipendone-6,6-diphosphonic acid 
27 Azacycloheptane-2,2-diphosphorac acid 
28 Pyrophosphonc acid 
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In a second series of experiments fifteen diphosphonates and one 
phosphonate were selected for further tissue distribution investigation. The 
selected compounds are listed in table 4.2. 
The labeling procedure of these compounds with technetium-99m was 
slightly modified to obtain better control of the pH. Of each phosphorus 
compound 0.06 - 0.07 mM was dissolved in 2 ml water together with 1 mg 
stannous sulphate. The pH of this solution was adjusted to 7.4 with sodium 
hydroxide. One milliliter pertechnetate (3 mCi Tc-99m) was added The 
solution with the labeled compound was filtered over a sterile millipore filter 
(Millex0.22 micron) into a sterile penicilline vial. Quality control was done 
as for the first series with paperchromatography (Whatman nr. 1 ; methanol 
85%). 
Each preparation was tested in at least 5 rabbits (except for HMDP and 
DCPDP). 
In order to find an explanation for unexpected high RES levels in some of 
the experimental rabbits Tc-99m-MDP was tested in three extra rabbits. 
High RES uptake levels are never found after administration of Tc-99m-
MDP to human patients. For the three extra rabbits one tenth of the dose of 
MDP and stannous tin was given, while the dose of Tc-99m and the 
injection volume remained unchanged. Based on the results with the 
reduced dose of MDP and tin, a dose reduction was also tested with HMDP 
and tin (dose ten times reduced) and with DCPDP and tin (dose forty times 
reduced). 
The rabbits in the second series of tissue distribution experiments were 
treated in the same way as in the first one. 
The criteria for selection for further investigation in the second series of 
tissue distribution experiments were the molecular structures of the 
compounds under consideration, the structural differences between various 
phosphonates, and the potential use for application in patients. Compounds 
with a high uptake in the reticuloendothelial system were excluded from the 
second series. 
4.2.2. Autoradiography. 
Images of the macroscopic distribution of six radiolabeled compounds in 
the femoral bones of rabbits were obtained by contact autoradiography. 
These compounds are listed in table 4.3 together with the administered 
doses. 
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Table 4.2. Phosphonates selected for further investigation in a second series of tissue 
distribution experiments. 
Group 1. Noncyclic phosphonates and diphosphonates. 
1. Methanediphosphonic acid, MDP. 
1A. Hydroxymethanediphosphonic acid, HMDP. 
2. Dichloromethanediphosphonic acid, DCMDP. 
3. Phenylchloromethanediphosphonic acid. 
4. p-Chlorophenylmethanediphosphonic acid, pCPMDP. 
6. l-Hydroxyethane-l,l-diphosphonic acid, EHDP. 
8. l-Hydroxy-3-aminopropane-l,l-diphosphonic acid, APD. 
9. 2,3-Dicarboxypropane-l,l-diphosphomc acid, DCPDP. 
11. 2-Phosphonobutane-1,2,4-tricarboxylic acid. 
Group 2. Ν,Ρ-heterocyclic diphosphonates. 
16. l-Methyl-2,6-dioxo-2-hydroxy-3-methylamino-3-phosphono-l,2-azaphosphacy-
clohexane. 
17. l-Methyl-2-6-dioxo-2-hydroxy-3-methylamino-3-phosphono-l,2-azaphosphacy-
clohexene-4. 
19. 2,7-Dioxo-2-hydroxy-3-amino-3-phosphono-l,2-azaphosphacycloheptane. 
Group 3. N-heterocyclic diphosphonates. 
21. Pyrrolidine-2,2-diphosphonic acid. 
22. Pyrrolidone-5,5-diphosphonic acid, PDP. 
24. N-ethylpyrrolidone-5,5-diphosphonic acid. 
26. Piperidone-6,6-diphosphonic acid. 
Table 4.3. Radiolabeled compounds used for autoradiography. 
P-32 - Orthophosphate 100 microcuries. 
P-32 - Polyphosphate 100 microcuries. 
Sr-89- Strontium chloride 80 microcuries. 
Tc-99m-Tripolyphosphate 10 millicuries. 
Tc-99m-l-hydroxyethane-l,l-diphosphonate 10 millicuries. 
Tc-99m-Stannous chloride 10 millicuries. 
P-32-orthophosphate and Sr-89-strontium chloride were purchased from 
the radiochemical centre Amersham, U.K. 
P-32-polyphosphate was prepared by evaporating to dryness a mixture of 
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P-32-orthophosphate and 0.1 ml 1 M hydrochloric acid, heating the dry 
residue for 24 hr at 200°, and purifying the product by liquid chromatogra-
phy on QAE-Sephadex-A25 with a sodium chloride gradient as eluens. 
Labeling with technetium-99m was done according to the method described 
for the first series of tissue distribution experiments. 
To elucidate the influence of hydrolytic enzymes, P-32-polyphosphate was 
given to two rabbits: one with a normal and one with an elevated level of 
alkaline phosphatase. 
The rabbits were sacrificed 3 hours after administration of technetium-99m 
and 24 hours after administration of phosphorus-32 or strontium-89. 
Immediately thereafter, the femoral bones were removed and immersed for 
ten minutes in a chilling mixture of dry ice and isopentane (-65° to -75°). 
Care was taken to proceed as quickly as possible. The bones were fixed by 
embedding them in a suspension of carboxymethylcellulose in water (5 
percent, medium viscosity, temperature 0°). 
After embedding the bones, the CMC suspension was frozen by chilling it to 
-15°. The CMC block was mounted on the movable stage of a cryomicro-
tome (Jung K) placed in a freezer (-15°). Sections of 30 micron thickness 
were fixed on tape ( Scotch 8103 AW) during cutting. The strips of adhesive 
tape were then stretched on cardboard sheets. Sections containing techne-
tium-99m were covered with a thin plastic foil and then placed in contact 
with a radiographic film. Sections containing other radioisotopes were 
stored in a freezer (-15 °) for 48 hr and then placed in contact with a film. The 
exposure time for Tc-99m was 48 hr and for P-32 and Sr-89 about five days. 
The film used is Agfa-Gevaert Stracturix D 7. 
4.3. RESULTS 
4.3.1. Tissue distribution experiments. 
The results of the first series of tissue distribution experiments are listed in 
table 4.4. Table 4.5. summarizes these results for compounds showing an 
RES uptake smaller than 0.1 percent of the dose per gram tissue. Tc-99m-
pyrophosphate appears to show the highest bone to soft tissue ratio and Tc-
99m-p-chlorophenylmethane diphosphonate the lowest 
The data in table 4.5 were obtained by averaging the corresponding 
individual data from table 4.4 for each compound. 
The phosphorus compounds, labeled with technetium-99m, which showed 
an elevated uptake in the reticuloendothelial system (RES, liver, spleen, 
bonemarrow), are listed in table 4.6 in order of decreasing RES uptake. 
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Table 4 4 Results of the first series of tissue distribution experiments 
The numbers in the column heads refer to compounds listed in table 4 1 
The data represent percentage of dose per gram tissue 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
Tibia 
Brain 
Bloodplasma 
B/S 
RES 
1A 
0 013 
0 004 
0 010 
0 582 
0 338 
0 033 
0 013 
0 060 
0 183 
0 150 
0 001 
0 Oil 
19 2 
0 32 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
ie 
0 
1A 
012 
004 
012 
821 
362 
060 
010 
102 
177 
137 
001 
009 
9 
41 
1A' 
0 018 
0 004 
0 008 
0 023 
0 015 
0 012 
0 013 
0 074 
0 282 
0 219 
0 002 
0 012 
25 6 
0 02 
IA' 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
23 
0 
017 
004 
008 
030 
012 
009 
010 
057 
245 
199 
001 
6 
02 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
16 
0 
016 
003 
007 
019 
024 
008 
013 
122 
154 
131 
002 
021 
7 
02 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
и 
0 
023 
005 
010 
Oil 
020 
009 
017 
107 
167 
178 
002 
028 
7 
01 
2 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
3 
0 
046 
008 
021 
014 
016 
016 
024 
179 
102 
087 
002 
067 
В 
02 
0 
0 
0 
0 
0 
0 
0 
0 
с 
0 
0 
с 
4 
0 
г 
042 
006 
019 
019 
017 
023 
023 
218 
111 
086 
001 
065 
5 
02 
3 
0 089 
0 008 
0 035 
0 021 
0 025 
0 030 
0 038 
0 210 
0 125 
0 112 
0 003 
0 122 
2 6 
0 03 
3 
0 084 
0 006 
0 032 
0 020 
0 029 
0 032 
0 034 
0 235 
0 103 
0 09В 
0 002 
2 4 
0 03 
i diphosphonates and tin diluted ten times 
Table 4 A (continued) 
4 
0 065 
0 Oil 
0 027 
0 022 
0 044 
0 017 
0 043 
0 228 
0 069 
0 072 
0 002 
0 085 
2 1 
0 03 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
1 
4 
072 
016 
032 
024 
054 
027 
041 
253 
076 
071 
003 
089 
β 
0 04 
5 
0 024 
0 006 
0 013 
0 020 
0 010 
0 010 
0 019 
0 101 
0 101 
0 082 
0 001 
0 035 
6 4 
0 01 
0 
0 
0 
5 
025 
005 
012 
0 022 
0 
0 
0 
0 
0 
0 
0 
0 
7 
0 
on 
009 
022 
137 
106 
089 
001 
0ЭВ 
0 
01 
6 
0 029 
0 003 
0 on 
0 007 
0 010 
0 009 
0 013 
С 098 
0 161 
0 123 
0 001 
0 037 
9 9 
0 01 
6 
0 033 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
11 
0 
006 
013 
010 
013 
013 
030 
101 
220 
163 
001 
045 
1 
01 
7 
0 019 
0 002 
0 008 
1 700 
0 507 
0 227 
0 040 
0 122 
0 084 
0 066 
0 001 
0 018 
7 8 
0.81 
7 
0 01S 
0 002 
0 008 
1 154 
0 478 
0 114 
0 038 
0 129 
0 062 
0.068 
0 001 
0 023 
7 9 
-0.S8 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
Tibia 
Brain 
Bloodplasma 
B/S 
RES 
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Table 4 4 (continued) 
t я 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
ТіЫа 
Brain 
Bloodplasma 
B/S 
RES 
β 
0 028 
0 004 
0 015 
0 128 
0 182 
0 040 
0 091 
0 093 
0 151 
0 112 
0 002 
0 032 
β 4 
0 12 
β 
0 027 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
7 
0 
003 
027 
431 
195 
031 
12В 
133 
158 
ПО 
003 
036 
0 
22 
9 
0 009 
0 
0 
1 
0 
0 
0 
0 
0 
0 
0 
0 
8 
0 
OOI 
οοβ 
669 
771 
150 
007 
039 
062 
050 
001 
009 
9 
86 
9 
0 008 
0 001 
С 006 
0 559 
1 060 
0 124 
0 013 
0 101 
0 050 
0 043 
0 001 
0 006 
9,7 
0 58 
9 
0 013 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
31 
0 
002 
006 
017 
Ol. 
008 
Oil 
049 
230 
229 
001 
010 
9 
Ol 
9 
0 021 
0 005 
0 οοβ 
0 015 
0 010 
0 on 
0 037 
0 090 
0 258 
0 231 
0 001 
0 007 
21 8 
0 Ol 
я diphosphonate and tin fourty times diluted 
Table 4 4 {continued) 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
Tibia 
Brain 
Bloodplasma 
B/S 
RES 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
10 
035 
004 
017 
162 
139 
291 
024 
252 
09B 
067 
0 002 
0 
4 
0 
045 
4 
20 
10 
0 044 
0 007 
0 022 
0 454 
0 162 
0 199 
0 029 
0 428 
0 092 
0 070 
0 002 
0 062 
3 3 
0 27 
U 
0 049 
0 005 
0 019 
0 013 
0 023 
0 01B 
0 023 
0 262 
0 115 
0 105 
0 001 
0 071 
4 5 
0 02 
11 
0 054 
0 008 
0 024 
0 020 
0 034 
0 025 
0 030 
0 325 
0 096 
0 08i 
0 002 
0 067 
3 1 
0 03 
0 
0 
0 
4 
1 
0 
1 
0 
0 
0 
0 
0 
0 
1 
12 
035 
002 
045 
339 
129 
132 
357 
378 
012 
008 
003 
013 
4 
87 
12 
0 032 
0 001 
0 042 
5 238 
1 001 
0 1Θ2 
2 532 
0 295 
0 007 
0 006 
0 002 
0 012 
0 3 
2 14 
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Tabi e 4.4. (continued). 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
Tibia 
Brain 
Bloodplasma 
B/S 
RES 
19 
0.015 
0.001 
0.005 
2.073 
0.952 
0.215 
0.021 
0.055 
0.049 
0.047 
0.001 
0.009 
6.7 
1.06 
13 
0.011 
0.001 
0.005 
1.729 
0.854 
0.217 
0.096 
0.057 
0.043 
0.043 
0.001 
0.009 
7.9 
0.93 
14 
0.005 
0.001 
0.003 
0.948 
1.217 
0.294 
0.040 
0.014 
0.007 
0.004 
0.001 
0.002 
2.0 
0.82 
14 
0.007 
0.001 
0.003 
1.070 
1.062 
0.306 
С 050 
0.023 
0.007 
O.OOS 
0.001 
0.003 
1.7 
0.81 
IS 
0.025 
0.008 
0.011 
0.008 
0.008 
0.012 
0.015 
0.094 
0.156 
0.127 
0.001 
0.033 
9.9 
o.o: 
15 
0.030 
0.005 
0.010 
0.009 
0.018 
0.013 
0.016 
0.107 
0.119 
0.131 
0.001 
0.037 
β.4 
0.01 
Table 4.4. (continued). 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
T-bia 
Brain 
Bloodplasma 
B/S 
RES 
16 
0.045 
0.008 
0.021 
0.025 
0.035 
0.019 
0.025 
0.151 
0.133 
0.112 
0.002 
0.066 
5.1 
0.03 
16 
0.035 
0.007 
0.016 
0.019 
0.018 
0.012 
0.020 
0.153 
0.127 
0.097 
0.001 
0.053 
6.1 
0.02 
17 
0.032 
0.003 
0.012 
0.022 
0.025 
0.011 
0.015 
0.150 
0.160 
0.141 
0.001 
0.042 
9.8 
0.02 
17 
0.029 
0.007 
0.013 
0.012 
0.012 
0.015 
0.016 
0.135 
0.154 
0.124 
0.OO1 
0.043 
8.5 
0.01 
18 
0.044 
0.004 
0.017 
1.452 
0.116 
0.280 
0.024 
0.100 
0.090 
0.072 
0.002 
0.047 
3.7 
0.62 
18 
0.040 
0.004 
0.016 
0.565 
0.142 
0.336 
0.022 
0.112 
0.095 
0.076 
0.001 
0.038 
4.3 
0.35 
Table 4.4. (continued). 
Blood 
Muscle 
Heart 
Spleen 
L i v e r 
Bonemarrow 
Lung 
Kidney 
Femur 
Т1Ыа 
Brain 
Bloodplasma 
8/S 
RES 
19 
0.042 
0.005 
0.017 
0.017 
0.019 
0.013 
0.022 
0.252 
0.159 
0.173 
0.001 
0.057 
7.8 
0.02 
19 
0.030 
0.006 
0.013 
0.008 
0.013 
0.014 
0.021 
0.125 
0.131 
0.105 
0.001 
0.046 
7.3 
0.01 
20 
0.035 
0 005 
0.014 
0.021 
0.02: 
0.016 
0.020 
0.124 
0.108 
0.098 
0.001 
0.047 
5.7 
0.02 
20 
0.036 
0.006 
C.015 
0.012 
0.017 
0.016 
0.021 
0.131 
0.087 
0.084 
0.002 
0.051 
4.5 
0.01 
21 
0.024 
0.004 
0.010 
0.008 
0.009 
0.010 
0.012 
0.128 
0.132 
0.118 
0.001 
0.033 
9.9 
0.01 
21 
0.024 
0.008 
0.015 
0.020 
0.023 
0.023 
0.016 
0.087 
0.181 
0.151 
0.001 
0.039 
10.6 
0.02 
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Table 4 4 (continued) 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bortenarrow 
Lung 
Kidney 
Femur 
T i b i a 
Bra in 
Bloodplasma 
B/S 
RES 
22 
0 030 
0 004 
0 01« 
0 010 
0 011 
0.010 
0 017 
0 113 
0 147 
0 139 
0.001 
0 040 
9 .1 
0 .01 
22 
0 026 
0.004 
0 011 
0.009 
0 010 
0 010 
0 OIS 
0.100 
0.139 
0.121 
0 001 
0 037 
10.0 
0 .01 
23 
0 026 
0 003 
0 OU 
e 269 
1 095 
1 340 
0 04В 
0 100 
0 116 
0 115 
0 001 
0 031 
β . β 
2.90 
23 
0 019 
0 002 
0 007 
4 370 
0 993 
1.142 
0.063 
0.064 
0.116 
0.073 
0 001 
0 012 
10 1 
2 17 
24 
0 041 
0 006 
0.019 
0 012 
0 OIS 
0 014 
0 019 
0.172 
0.097 
0 079 
0 001 
0 055 
4 . 1 
0 . 0 1 
24 
0 037 
0 006 
0.01Θ 
0 015 
0.014 
0.022 
0.019 
0.156 
0.079 
0.063 
0 .001 
0.051 
Э.5 
0.02 
25 
0 025 
0.006 
0 on 
0 009 
0 οοβ 
0 009 
0.014 
0.082 
0 .128 
0 .099 
0 001 
0 034 
8.2 
0 . 0 1 
25 
0.031 
0 009 
0 .013 
0.008 
0.009 
0.015 
0.017 
0 .080 
0.150 
0.124 
0.001 
0.044 
7.7 
0 . 0 1 
Table 4.4. (continued) 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
T i b i a 
Brain 
Bloodplasma 
8/S 
RES 
26 
0 026 
0 005 
0 010 
0 on 
0 012 
0 009 
0 013 
0 IIB 
0 149 
0.117 
0.001 
0.035 
9 .6 
0 01 
26 
0 026 
0 004 
0 Oil 
0.010 
0 010 
0 010 
0.015 
0.0B6 
0 196 
0 128 
0.001 
0 .035 
11 9 
0 .01 
27 
0 032 
0 009 
0 017 
0 010 
0 010 
0 015 
0 018 
0.137 
0 139 
0.099 
0 001 
0.048 
6 2 
0 .01 
27 
0 028 
0 004 
0 010 
0 008 
0 009 
0 010 
0 013 
0 091 
0 145 
0 134 
0 001 
0 037 
10.2 
0 .01 
28 
0 029 
0 002 
0 013 
0 276 
0 07B 
0 018 
0 01B 
0 123 
0 238 
0 190 
0 001 
0.034 
14.4 
0 12 
28 
0 021 
0 003 
0 009 
0.012 
0.010 
0 014 
0.013 
0 112 
0 219 
0 187 
0.001 
0 .025 
IB 6 
0 .01 
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Table 4.5. Summary of the relevant findings in the first series of tissue distribution 
experiments for Tc-99m labeled phosphorus compounds, with an RES 
uptake smaller than 0.1 % per gram tissue. Listing in order of decreasing 
bone uptake P/B = plasma to full blood ratio. 
jnd number 
28 
6 
1 
26 
21 
22 
17 
19 
15 
27 
25 
16 
3 
2 
11 
5 
20 
24 
4 
Bone 
0.21 
0.17 
0.16 
0.15 
0.15 
0.14 
0.14 
0.14 
0.13 
0.13 
0.13 
0.12 
0.11 
0.10 
0.10 
0.09 
0.09 
0.08 
0.07 
Soft tissue 
0.01 
0.02 
0.01 
0.01 
0.01 
0.01 
0.02 
0.02 
0.01 
0.02 
0.02 
0.02 
0.04 
0.02 
0.03 
0.01 
0.02 
0.02 
0.04 
B/S 
16.5 
10.5 
15.2 
10.8 
10.3 
9.5 
9.2 
7.6 
9.2 
8.2 
8.0 
5.5 
2.5 
4.1 
3.8 
6.7 
5.1 
3.8 
2.3 
RES 
C.07 
0.01 
0.02 
0.01 
0.02 
0.01 
0.02 
0.02 
0.01 
0.01 
0.02 
0.03 
0.03 
0.02 
0.03 
0.01 
0.02 
0.02 
0.04 
P/B 
1.2 
1.4 
1.3 
1.4 
1.5 
1.4 
1.4 
1.5 
1.3 
1.4 
1.4 
1.5 
1.5 
1.6 
1.4 
1.5 
1.4 
1.4 
1.3 
High uptake levels of technetium labeled compounds in liver, spleen, and 
bonemarrow (RES) are expected if no complex between tin and the 
compound to be labeled is formed The free tin will hydrolyze and become 
partly colloidal. Pertechnetate will react with free tin and will also become 
colloidal or will precipitate. The precipitated technetium species will be 
withdrawn by millipore filtration (see procedure for labeling with techne-
tium-99m). If the compound to be labeled is poorly soluble in the reaction 
medium, a colloidal technetium species would also be expected 
Blood disappearance curves for seven technetium-99m-labeled diphospho-
nates are shown in figures 4.1 - 4.2. The curves represent the percentage of 
the administered activity in blood at different time intervals after injection. 
Table 4.6 A gives the percentage of the injected activity in blood at various 
time intervals after injection for 16 Tc-99m-diphosphonates. 
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Table 4.6. RES uptake values (percent of dose per gram) of Tc-99m labeled 
phosphorus compounds, showing uptake values over 0.1% per gram 
tissue. 
Compound number RES P/B 
23 
12 
13 
14 
9 
7 
18 
1A 
10 
8 
2.53 
2.00 
1.01 
0.82 
0.72 
0.70 
0.48 
0.37 
0.23 
0.17 
0.9 
0.4 
0.7 
0.4 
0.9 
1.2 
1.1 
0.8 
1.4 
1.2 
7o 
OO-i 
8 0 -
6 0 -
4 0 -
2 0 -
\ 
1 · 
14 
ι I I 
20 40 60 min 
Fig. 4.1 Blood disappearance of Tc-99m-pyrophosphate (У.), Tc-99m-
piperidone diphosphonate (+), Tc-99m-methane diphosphonate 
(9) and Tc-99m-dichloromethane diphosphonate (O) (lower 
curve) and blood disappearence of Tc-99m-p-chlorophenylme-
thane diphosphonate (upper curve). 
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~Ί 1 1 
20 40 60 min 
Fig. 4.2. Blood disappearance ofTc-99m-hydroxymethane diphosphonate 
(X) and Tc-99m-dicarboxypropane diphosphonate (9). 
The results of the second series of tissue distribution experiments are listed 
in table 4.7. Table 4.8 summarizes bone, soft tissues, and RES uptake as 
well as the bone to soft tissue uptake ratio and the plasma to blood ratio for 
compounds tested in this second series. The data from table 4.8 were 
calculated by averaging the corresponding values from table 4.7 for each of 
the various diphosphonates. 
In comparison with the results of the first series of tissue distribution 
experiments (tables 4.4 and 4.5) the main differences are: 
- the higher bone uptake of dichloromethane diphosphonate (2) and 
phosphonobutane tricarboxylate ( 11 ) in the second series, whereas most 
other diphosphonates showed a lower bone uptake under these condi­
tions. 
- the higher B/S values for most diphosphonates in the second series. 
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after injection as percentage of the administered dose. 
t 1 1A 2 4 5 6 9" 15 16 19 21 22 25 26 27 28 
fmin) 
5 15.6 23 6 25.5 63.3 21.6 25 0 24.0 20.1 26.3 23.0 18.7 24.0 22.6 21.2 16.4 
10 15.5 17.1 14.1 16.2 13.8 19.9 16.1 16.1 10.7 16.2 16.4 15.5 10.6 
15 10.3 11.9 15.1 36.6 13.4 11.1 11.5 11.2 15.4 12.Э 11.8 12.4 12.8 12.4 7.9 
30 4.6 6.7 10.4 24.2 8.7 6.4 6.1 6.8 10.1 6.3 7.5 6 5 8.1 8.9 8.3 4.9 
60 2 5 2.9 7.0 16.6 4.8 3.8 2.1 4.0 5.4 4.8 4.4 3.0 4.4 5.1 5.0 2.8 
Table 4.7. Results of the second series of tissue distribution experiments. 
The numbers in the column heads refer to compounds l isted in table 4.2. 
The data represent percentage of dose per gram tissue. 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
Tibia 
Brain 
Bloodplasma 
B/S 
RES 
1 
0.022 
0.003 
0.009 
0.008 
0.009 
0.010 
0.013 
0.118 
0.16B 
0.129 
0.001 
0.027 
13.3 
0.01 
1 
0.020 
0.003 
0.009 
0.38Θ 
0.063 
0.054 
0.016 
0.149 
0.173 
0.153 
0.001 
0.024 
15.6 
0.13 
1 
0.017 
0.003 
0.009 
0.024 
0.033 
0.011 
0.014 
0.085 
0.180 
0.150 
C.001 
0.023 
17.4 
0.02 
1 
0.014 
0.003 
0.007 
0.307 
0.092 
0.039 
0.011 
0.091 
0.203 
0.182 
0.002 
0.019 
23.2 
0.12 
1 
0.017 
0.002 
0.007 
0.325 
0.119 
0.027 
0.012 
0.157 
0.179 
0.145 
0.001 
0.021 
19.2 
0.12 
K«) 
0.018 
0.003 
0.009 
0.008 
0.010 
0.009 
0.011 
0.086 
0.176 
0.158 
0.001 
0.022 
16.5 
0.01 
1(«) 
0.015 
0.003 
0.007 
0.008 
0.008 
0.008 
0.009 
0.088 
0.177 
0.137 
0.001 
0.020 
18.7 
0.01 
1(«) 
0.013 
0.003 
0.007 
0.009 
0.009 
0.009 
0.010 
0.059 
0.235 
0.181 
0.001 
0.014 
26.7 
0.01 
* MDP-tin was ten-times diluted. 
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Table 4 7 (continued) 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
ТіЫа 
Brain 
Bloodplasma 
B/S 
RES 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
5 
0 
2 
038 
007 
018 
016 
019 
020 
023 
235 
130 
116 
002 
055 
9 
02 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
7 
0 
2 
039 
009 
017 
016 
021 
017 
022 
195 
157 
160 
001 
049 
3 
02 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
8 
0 
2 
033 
004 
015 
014 
018 
014 
018 
149 
165 
119 
001 
046 
2 
02 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
6 
0 
2 
026 
003 
014 
012 
on 
009 
015 
108 
103 
087 
001 
033 
7 
01 
2 
0 031 
0 004 
0 014 
0 012 
0 015 
0 Oil 
0 018 
0 126 
0 089 
0 078 
0 001 
0 042 
5 2 
0 01 
Table 4 7 (continued) 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
Tibia 
Brain 
Bloodplasma 
B/S 
RES 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
2 
0 
3 
081 
010 
037 
031 
033 
037 
037 
239 
103 
099 
002 
111 
4 
03 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
2 
0 
3 
085 
010 
035 
031 
032 
033 
043 
254 
120 
102 
002 
108 
6 
03 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
3 
0 
3 
082 
013 
033 
033 
033 
028 
041 
133 
151 
140 
002 
107 
4 
03 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
3 
0 
3 
063 
006 
027 
023 
031 
026 
032 
150 
120 
112 
002 
093 
6 
03 
3 
0 060 
0 007 
0 028 
0 021 
0 028 
0 022 
0 027 
0 166 
0 091 
0 080 
0 001 
0 081 
2 7 
0 02 
123 
Table 4.7 (continued) 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
Tibia 
Brain 
Bloodplasma 
B/S 
RES 
4 
0.065 
0.011 
0.027 
0.022 
0.044 
0.017 
0.043 
0.228 
0.069 
0.072 
0.002 
0.085 
2.1 
0.03 
4 
0.072 
0.016 
0.032 
0.024 
0.054 
0.027 
0.041 
0.253 
0.076 
0.071 
0.003 
0.089 
1.8 
0.04 
4 
0.090 
0.011 
0.031 
0.030 
0.056 
0.029 
0.041 
0.245 
0.080 
0.081 
0.0O2 
0.141 
2.9 
0.04 
4 
0.084 
0.008 
0.036 
0.022 
0.040 
0.022 
0.049 
0.172 
0.085 
0.091 
0.002 
0.077 
2.1 
0.03 
4 
0.068 
0.011 
0.029 
0.020 
0.046 
0.025 
0.044 
0.201 
0.089 
0.092 
0.002 
0.096 
2.5 
0.03 
Table 4.7 (continued). 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
Tibia 
Brain 
Bloodplasma 
B/S 
RES 
6 
0.024 
0.004 
0.011 
0.007 
0.010 
0.010 
0.014 
0.082 
0.141 
0.109 
0.001 
0.045 
9.6 
0.01 
6 
0.023 
0.004 
0.010 
0.007 
0.008 
0.010 
0.013 
0.071 
0.155 
0.135 
0.001 
0.031 
11.7 
0.01 
6 
0.O28 
0.O13 
0.017 
0.O1O 
0.007 
0.020 
0.015 
0.102 
0.176 
0.116 
0.001 
0.039 
7.6 
0.01 
6 
0.015 
0.005 
0.007 
0.005 
0.006 
0.005 
0.008 
0.064 
0.168 
0.156 
0.001 
0.022 
18.6 
0.01 
6 
0.023 
0.006 
0.010 
0.006 
0.008 
0.013 
0.013 
0.075 
0.115 
0.126 
0.001 
0.030 
9.1 
0.01 
124 
Table 4.7 (continued). 
Blood 
Muscle 
Heart 
Spleen 
L iver 
Bonemarrow 
Lung 
Kidney 
Femur 
T ib ia 
Brain 
Bloodplasma 
B/5 
RES 
8 
0.015 
0.003 
0.012 
0.269 
0.105 
0.011 
0.069 
0.095 
0.137 
0.114 
0.002 
0.019 
12.4 
0.13 
8 
0.020 
0.003 
0.020 
0.265 
0.132 
0.023 
0.108 
0.089 
0.12B 
0.116 
0.002 
0.017 
8.6 
0.14 
8 
0.Q17. 
0.003 
0.022 
0.135 
0.164 
0.018 
0.091 
0.134 
0.154 
0.154 
0.001 
0.021 
11.0 
0.13 
8 
0.017 
0.004 
0.015 
0.261 
0.099 
0.019 
0.079 
0.147 
0.139 
0.128 
0.001 
0.019 
11.1 
0.13 
8 
0.024 
0.004 
0.024 
0.651 
0.234 
0.022 
0.238 
0.106 
0.166 
0.133 
0.001 
0.024 
8.6 
0.30 
Table 4.7 (continued). 
Blood 
Muscle 
Heart 
Spleen 
L iver 
Bonemarrow 
Lung 
Kidney 
Femur 
T ib ia 
Brain 
Bloodplasma 
B/S 
RES 
11 
0.048 
0.006 
0.022 
0.020 
0.035 
0.023 
0.022 
0.19B 
0.134 
0.138 
0.002 
0.055 
5.5 
0.03 
11 
0.051 
0.008 
0.026 
0.049 
0.038 
0.037 
0.031 
0.286 
0.117 
0.099 
0.002 
0.065 
3.9 
0.04 
11 
0 060 
0.010 
0.030 
0.037 
0.048 
0.039 
0.037 
0.837 
0.097 
0.095 
0.002 
0.077 
2.9 
0.04 
11 
0.061 
0.007 
0.026 
0.023 
0.033 
0.024 
0.026 
0.231 
0.142 
0.155 
0.002 
0.065 
5.3 
0.03 
11 
0.051 
0.005 
0.021 
0.031 
0.038 
0.022 
0.033 
0.261 
0.119 
0.114 
0.002 
0.057 
4.6 
0.03 
125 
Table 4.7 (continued). 
Blood 
Muscle 
Heart 
Spleen 
L iver 
Bonemarrow 
Lung 
Kidney 
Femur 
T ib ia 
Brain 
Bloodplasma 
B/5 
RES 
16 
0.027 
0.005 
0.013 
0.008 
0.009 
0.011 
0.016 
0.106 
0.106 
0.098 
0.001 
0.042 
6.7 
0.01 
16 
0.028 
0.004 
0.013 
0.008 
0.011 
0.012 
0.016 
0.109 
0.093 
0.087 
0.001 
0.040 
6.0 
0.01 
16 
0.017 
0.003 
0.008 
0.005 
0.008 
0.008 
0.010 
0.O82 
0.105 
0.109 
0.001 
0.024 
11.4 
0.01 
16 
0.018 
0.003 
0.007 
0.005 
0.006 
0.006 
0.011 
0.073 
0.097 
0.092 
0.002 
0.023 
10.0 
0.01 
16 
0.028 
0.004 
0.011 
0.010 
0.018 
0.008 
0.012 
0.149 
0.099 
0.083 
0.001 
0.041 
6.3 
0.01 
Table 4.7 (continued). 
17 17 17 17 17 
Blood 
Muscle 
Heart 
Spleen 
L iver 
Bonemarrow 
Lung 
Kidney 
Femur 
T1Ma 
Brain 
Bloodplasma 
B/S 
RES 
0.034 
0.006 
0.016 
0.010 
0.017 
0.011 
0.018 
0.293 
0.120 
0.117 
0.002 
0.043 
6.4 
0.01 
0.034 
0.004 
0.015 
0.010 
0.015 
0.010 
0.019 
0.227 
0.114 
0.093 
0.002 
0.047 
5.9 
0.01 
0.024 
0.004 
0.011 
0.008 
0.011 
0.O09 
0.013 
0.177 
0.120 
0.098 
0.001 
0.031 
8.6 
0.01 
0.038 
0.005 
0.014 
0.010 
0.017 
0.012 
0.020 
0.218 
0.134 
0.114 
0.001 
0.046 
6.6 
0.01 
0.050 
0.008 
0.022 
0.014 
0.019 
0.016 
0.028 
0.366 
0.102 
0.093 
0.002 
0.063 
3.7 
0.02 
126 
Table 4.7 (continued). 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
Tibia 
Brain 
Bloodplasma 
B/S 
RES 
19 
0.023 
0.006 
0.010 
0.012 
0.012 
0.007 
0.013 
0.090 
0.131 
0.136 
0.001 
0.022 
10.2 
0.01 
19 
0.020 
0.003 
0.008 
0.016 
0.017 
0.010 
0.011 
0.092 
0.145 
0.14S 
0.001 
0.026 
14.2 
0.01 
19 
0.024 
0.004 
0.010 
0.018 
0.026 
0.014 
0.014 
0.114 
0.139 
0.129 
0.001 
0.033 
10.3 
0.02 
19 
0.024 
0.005 
0.012 
0.018 
0.021 
0.013 
0.014 
0.116 
0.141 
0.134 
0.001 
0.031 
10.1 
0.02 
19 
0.024 
0.006 
0.011 
0.104 
0.053 
0.041 
0.014 
0.096 
0.144 
0.133 
0.002 
0.034 
10.2 
0.06 
Table 4.7 (continued). 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
T1b1a 
Brain 
Bloodplasma 
B/S 
RES 
21 
0.029 
0.007 
0.013 
0.008 
0.010 
0.012 
0.016 
0.108 
0.130 
0.106 
0.001 
0.041 
7.2 
0.01 
21 
0.029 
0.009 
0.011 
0.008 
0.009 
0.007 
0.017 
0.128 
0.162 
0.127 
0.002 
0.036 
8.8 
0.01 
21 
0.023 
0.006 
0.011 
0.008 
0.010 
0.007 
0.016 
0.098 
0.108 
0.092 
0.001 
0.034 
7.7 
0.01 
21 
0.023 
0.004 
0.011 
0.008 
0.009 
0.009 
0.013 
0.076 
0.115 
0.108 
0.001 
0.032 
8.9 
0.01 
21 
0.026 
0.008 
0.011 
0.00B 
0.008 
0.009 
0.013 
0.103 
0.172 
0.127 
0.001 
0.034 
10.1 
0.01 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
ТіЫа 
Brain 
Bloodplasma 
B/S 
RES 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
Tibia 
Brain 
Bloodplasma 
B/S 
RES 
Blood 
Muscle 
Heart 
Spleen 
Liver 
Bonemarrow 
Lung 
Kidney 
Femur 
Tibia 
Brain 
Bloodplasma 
B/S 
RES 
гг 
0.017 
0.005 
0.008 
0.005 
0.005 
0.006 
0.010 
0.092 
0.125 
0.098 
0.001 
0.021 
11.4 
0.01 
0 
0 
0 
0 
0. 
0, 
24 
.033 
.005 
.016 
.011 
.013 
.012 
0.021 
0 
0. 
0. 
0, 
0, 
4, 
0, 
.127 
.077 
.083 
.001 
.047 
,5 
.01 
26 
0.023 
0.004 
0.011 
0.007 
0.011 
0.009 
0.014 
0.124 
0.143 
0.110 
0.002 
0.031 
9.9 
0.01 
22 
0.020 
0.005 
0.009 
0.006 
0.006 
0.009 
0.012 
0.106 
0.112 
0.131 
0.001 
0.031 
10.7 
0.01 
0 
0 
0 
0 
0 
0. 
0. 
0, 
0, 
0. 
0, 
0, 
3, 
0, 
24 
.032 
.006 
.015 
.010 
.012 
.013 
.020 
.109 
.063 
.061 
.001 
,044 
,5 
,01 
0. 
0, 
0, 
0. 
0. 
0, 
0, 
0, 
0, 
0. 
0, 
0, 
7, 
0, 
26 
,030 
,005 
,013 
,008 
.009 
.013 
.016 
.107 
.122 
.106 
.002 
.043 
.2 
.01 
22 
0.032 
0.004 
D.010 
0.008 
0.008 
0.009 
0.014 
0.061 
0.112 
0.105 
0.002 
0.076 
7.0 
0.01 
0 
0. 
0 
0 
0, 
0, 
0. 
0. 
0, 
0, 
0. 
0. 
4, 
0, 
24 
.036 
.008 
.017 
.011 
.015 
.016 
,023 
.120 
,085 
.103 
,001 
,054 
,5 
,01 
0, 
0, 
0, 
0, 
0, 
0 
0, 
0 
0 
0. 
0, 
0 
8. 
0 
26 
.028 
.009 
,012 
.008 
.009 
.011 
.016 
.115 
.159 
.106 
.001 
.039 
.2 
.01 
22 
0.018 
0.003 
0.009 
0.008 
0.009 
0.010 
0.010 
0.083 
0.088 
0.103 
0.002 
0.022 
9.8 
0.01 
24 
0.029 
0.004 
0.014 
0.008 
0.011 
0.012 
0.017 
0.159 
0.087 
0.079 
0.001 
0.044 
5.3 
0.01 
26 
0.027 
0.005 
0.012 
0.009 
0.010 
0.009 
0.017 
0.109 
0.131 
0.115 
0.001 
0.039 
8.4 
0.01 
22 
0.032 
0.008 
0.014 
0.010 
0.009 
0.017 
0.020 
0.107 
0.11B 
0.086 
0.001 
0.046 
5.6 
0.01 
24 
0.038 
0.005 
0.017 
0.010 
0.014 
0.013 
0.022 
0.223 
0.072 
0.083 
0.001 
0.054 
3.9 
0.01 
26 
0.025 
0.005 
0.013 
0.008 
0.007 
0.012 
0.017 
0.113 
0.125 
0.103 
0.001 
0.038 
8.0 
0.01 
128 
Table 4.8 Summary of the main findings in the second series of tissue distribution 
experiments. 
Listing in order of decreasing bone uptake. 
Compound number 
9 
1A 
1 
6 
19 
8 
21 
26 
2 
11 
22 
17 
3 
16 
24 
4 
Bone 
0.24 
0.24 
0.17 
0.14 
0.14 
0.14 
0.12 
0.12 
0.12 
0.12 
0.11 
0.11 
0.11 
0.10 
0.08 
0.08 
Soft tissue 
0.01 
0.01 
0.01 
0.01 
0.01 
0.01 
0.01 
0.01 
0.02 
0.03 
0.01 
0.02 
0.04 
0.01 
0.02 
0.04 
B/S 
26.9 
24.6 
18.8 
11.3 
10.9 
10.4 
8.5 
8.4 
6.7 
4.4 
9.7 
6.2 
2.9 
8.1 
4.3 
2.3 
RES 
0.01 
0.02 
0.05 
0.01 
0.02 
0.16 
0.01 
0.01 
0.02 
0.03 
0.01 
0.01 
0.03 
0.01 
0.01 
0.03 
P/B 
0.6 
0.7 
1.3 
1.5 
1.3 
1.1 
1.4 
1.4 
1.4 
1.2 
1.4 
1.3 
1.4 
1.4 
1.4 
1.3 
4.3.2. Autoradiography. 
The results from the autoradiographical experiments are shown in figure 4.3 
till figure 4.9. 
К 
f 
Fig. 4.3. P-32-Orthophosphate (100 μϋϊ). 
129 
Fig. 4.4. P-32-polyphosphate (100 μϋί). High level of alkaline phospha­
tase. 
Fig. 4.5. P-32-Polyphosphate (100 μϋΐ). Normal level of alkaline phospha 
tase. 
Fig. 4.6. Sr-89-Strontium chloride (80 μϋί). 
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'*.. 
Fig. 4.7. Tc-99m-Polyphosphate (10 mCi). 
L· 
.<-
Fig. 4.8. Tc-99m-EHDP(10 mCi). 
Fig. 4.9. Tc-99m-Stannous chloride (10 mCi). 
All autoradiographical images, except the one shown in figure 4.9, 
demonstrate the highest level of activity in the spongiosa just beneath the 
epiphyseal plate. Other zones with significant accumulation of activity are 
the endocortical and the subperiosteal bone surfaces (see figures 4.3 - 4.8). 
These three areas correspond to regions of highest metabolic bone activity. 
In figures 4.3 and 4.4 in addition to the bone uptake, some activity is also 
seen in the bone marrow. Orthophosphate is known to be taken up by bone 
marrow, but polyphosphate is not Bone marrow uptake after administration 
of P-32-polyphosphate reflects the hydrolytic influence of high levels of 
phosphatase enzymes on polyphosphate. 
The distribution of polyphosphate and strontium in bone (see figures 4.5 
and 4.6) is essentially the same. Strontium uptake under the bone surfaces 
throughout the compact bone seems to be higher than the corresponding 
polyphosphate uptake. The latter is more exclusively taken up at sites of 
high bone turnover. 
The distribution of technetium in bone after administration of Tc-99m-
tripolyphosphate and Tc-99m-EHDP is very similar to the distribution of 
P-32-polyphosphate under normal conditions. Administration of Tc-99m-
polyphosphate seems to cause some accumulation of technetium activity in 
the bone marrow presumably due to the presence of some colloidal 
technetium activity in the technetium-polyphosphate preparatioa Tc-99m-
EHDP shows no bone marrow uptake. 
Figure 4.9 shows the distribution of technetium activity after administration 
of Tc-99m-stannous chloride. The uptake is highest in the marrow cavity 
and in the bone marrow between the bone spicules in the spongiosa. A little 
amount of activity is also seen in the subperiosteal bone surface and in the 
zone just beneath the epiphyseal plate. The technetium uptake in the bone 
marrow is undoubtedly due to the colloidal properties of the technetium-tin 
preparation. The activity at the subperiosteal bone surface and beneath the 
epiphyseal plate illustrates that technetium, after reacting with tin, can settle 
in bone even without the presence of polyphosphate or diphosphonate. 
4.4. DISCUSSION 
The labeling procedure of the phosphonates and pyrophosphate with 
technetium-99m for the first series of tissue distribution experiments 
differed from the labeling procedure for the second series. The pH of the 
labeled compounds used in the first series was not measured. Measurements 
of identically prepared samples demonstrated that the pH was between 4 
132 
and 6. The labeled preparations used for the second series of tissue 
distribution experiments had a pH value between 7.2 and 7.4. The ratio 
between the tin and phosphonate (pyrophosphate) concentrations was the 
same for both series, but the absolute tin and phosphonate concentrations in 
the second series were almost twice as high as in the first one. 
Nevertheless, for most (di)phosphonates the results of the first and second 
series of tissue distribution experiments are very similar (compare table 4.5 
and 4.8). 
Four diphosphonates (16, 17, 22, and 26) however demonstrated a 
significantly lower bone uptake in the second series. The composition of 
solutions containing tin and diphosphonate varies with the pH (see chapter 
5). Thus, an effect of the pH at preparation of a technetium labeled 
diphosphonate on the tissue distribution is not unexpected. Perhaps, it is 
more surprising, that only four diphosphonates (all four cyclic, and two by 
two closely interrelated) show the pH effect Two diphosphonates ( 16 and 
19) showed a significantly lower technetium activity in the soft tissues in the 
second series. This is probably a pH effect, because a dose effect may be 
expected to act in the opposite directioa 
Reviewing the tissue distribution data from both series, three compartments 
appear to be of importance: 
- bone; 
- the renal system (incl. the bladder); 
- the reticuloendothelial system (liver, spleen, bone marrow). 
The RE.-system is known to clear the blood from colloidal material and it 
is generally accepted [3], that RES uptake after administration of techne-
tium labeled phosphorus compounds is due to the colloidal technetium 
content of the administered preparatioa Stannous tin, after hydrolysis, is in 
part a colloidal solutioa Added pertechnetate can combine with the 
stannous tin, producing a technetium labeled colloidal species. Techne-
tium-99m on its own is not likely to form a colloidal solution, because the 
technetium mass of a carrier-free technetium-99m solution is very small. 
Prevention of tin hydrolysis at neutral pH values can be achieved by 
complex formation. The formation of a colloidal stannous solution can also 
be prevented by addition of growth inhibitors [4]. Growth inhibitors act in 
the concentration area of heterogeneous nucleation through adsorption of 
the inhibitors at the growing sites of crystal nuclei. 
Diphosphonates can act through complex formation and growth inhibitioa 
Phosphonates belong to the most effective inhibitors. They are very stable 
and, unlike polyphosphates, do not hydrolyze in water at any pH value, even 
133 
at high temperatures. Complex formation of diphosphonates with stannous 
tin can occur at pH values between 4 and 8 ( see chapter 5 ). If a phosphorus 
compound can neither act as a growth inhibitor nor can form a complex with 
stannous tin, the resulting technetium labeled radiopharmaceutical, being 
colloidal in nature, will accumulate in the R.E.-system. If, for some reason, 
the solubility of the phosphonate in the stannous tin containing medium is 
too sparse, the same thing will happea The compounds listed in table 4.6 
showed a significant uptake in the RES. 
A remarkable observation was found for MDP ( 1 ), hydroxy MDP ( 1 A), and 
dicarboxypropane diphosphonate (9). These compounds, when labeled 
with technetium according to the standard prescription, often showed 
appreciable uptake in the R.E.- system. When however, the diphosphonate-
tin mixture was ten times resp. forty times diluted prior to addition of 
pertechnetate, the RES uptake was no longer elevated. In clinical experien-
ce technetium labeled MDP, HMDP and dicarboxypropane diphosphonate 
do not accumulate in the RES of patients. MDP and DCPDP were found to 
form very weak complexes with tin (see chapter 5); for HMDP no data are 
available. According to van Rosmalen [5] MDP is expected to be a weak 
growth inhibitor and DCPDP (9) a strong one. Colloid formation does not 
occur in the preparation vial, because injection from one and the same vial 
gives RES uptake in rabbits, but not in humans. Colloid formation thus 
occurs in the circulation of rabbits after injection, but this can be prevented 
by lowering the diphosphonate-tin dose administered to rabbits. The effect 
of dilution after injection apparently diminishes the stabilizing capacity of a 
weak complex former like MDP and causes tin colloid to be formed, unless 
the tin concentration remains under a certain level. It is possible, that for the 
other diphosphonates, which did not show this effect, complex formation 
prevents the formation of a tin colloid. 
Ring strain seems to be the reason for the poor compiexing capacities of the 
two azaphosphacyclopentane compounds (13) and (14) and thus when tin 
and pertechnetate are added according to the standard procedure, after 
injection an elevated RES uptake of technetium is found (cf. table 4.6.). 
APD (8) combines an appreciable bone uptake with an elevated level of 
technetium activity in the RE-system. Since APD is poorly soluble in water 
and its calcium complex precipitates at pH = 6, this probably explains the 
colloidal technetium activity, despite the fact that APD itself is known to be 
an excellent bone seeker. It is also possible, that the dilution effect is the 
reason for the RES uptake. For compounds 7, 14, and 18 the limited 
solubility may also be responsible for the technetium uptake in the RES. 
Technetium labeled phosphorus compounds, which are not taken up by the 
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liver, spleen or bone marrow, can only be extracted from the circulating 
blood by the hydroxyapatite in the skeleton or by the kidneys. Reviewing 
tables 4.4 and 4.7 no other tissues, except those mentioned above, are 
found, which show an elevated uptake of the investigated compounds. 
An elevated bone uptake may be expected with diphosphonates, which form 
relatively instable complexes. A high affinity of a diphosphonate for 
hydroxyapatite also favours the bone uptake (cf. chapters 3 and 5). An 
elevated soft tissue uptake may be expected with instable diphosphonate 
complexes, which dissociate in the blood circulation without colloid 
formation. Stable diphosphonate complexes which are slowly excreted also 
cause an elevated soft tissue uptake. 
Because maximum contrast in bone imaging is desirable, the suitability of a 
technetium labeled (di)phosphonate or pyrophosphate for skeletal scinti-
graphy can be judged by its bone to soft tissue ratio. The soft tissue uptake 
value reflects the technetium activity in blood and muscle tissue and is 
mainly determined by the blood activity. A high bone to soft tissue ratio 
requires a high bone uptake value and/ or a low soft tissue activity level. Also 
the ease of excretion by the kidneys of a circulating technetium labeled 
phosphorus compound plays a role in the overall suitability of this 
preparation for bone scintigraphy. 
Technetium labeled MDP combines rapid blood clearance with high bone 
uptake. Dichloro-MDP, has almost the same bone uptake value as MDP 
(see table 4.8), but a much slower blood disappearance (see figure 4.1) than 
MDP. The B/S value for DCMDP is only half the B/S value for MDP. 
Phenylchloro-MDP (3) and p-Chlorophenyl-MDP (4) show the highest 
soft tissue values. This is due in part to the low bone uptake, but the major 
factor is the slow renal excretion. 
Stronger binding to plasma proteins of these phenyl diphosphonates, or 
possibly marked renal tubular backresorption may be the reasoa 
In general, there is no significant difference between the bone uptake of the 
three groups of diphosphonates. Smaller diphosphonate molecules and a 
hydroxyl group at Cj seem to favour the concentration in bone. Most 
geminai diphosphonates show a higher bone to soft tissue ratio than the 
monophosphonate (11). Carboxylate groups can not take over the place of 
phosphonate groups in a diphosphonate molecule. It was already mentioned 
in the previous chapter, that the affinity of carboxylic acids for hydroxy-
apatite is much smaller than the corresponding property of diphosphonates. 
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The presence of an amino group in a noncyclic diphosphonate molecule 
hampers the dissolution in water. 
In Ν,Ρ-heterocyclic diphosphonates (group 2), the five membered ring has 
too much strain to permit the phosphorus atoms the mobility necessary for 
complex formation or growth inhibition. The corresponding six and seven 
membered ring molecules can prevent tin colloid formatioa The seven ring 
is a slightly better bone seeker than the six membered ring. This might be 
explained by the greater mobility of the phosphorus atoms in the seven 
membered ring which may favour the affinity for hydroxyapatite. The seven 
ring also has a higher soft tissue uptake level. This may be due to a higher 
degree of binding to plasma proteins, increased renal tubular resorption or 
dissociation in blood. Nonspecific binding to proteins almost invariably 
increases with increasing length of alkyl chains, by virtue of the hydropho­
bic properties of polymethylene chains [6]. The same holds concerning 
renal tubular backresorption, so a delayed excretion probably is responsible 
for the elevated soft tissue uptake with the seven membered ring. N-Methyl 
substitution seems to cause higher soft tissue uptake values, but the 
differences are not significant N-Ethyl substitution makes a molecule 
insoluble under the conditions of the labeling with technetium and thus 
causes an elevated RES uptake. 
Of the group of N-heterocyclic diphosphonates (group 3) pyrrolidine 
diphosphonate (21), pyrrolidone diphosphonate (22), and piperidone di­
phosphonate (26) give slightly better results, than other members of the 
group. These compounds combine an hydrogenated nitrogen atom with an 
appreciable rigidity of their ring structures. Probably, the ring rigidity inhi­
bits intramolecular hydrogen bond formation in these molecules, unlike 
more flexible structures (piperidine diphosphonate (25) and azacyclohep-
tane diphosphonate (27). Intramolecular hydrogen bonding between an 
hydrogen atom from the ring nitrogen and an oxygen atom from a 
phosphonate group might interfere with the adsorption to hydroxyapatite. 
For compounds 21,22, and 26 only intermolecular hydrogen bonding seems 
possible. N-Ethyl substitution on the pyrrolidone ring greatly reduces the 
bone uptake values, but has less influence on the soft tissue uptake. Absence 
of elevated RES uptake suggests, that tin complex formation is undisturbed. 
The absence of intermolecular hydrogen bonding and steric influences 
might interfere with the binding of this diphosphonate to hydroxyapatite and 
reduce the bone uptake of technetium. 
Blood may be roughly divided into two parts: the cellular part (containing 
erythrocytes, leucocytes and blood platelets) and the noncellular part 
(containing dissolved proteins, salts and other compounds). The cellular 
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walls of blood cells can act as a barrier regulating the transport of dissolved 
compounds between the interior and exterior of the cell. Cellular walls may 
also act as adsorption surfaces for certain compounds in the noncellular 
part of blood. If the cellular walls do not act as barriers and no adsorption of 
dissolved substances on to the cell walls occurs, the concentrations of a 
substance in blood and plasma (the noncellular blood part) will be equal. If 
the cellular walls prevent transport of a substance from the outer side to the 
interior of the cell completely, the plasma concentration will be about 1 ¥t 
times the total blood concentratioa The same will happen, if plasma 
proteins bind a substance completely. If, however accumulation of a 
substance occurs on or in a blood cell, the total blood concentration may be 
expected to be higher, than the plasma concentration. For most substances 
added to blood, the plasma concentration will be higher, than the concentra-
tion in full blood. For most technetium labeled diphosphonates the 
concentration ratio between plasma and full blood was between 1.2 and 1.5 
(See table 4.5 and 4.8). 
Table 4.9 Plasma lo full blood concentration ratios with corresponding plasma to 
blood cell concentration ratios, assuming an hematocrit value of 0.4. 
P/B Р/С 
1.67 
1.43 4 
1.25 2 
1.0 1 
0.71 0.5 
0.45 0.25 
The plasma concentration of most technetium diphosphonates is thus twice 
or more times the blood cell concentration ( See table 4.9). The samples of 
full blood and plasma were taken 1 hr after administration. From the blood 
disappearance curves we see, that for most diphosphonates 1 hr after 
administration less than 10% of the administered technetium activity 
remains in the circulation. Binding of technetium through tin to erythrocytes 
is known to be relatively stable. If one hour after administration 30% or less 
of the remaining blood activity is bound to the erythrocytes, one might draw 
the conclusion, that less than 3% of the initially given activity is taken up by 
the red blood cells. Red blood cells binding of technetium under the 
conditions described in section 4.2 seems not to be of great importance for 
most of the tested diphosphonates. Although interaction between techne­
tium diphosphonate and plasma proteins can not be excluded, for most 
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diphosphonates the binding of technetium to plasma proteins is not very 
strong, because 60 minutes after injection more than 90% of the administe-
red activity has left the circulation. 
For a few technetium labeled diphosphonates the concentration ratio 
between plasma and full blood was between 0.4 and 0.7. This means, that 
one hour after administration the technetium concentration in the blood 
cells is two to four times the plasma concentration. In all these cases the 
RES activity, especially in the spleen, was highly elevated (except for 
dicarboxypropane diphosphonate (9) forty times diluted). A high RES 
uptake is an indication for tin colloid formation as a result of hydrolysis of 
free tin with occlusion in or adsorption on the tin colloid of reduced 
technetium. The relatively high concentration of technetium associated 
with the blood cells is probably due to binding to the walls of these cells. 
Stannous tin is known to bind to blood cells. It is not known yet whether 
reduced technetium binds directly to blood cells or through tia Anyhow, 
technetium binding to blood cells is characteristic for instable technetium 
complex formation. Red blood cells, especially when damaged, are known 
to accumulate in the spleea Reduction of the administered dose of 
dicarboxypropane diphosphonate and tin by a factor of forty prevents the tin 
from colloid formation, but does not inhibit red cell binding. Apparently 
after injection into the circulation only a weak interaction exists between 
dicarboxypropane diphosphonate and technetium and tin, while before 
injection the interaction was strong enough to prevent hydrolysis of 
stannous tin. 
Dicarboxypropane diphosphonate is known to be an excellent growth 
inhibitor and forms relatively weak complexes with tin (See chapter 5). 
MDP-tin complexes are also very weak (see chapter 5). From the fact, that 
MDP-tin had to be diluted ten times to prevent an elevated RES uptake, 
while dicarboxypropane diphosphonate needed a fortyfold dilution, the 
conclusion might be drawn, that the interaction between MDP and tin in 
blood is stronger, than between dicarboxypropane diphosphonate and tia 
This is also supported by the value for the plasma to full blood ratio, which is 
1.2 for MDP and 0.6 for dicarboxypropane diphosphonate. 
Bone uptake was measured in the shafts of femur and tibia. The uptake in the 
femur was higher, than in the tibia. The tibia is known to have a smaller 
metabolic activity, than the femur, which confirms the tissue distribution 
results. 
Lung tissue is not expected to have any specific interaction with technetium 
diphosphonates under normal circumstances. If the RES uptake and the 
binding of technetium to red blood cells are not elevated, the lung uptake 
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values are almost equal to the calculated soft tissue uptake values. In cases 
of massive tin hydrolysis however, the tin particles might grow to such an 
extent as to block the lung capillaries after injection. Under these 
circumstances, elevated lung uptake values may be expected 
None of the tested diphosphonates demonstrated significant uptake of 
technetium diphosphonate in the braia 
The autoradiography with strontium (figure 4.6) shows, that strontium not 
only accumulates at the endosteal and periosteal surfaces of the femoral 
bone, but also throughout the cortex, though at a lower level than at the 
surfaces. Technetium-EHDP does not reach the interior of the femoral 
bone. This suggests, that the binding of technetium to bone tissue is more 
irreversible than the binding of strontium or that the affinity for bone of 
strontium is less, than of technetium-E HDP. 
Probably both factors are of importance. 
Macroscopic autoradiography suggests, that technetium and polyphos-
phate accumulate in the same bone regions. This does not necessarily mean, 
that technetium and polyphosphate bind to the same component of bone 
tissue. However, the fact that technetium after interaction with stannous tin 
can bind to hydroxyapatite ( see chapter 3), which is also the most probable 
component to bind polyphosphate, together with published data from 
microscopic autoradiography (see chapter 2) strongly suggests, that techne-
tium and polyphosphate (or diphosphonate) bind to one and the same bone 
tissue component 
4.5. CONCLUSIONS 
- Diphosphonates which give the highest bone to soft tissue ratios after 
labeling with technetium, form relatively instable complexes with tin. 
- Technetium and diphosphonate settle in the same region of bone. 
- The choice of the diphosphonate strongly influences the technetium tissue 
distribution, as well as the blood disappearance rate. 
- If the pH at the time of labeling is between5 and 7.5, it has only a minor 
influence on the tissue distribution. At pH = 7.5 slightly better tissue di-
stribution results can be achieved than at pH = 5. 
- Red blood cell labeling with technetium is favoured by instable complex 
formatioa 
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- Diphosphonates with more hydrophobic residues show slower blood 
disappearance. 
- For weak complexing diphosphonates the amount of tin added should be 
kept as small as possible, to prevent colloid formatioa 
- 2,3-Dicarboxypropane-1,1 -diphosphonate and hydroxymethane diphos-
phonate, when labeled with Tc-99m, seem to be even better bone seekers, 
than Tc-99m-MDP. 
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CHAPTER 5 
COMPLEX STABILITY ESTIMATIONS 
5.1. INTRODUCTION 
In the preceding chapters the experimental results presented indications of 
the importance of the instability of diphosphonate complexes for the 
accumulation of technetium in bone. Adsorption experiments demonstrated 
an individual adsorption behaviour for diphosphonate, tin, and technetium, 
while tissue distribution experiments in rabbits showed, that instable 
diphosphonate complexes have the highest values for accumulation in bone. 
In this chapter the determination is described of the stability constants of 
calcium and tin complexes of six diphosphonates. The results confirm the 
negative correlation between the complex stability of a diphosphonate and 
the uptake of this technetium labeled diphosphonate in bone. 
5.2. THEORETICAL CONSIDERATIONS 
5.2.1. Definitions. 
For the reaction: 
M + L ^ M L (5.1) 
where "M" stands for "metal" and "L" for "ligand", the stability constant 
for the complex ML is defined as: 
[ML]
 ( 5 . 2 ) 
K M L
= Птц-
Because activity coefficients under most circumstances are unknown, 
equilibrium concentration values are entered between the brackets. The 
calculated value for KM, represents the stoichiometric stability constant, 
instead of the thermodynamic stability constant A disadvantage of 
stoichiometric stability constants is, that a comparison of the various 
constants is only possible, in the same ionic medium. 
For the reaction 
M + H L - M H L (5.3) 
X X ч ' 
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as equilibrium constant ca- be written: 
_ [MHxL] 
K M H
«
L = [ M H H L ] ( 5 4 ) 
X 
KMH L ' s t n e '"dividual o r s teP stability constant for the complex MH L. 
Equation 5.3 represents the last step in the formation of the complex MH L. 
An equation, describing the overall formation of the complex MH L, can be 
written as: 
M + xH + L ^ MHxL (5.5) 
[MHL] 
^MHL 
(5.6) 
*
L
 [M] [H]* [L] 
ß M H , is the overall stability constant for the complex MH L. Overall and 
step stability constants are related by the expression: 
0 „ = K i · «2 * K3 · · · · Κ η = ΠΚ ; (5.7) 
According to equation 5.7 /?M H L can be rewritten as: 
^MHL = K H L " K H , L ' " " K H V L *
 K M H L ( 5 · 8 ) 
If in equation 5.6 concentration values are entered for the species MH L, M, 
and L and if for the hydronium ions the antilogarithme of the negative value 
of the pH is used, /?M H L does not represent a stoichiometric stability 
constant, but instead a mixed stability constant The reason for this is, that 
pH measurements give activities, instead of concentrations. We preferred to 
use stoichiometric stability constants instead of mixed stability constants. 
With help of the activity coefficient for hydronium ions, which was 
estimated for the conditions of the underlying experiments, the hydronium 
¡on concentrations were calculated from the pH measurements. 
5.2.2. The medium. 
From the foregoing it is clear, that stability constants should be measured in a 
constant ionic medium. This condition was met by addition of a constant 
excess of an inert electrolyte (background salt) to the solutions to be 
measured. In the experiments described in this chapter, the concentrations 
of diphosphonate and metal ion were in the order of 10 3 M, while the 
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concentration of the background salt was 10"1 M. The nature of the 
background salt should be such, that it will not interact with the species to be 
measured. Salts of the alkali metals with singly charged anions (often the 
Perchlorate ion) have been most widely used as background salt Alkali 
metal ions however, are known to form weak complexes with diphospho-
nates. Instead, the tetramethylammonium ion was choosen as cation. The 
solubility of tetramethylammonium Perchlorate in water however is too 
small to prepare a 0.1 M solutioa Halogenide ions were excluded from the 
medium, to prevent halogenocomplex formation with the metal ions under 
investigatioa So, we used 0.1 M tetramethylammoniumnitrate as back-
ground salt in all experiments to be described in this chapter. 
5.2.3 The method. 
Acid dissociation and complex stability constants can be determined by a 
method, which in its original form was described by Schwarzenbach in 
1950 [1]. We used a modem version of this method, using computer instead 
of graphical techniques to process the experimental data [2]. This modem 
version of the Schwarzenbach method appeared most useful, because it 
delivered stoichiometric stability constants not only of equimolar comple-
xes but also of protonated, hydroxylated, and binuclear complexes, and 
complexes with more than one ligand. 
In an internal report from the inorganic chemistry department of the 
research laboratory of Henkel & Cie, Düsseldorf, GFR, the estimation is 
described of the stability constants of some diphosphonate complexes with 
magnesium, calcium, cadmium, mercury, and lead 
In this report the computerized version of the Schwarzenbach method 
approved itself as most useful. 
The technique described by Schwarzenbach is based on the fact, that when a 
metal ion enters a solution in water of a ligand, which can interact with 
protons, a competition arises between the metal ions and protons for binding 
sites at the ligand molecules. Complex formation causes a pH shift 
Figure 5.1 shows an acidimétrie titration curve of DCMDP, together with a 
second acidimétrie titration curve, obtained after addition of an equimolar 
amount of calcium ions. Addition of calcium ions to the diphosphonate 
solution causes a fall in the pH value, if complex formation occurs. At low 
pH values no complex formation is expected and thus under these 
circumstances calcium addition causes no pH shift At higher pH values 
hydrolysis of a metal ion and formation of the hydroxide may also cause a 
fall in the pH value. This can be recognized by titration of the metal ion in 
the absence of ligand molecules. 
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1 2 3 4 
eq.Base 
Fig. 5.1. (See text) 
By titration of the ligand in absence of complexing metal ions, the acid 
dissociation constants of the ligand can be obtained From a second titration 
curve of the ligand plus a known amount of metal ions the complex stability 
constants can be calculated using the values for the acid dissociation 
constants, estimated previously. 
At the time when Schwarzenbach introduced his method ( 1950), computer 
facilities were not available for these calculations and he had to design his 
experiments in such a way, that a maximum number of approximations was 
allowed Acid dissociation constants could only be derived directly from the 
titration curve, if the successive dissociations in the titration curve were 
sufficiently apart. 
For titrations of ligand plus metal, large excesses of metal ions were used to 
obtain a constant metal ion concentration, unchanged by complex forma-
tion. Under these conditions the formation of complexes with more than one 
ligand could be neglected. Sets of equations describing the complex 
equilibria were graphically solved. 
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Today, numerous computer programmes are available [3] to evaluate most 
kinds of complex equilibria The design of an experiment can now be 
governed by chemical instead of mathematical considerations. With the 
modern computer support it is no longer necessary to titrate the ligand in the 
presence of a large excess of metal ions. It is even possible to titrate in the 
presence of an excess of ligand and still get the correct values for the stability 
constants of complexes existing in the experimental medium The greater 
flexibility allowed in the choice of the chemical conditions for the 
determination of complex stability constants, made it possible to reduce the 
risk of precipitate formatioa This greatly facilitated the determination of 
the stability constants of the stannous tin diphosphonate complexes, which 
will be described in the next sections of this chapter. 
5.2.4. Calculations. 
The computer procedures, employed to evaluate complex equilibria, may 
be divided into two groups: 
- Nonstatistical programmes. 
- Programmes based on the least-squares principle. 
5.2.4.1. Nonstatistical programmes. 
In general, more accurate results are obtained through the more sophisti­
cated fitting techniques of the second group of computer programmes. 
However, nonstatistical computer procedures may be helpful in calculating 
preliminary values for acid dissociation and complex stability constants. 
The advantage of these procedures is, that they can be executed with 
relatively cheap calculators, that can handle matrix inversion routines. By 
entering approximate values into the more sophisticated procedures, more 
accurate overall results can be obtained and less time is consumed for 
execution of a job on a more powerful and more expensive computer. 
For the preliminary calculation of acid dissociation constants we used a 
programme described by Hendrickson [4]. 
The protonation of the ligand, Hj jL is described by the following general 
expression: 
[HjL N + J ] (5.9) 
K j =
 [Η^ΤΪ^Ν^Γ 
where J = 1,2 N. 
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The total ligand concentration (CL) can be described as follows: 
C L = Σ [ИХ"™] (5.10) 
J=0 
The requirement of electroneutrality gives: 
N 
[H+] + BA · CL = [OH] + Σ (N-J) [ H , L N + J ] (5.11) 
J=0 
where BA is the number of moles OH" added, per mole ligand. 
Starting from equations 5.9 - 5.11 the next equation can be derived: 
N j 
Σ (N-J-XA) [H + ] J · ΠΚ
η
 = XA-N (5.12) 
J = l 
[H+] K W 
where XA = + BA - — ¡ _ — (513) 
CL [H+]CL 
and πκ„ is the overall acid association constant (/3j) (see eq. 5.7) (n = 
1 J) 
Acid association constants can be evaluated from a titration curve of ligand 
with base. N sets of data (BA and [H+]), from the buffering regions of the 
titration curve, are used to set up N simultaneous linear equations in the 
form of equation 5.12. These equations can then be solved for the N overall 
acid association constants πκ„ , by a matrix inversion technique run by a 
computer. From the resulting set of overall acid association constants, the 
individual constants can be calculated From the acid association con­
stants, the acid dissociation constants can be calculated. 
logKj = -logK'N + ] j = p K ' N + 1 J (5.14) 
where K' represents an acid dissociation constant 
An equation, similar to 5.12 can be derived for complex stability constants. 
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[ M H , L N + J + 2 ] 
К = - (5.15) 
M H J L [ Μ 2 + ] [ Η ^ Ν + ί ] 
For the total metal ion concentration, assuming a charge of 2+, can be 
written: 
N 
CM = [M 2 +] -! Σ rMH,L-N+ J + 2] (5.16) 
J=0 
In the presence of metal ions, equation 5.10 should be rewritten as follows: 
Ν N 
CL = Σ [HjL-N+J] + Σ [MHjL-N + J + 2] (5.17) 
J=0 j=0 
In the presence of metal ions, the requirement of electroneutrality turns into: 
[H+] + BA · CI + 2[M2+] = CM + [OH] + 
Σ {(N-J)[H JLN + J]+(N-J-2)[MH JLN + J + 2]} (5.18) 
J=0 
where 2 CM represents the charge of the anion present in the metal salt 
From equations 5.15-5.18 the next equation can be derived: 
Σ (N-J-XA)· ПК [H + ] J -[M 2 + ]-K M H j L = 
J=0 
N j 
Σ (XA+J-N) ПК [H + ] J (5.19) 
J=0 
For known values of πκ
η
 and first approximations of the free metal ion 
concentrations, first approximations of the complex stability constants can 
be calculated by matrix inversion, using N sets of data (BA and [H+]) from 
the buffering regions of the titration curve of the ligand in the presence of me­
tal ions. 
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From equations 5.15-5.17 an equation can be derived, solving the free 
metal ion concentration at a given point of the titration curve with known 
values of K M H L and ίικ,, •: 
-В + %/В2 + 4 AC (5.20) 
2А 
N J 
[M¿+] = 
where А = τ. ПК [H+] J-KX / I U I 
j = 0 η ι J MHjL 
Ν j 
В = (CL - СМ)А+ т ПК
п
 [H + ] J 
Ν J 
C = CM· Σ ПК [ H + ] J 
J=0 
With equation 5.20 second approximations of the free metal ion concentra­
tions are calculated for the selected points on the titration curve. The 
calculated values for [M ] are entered into equation 5.19 in order to 
calculate second approximations of K M H L. By means of an iterative 
process, accurate values of the stability constants can be calculated. 
A set of equations, similar to 5.19 and 5.20, can be derived for the calcula­
tion of KM H L from N sets of data (BA and [H+]) with known values of 
πκ
η
 a n d K ^ L · 
Equations 5.19 and 5.20 only account for equimolar complexes. These 
equations can not be used if binuclear complexes and metal hydrolysis exist 
together with the mononuclear complex. 
Because of the extensive hydrolysis of the stannous tin and the presence of 
appreciable amounts of binuclear tin diphosphonate complexes together 
with the mononuclear complex, even with excess diphosphonate, the 
programme by Hendrickson appeared not suited for the calculation of 
stability constants of tin diphosphonate complexes. The Hendrickson 
programme was only used to obtain preliminary values of the acid 
dissociation constants of the diphosphonates involved. 
149 
5.2.4.2. The SCOGS programme. 
The SCOGS programme (stability constants of generalized species) is an 
excellent example of a computer programme, which employs a nonlinear 
least squares approach. This method is long used by crystallographers in the 
reduction of X-ray data and calculates the "best" values of the desired 
parameters, i.e. those values for which the sum of the squares of the 
residuals of the measured and calculated quantities is minimum SCOGS is 
in fact an extension of the GAUSS program, which also uses the nonlinear 
least squares approach [5]. SCOGS, like GAUSS may be used to analyze 
appropriate pH titration data to yield acid association constants, metal ion 
hydrolysis constants, and stability constants of simple and polynuclear 
complexes, provided that the degree of species formation is pH-dependenL 
In addition SCOGS may be used to calculate constants for mixed 
complexes containing two different metals, or two different ligands. The 
general applicability of the GAUSS method was pointed out by Gaizer, 
who carried out evaluations of Potentiometrie [6], pH-metric, solubility [7] 
and spectrophotometric [8] measurements with one and the same algorithm. 
A further difference between the GAUSS and the SCOGS programme is 
that the former minimizes the sum of the squares of the weighed residuals in 
the "analytical hydrogen ion concentration". The value of this quantity 
varies considerably in the course of a titration, thus it appeared necessary in 
the calculation to apply a statistical weight factor. In SCOGS, refinement 
consists of minimizing the sum of the squares of residuals in the added 
amount of base, where residual means the difference between the actual and 
the calculated amount of base added The variance of the residuals in the 
added amount of base is not expected to change as markedly during a 
titration as it does when residuals are defined in terms of analytical 
hydrogen ion concentratioa For this reason a constant ( unit) weight factor 
is used in the SCOGS programme. 
The SCOGS programme is suitable for the calculation of the constants of as 
many as 20 species of type 
M M' ,L L' Η
 τ 
Ρ ρ q q -г 
where M and M' represent two different metal ions while L and L' stand for 
two different ligands. p, p', q and q' are positive integers or zero, г is a 
negative integer for protonated species and a positive integer for hydroxo-
compounds. 
r may also be zero. 
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The programme calculates overall formation constants ß M L H : 
_ [MpLqH r] [H+] r 
/ W H - p ^ ] q (5.21) 
According to equation 5.21, the overall stability constant for stannous 
hydroxide can be written as: 
[Sn(OH)2][H+]2 [Sn(OH)2] 
[Sn2+] ~ [Sn2+] [OH]2 0Sn(OH)2 - r Q„2+, - ГЯп2 НП№і2 ' V ( 5 " 2 2 ) 
^Sn(OH)2 K Sn(OH) 2 ' K w ^ 5 · 2 3 ) 
where K„ ,„„. represents the stoichiometric stability constant for stan­
nous hydroxide 2and К the ionization constant for water. 
According to equation 5.8, the following equations hold 
l o g 0 M 2 L = l o g K M 2 L + l o g K M L (5.24) 
' ° g / W = l°ßKMHL + loe KHL (5·25) 
For accurate work the SCOGS programme is able to accept data from 
titrations at several reagent concentrations, up to a total of 200 titration 
readings. The constants are then adjusted to fit all points simultaneously. 
In the input data the composition of each species must be given together with 
an estimate of the overall formation constant If the value of any constant is 
accurately known, it may be retained in the calculation, otherwise it may be 
adjusted by the computer to give the best fit of the data 
From the estimated values of the overall formation constants, by means of 
the Newton-Raphson iteration procedure [9] for each experimental point 
the concentrations are calculated for each species present From the 
calculated value of the hydrogen ion concentration, the added amount of 
base is calculated. Together with the actual added amount of base this gives 
the residual value, which is to be minimized by means of the least squares 
procedure. 
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Progressing through each experimental point, the least squares equations 
are built up, and are solved by matrix inversion to yield the shifts in the 
overall formation constants. The improved constants are calculated, 
together with their estimated standard deviations. 
This cycle is repeated for a specified number of times. 
On completion of the calculation a table is printed showing, for each 
experimental point, the pH, the actual added amount of base, the residual 
i.e. the difference between the actual and calculated amount of base, the 
total concentrations of each metal and ligand, the concentrations of each 
free metal and free ligand, and finally the concentrations of each complex 
species. These quantities are all calculated from the final values of the 
constants. 
After each cycle the calculated values of the overall formation constants 
and their estimated standard deviations are printed together with the 
standard deviation of the consumed amount of base. Both standard 
deviations should become minimal during the running of the programme. 
These standard deviations can give an indication of the existence of a 
complex species in the experimental medium: for a nonexisting complex 
the standard deviation of the overall formation constant becomes greater 
and greater after each calculation cycle. At the same time the overall 
formation constant becomes smaller. 
There remains, however, one serious limitation to the usefulness of 
programmes of this type. For reliable constants to be calculated for many 
coexistent species, it is essential to have experimental data of the highest 
attainable accuracy, covering a wide range of experimental concentrations 
and acidities. 
5.3. EXPERIMENTAL ASPECTS 
5.3.1. The equipment. 
The titrations were carried out with a Mettler software controlled titration 
system. A schematic representation of this system is given in figure 5.2. 
Several titration programmes can be executed under control of the soft 
ware, running on the Hewlett Packard HP 9815 calculator. The software 
package, together with the complete system ( except for the pH meter, which 
was from Radiometer, Copenhagen, Danmark), was purchased from 
Mettler Instruments, Zürich, Switzerland. The programme used for the 
complex stability estimations, is called "equilibrium titration programme". 
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Fig. 5.2. The software controlled titration system used for the determina­
tion of stability constants of diphosphonate complexes. 
The programme permitted the addition of a selectable amount of base to the 
solution in the titration vessel, followed by a pH readout, when the pH was 
constant within selectable limits for a selectable period of time. The pH was 
accepted as constant, when its drift was less than 0.001 pH units in 60 
seconds. The pH readout was recorded on the calculator's printer. It was 
assumed, that the solution was in the equilibrium state at each moment, 
when a pH value was collected in the described way. 
This cycle of base addition and pH reading was repeated, until a chosen 
endpoint was reached. 
The pH was measured with a Philips C-13 AA combination electrode and a 
PHM-64 research pH meter (Radiometer). The electrode was chosen 
because of the nondetectable chloride leakage into the titration solutioa 
The Mettler buret drive DV10 in combination with the 10 ml interchange­
able buret DV210 allowed base additions with an accuracy of ± 0.6 %. 
The automatic valve DV-13/131 permitted the automatic refilling of the 
interchangeable buret during a titration course, when more than 10 ml of 
base was needed to reach the endpoint 
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The temperature in the titration vessel (50 ml, Ingold) was kept constant at 
25° С ± 0.5° by means of a thermostatic circulation bath (Tamson 
T.X.Z.3/100). 
The contents of the titration vessel were mixed with a magnetic stirrer 
(Mettler). 
In order to exclude the presence of oxygen or carbon dioxide gas, the 
solutions in the titration vessel were flushed with argon gas before the 
titration. The argon gas was saturated with solvent. During the titration 
argon was blown over the surface of the titration solution. A soda lime tube, 
filled with potassium hydroxide pellets, was fitted on the head of the titration 
vessel to prevent entrance of carbon dioxide. 
5.3.2. Preparation of the solutions. 
Acid dissociation and complex stability constants were estimated for six 
diphosphonates: 
- Methane diphosphonic acid (MDP); 
- Dichloromethane diphosphonic acid (DCMDP); 
- p-Chlorophenylmethane diphosphonic acid (pCPMDP); 
- l-Hydroxyethane-l,l-diphosphonic acid (EHDP); 
- 2,3-Dicarboxypropane-l,l-diphosphonic acid (DCPDP); 
- Pyrrolidone-5,5-diphosphonic acid (PDP). 
MDP was purchased from Sigma Chemical corporation, StLouis, U.S.A. 
(M 9508). The other diphosphonates were kindly supplied by Henkel and 
Cie, Düsseldorf, F.R.G. 
The diphosphonates as disodium salt(pH = 4.5 - 5.5) were recrystallized 
from hot water. The diphosphonates were converted into their free acids by 
treatment with a five fold excess of strong acidic cation exchanger (Biorad 
AG 50 W - X . 4, 5.2 meq/g, 200 - 400 mesh, H+-form). The cation 
exchanger was previously treated with excess of 3 N H2SO. and washed 
with distilled water until the pH of the eluate was about five. 
Stock solutions of 20 ml 0.1 M diphosphonic acid were prepared. The purity 
was always better than 98% as judged from the acidimétrie titration curves. 
Tetramethyl ammonium hydroxide (about 0.1 M) was used as base in the 
titration. This solution was prepared from a 10% TMA-OH solution 
(Merck, 8123, for polarography). 
Contamination with carbonate was removed by treatment with excess 
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strong basic anion exchanger (Amberlyte IRA-400, СГ-form, analytical 
grade, BDH, treated with excess of 6 M NaOH (freshly prepared with 
freshly boiled distilled water) to convert it into the hydroxide form). The ion 
exchanger was washed with freshly boiled distilled water until the TMA-
OH solution had the desired concentration. The stock solution of 0.1 M 
TMA-OH was stored under argon gas. When in use, the solution was 
protected with a soda lime tube, filled with potassium hydroxide pellets. 
The TMA-OH solution was standardized by acidimétrie titration against 
hydrazinium sulphate p.a (Merck, 4603, 99%). The endpoint was poten-
tiometrically detected. 
Calcium nitrate - 4- hydrate p.a. (Merck, 2121, 98%) was used as calcium 
source without further purification. It's purity was determined by Potentio-
metrie titration of EDTA with calcium nitrate, using a divalent cation 
electrode (Orion 93-32). Stannous sulphate p.a. (Merck 7823) was used as 
stannous tin source without further purification. 
It's purity was determined by jodometric titration in diluted HCl with 
standard 0.1 N potassium iodate. The endpoint was detected potentiome-
trically with a combination redox electrode (Orion 96-78). The stannous tin 
contents fell from 98% in 1977 to 96% in 1979. 
Tetramethylammonium nitrate was prepared from tetramethylammonium 
chloride ( Merck 8 2215 6 ) by distilling off hydrochloric acid from a solution 
of TMA chloride in a 1 : 1 mixture of concentrated nitric acid and water 
[10]. When the distillate was free of chloride, the treatment was stopped. 
The residue was cooled to room temperature and then poured into 
isopropanoL The precipitate was filtered over a glass fiber filter. The raw 
product was recrystallized from isopropanol-water(5 :1 ) until it was free of 
acid and chloride. Two recrystallizations were mostly sufficient The 
product was stored dry, cool, and in the dark. Sometimes it appeared 
necessary to recrystallize the TMA nitrate immediately before a 0.1 M 
solution was prepared in order to remove free acid. The 0.1 M TMA nitrate 
solution was prepared with freshly boiled distilled water and stored under 
argon. If necessary, the pH was adjusted to 7.0 with a few drops of TMA 
hydroxide. A volume of 250 ml 0.1 M TMA nitrate was prepared, whenever 
necessary. 
5.3.3. The titrations. 
The diphosphonic acid concentration in the titration solutions was about 2.5 
X 10"^  M (1 ml 0.1 M stock solution weighed and diluted to 40 ml). The 
start volume of the titration solutions was 40 milliliters. This volume was 
reached by addition of 0.1 M TMA nitrate. 
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Calcium nitrate or stannous tin sulphate was weighed dry. The molar metal 
to diphosphonic acid ratio was 1:1, 1:2, 1:4, or 1:8. So the metal 
concentrations varied between 0.3 - 2.5 X 10"3 M. For MDP, a tin to 
diphosphonic acid ratio of 1:4 was never exceeded to prevent precipitate 
formatioa 
For metal to diphosphonic acid ratios of 1:8 the amount to be added was too 
small to weigh it directly. In this case a solution was prepared of known 
concentration. Calcium nitrate was dissolved in water, stannous sulphate in 
0.1 N sulphuric acid. The tin solution was freshly prepared under argon, 
immediately before titration. The acid concentration in the tin solution was 
estimated carefully to take into account in the calculations of the SCOGS 
programme. An appropriate amount of the calcium or tin solution was 
added to the diphosphonic acid solution in order to obtain the desired metal 
to diphosphonic acid ratio. 
Before each titration the zero point and the slope of the pH measuring 
system were calibrated with buffers at 25°. The zero point was calibrated 
with a phosphate buffer (pH = 7.00 at 25° C, Radiometer S 1326). The 
slope was calibrated with a phthalate buffer (pH = 4.01 at 25° C, 
Radiometer S 1316). 
After each titration the pH electrode was placed in the phosphate buffer at 
25° C. If the pH reading differed more than 0.01 pH unit from 7.00, the 
collected titration data were abandoned. If major differences occurred 
repeatedly, the electrode was replaced. 
Duplicate titration curves were accepted when point by point the difference 
was less than 0.005 pH unit (except for the steeper parts of the curves). 
5.3.4. Determination of the hydronium ion concentration and the disso­
ciation constant of water (KJ. 
As described in section 5.2.1., equilibrium concentration values instead of 
activity values are needed to calculate stoichiometric stability constants. If 
hydronium ions take part in the equilibrium, hydronium ion concentrations 
can be calculated from measured pH values. For this purpose a method 
described by Irving et al. [11] was used. 
By definition, 
A = F . С (5.26) 
where A represents an activity value, С a concentration, and F the activity 
coefficient for the underlying conditions. 
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For pH measurements equation 5.26 can be rewritten as: 
p H
x p _ = - logF-log[H4 (5.27) 
where [H+] stands for the hydronium ion concentratioa 
From the experimentally determined equivalence point the hydronium ion 
concentration can be calculated for each point of the titration of 1 ml 0.1 N 
nitric acid in 39 ml 0.1 N TMA nitrate with 0.1 N TMA hydroxide. From a 
measured pH value and the matching calculated hydronium ion concentra­
tion, an activity coefficient can be calculated Only below pH = 3 the 
calculated activity coefficients are reliable. These values were averaged 
together with the corresponding data from a duplicate titration curve. The 
result (0.81) was used in the SCOGS computer programme. It was in good 
agreement with literature data [12]. 
Beyond the equivalence point the hydroxide ion concentration can be 
calculated analogous to the hydronium ion concentration calculation. From 
the matching pH value and the hydronium ion activity coefficient, the 
hydronium ion concentration can be calculated From the hydroxide 
concentration and the matching hydronium ion concentration the ionization 
constant of water is calculated The result 13.87 was also used in the 
SCOGS calculations. 
5.3.5. Processing of the titration data. 
The programme, described in section 5.2.4.1., was only used to obtain 
preliminary values for the acid dissociation constants. To prevent erroneous 
results, not more than three constants were calculated in each computer run. 
Ina first run Кд , Кд , and Кд were calculated For a four basic acid in the 
second run Кд , Кд , and Кд were calculated In the second computing run 
Кд was neglected and only those pH data were used for the calculations, 
for which could be assumed that one proton was completely dissociated 
The base volume data, which had to be entered into the computer, were 
adapted the volume of base, consumed to neutralize one equivalent of acid 
was set as the new zero point of base volume. The other base volume data 
were adapted correspondingly, as well as the starting volume of the titratioa 
Refined results for the acid dissociation constants were obtained with the 
SCOGS programme. The dissociation constant for the first deprotonation, 
having a value of about 1.5, was never accurately calculated The refine­
ment calculations were started at those points of the titration curves, where 
the first equivalent of acid was neutralized. The volume data were adapted 
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as described above. To obtain optimal results, not more than one 
dissociation constant at a time was entered as a variable into the computer 
calculations. When an optimal value for a dissociation constant was 
reached, it was further considered as a constant in the calculations and a 
next dissociation constant was entered as a variable. This was repeated until 
optimal values for all constants were calculated. 
As many pairs of pH and base volume as possible, to a maximum of 200, 
were entered into the calculations. From the steeper parts of the titration 
curve some points were abandoned in order to obtain better fitting. 
It was supposed, that calcium complexes were not formed before the second 
proton was dissociated. For this reason and to reduce the number of 
variables, the calculations of calcium complex stability constants were 
started at those points of the titration curves, where two equivalents (related 
to the amount of diphosphonic acid present) of base had been added. The 
volume data were adapted properly. 
For the estimation of stannous tin complex stability constants only those 
titration data were taken into account, for which could be assumed, that Кд 
could be neglected. The volume data were adapted properly. 
The validity of the results of the calculations with the SCOGS programme 
can be judged by two parameters: the standard deviation of the calculated 
base volumes and the standard deviations of the calculated constants. The 
former parameter gives an impression of the overall quality of the outcome 
of the fitting process; the latter parameters allow a judgement of the 
existence of entered complexes and of the accuracy of calculated constants. 
A nonexisting complex was characterized by the fact, that after each 
calculation cycle the calculated formation constant became smaller, while 
the standard deviation of that constant became greater. 
Optimal results were supposed to have been achieved, when the standard 
deviation in the consumed amount of base was not greater than a few 
hundredth's of a milliliter, while the standard deviations of the calculated 
constants were not greater than one percent 
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5.4. RESULTS 
Table 5.1. gives the acid dissociation constants for six diphosphonic acids. 
Table 5.1. 
MDP 
DCMDP 
pCPMDP 
EHDP 
DCPDP 
PDP 
Acid dissociation constants of six diphosphonic 
tions are placed between 
pK2 
2.75 (0.02) 
2.77 (0.02) 
2.77(0.01) 
2.66 (0.02) 
2.25 (0.03) 
pK3 
7.10(0.01) 
5.97 (0.02) 
6.94 (0.02) 
6.99(0.01) 
4.89 (0.02) 
6.75(0.01) 
parentheses. 
ρκ4 
10.75(0.01) 
9.72(0.01) 
11.15(0.02) 
11.23(0.01) 
6.40(0.01) 
10.69(0.01) 
pK5 
___ 
— 
: acids. Standard devia-
9.19(0.01) 
12.2 (0.12) 
PK* 
— 
11.89(0.02) 
The stability constants of the calcium complexes of these diphosphonic 
acids are tabulated in table 5.2., while the stability constants of the 
corresponding stannous tin complexes are tabulated in table 5.3. 
Table 5.2 Step stability constants of calcium complexes of six disphonic acids. 
Standard deviations are placed between parentheses (0.1 M Tetramethyl­
ammonium nitrate, 25° С) 
log К, Cai- log К, CaHL log К Ca2L '°g Kcal.2 
MDP 
DCMDP 
pCPMDP 
EHDP 
DCPDP 
PDP 
5.97 (0.06) 
5.95(0.01) 
5.87(0.07) 
6.18(0.03) 
ЬвКсл 
4.1 (0.16) 
2.89 (0.08) 
3.2 (0.12) 
2.6 (0.1 ) 
3.12(0.06) 
l o 6 KcaHL 
4.15(0.03) 
6.86 (0.06) 
3.84 (0.08) 
3.0 (0.3 ) 
3.0 (0.25) 
4.63 (0.06) 
l o 6 KCaH2L 
2.91 (0.03) 
3.73 (0.06) 
3.7(0.1) 
l o 6 ^ H L 
3.83 (0.07) 
The stoichiometric stability constant for Sn(OH)2 is: 
lo
e
K
sn(OH)2 = 2 1 - 3 0 ( 0 0 7 ) 
(0.1 M Tetramethylammonium nitrate, 25° С). 
(5.28) 
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Table 5.3. Step stability constants of stannous tin complexes of six diphosphonic 
acids. Standard deviations are placed between parentheses (0.1 M 
Tetramethylammonium nitrate, 25° С). 
log К, SnL log K s logK, Sn2L 
MDP 13.6 (0.4 ) 7.7 (0.15) 
DCMDP 13.59(0.09) 8.9(0.13) 
pCPMDP 17.0 (0.08) 
EHDP 15.68 (0.07) 
8.0(0.4 ) 
12.5(0.16) 
9.6(0.13) 
l o 6 K S n L l o 6 K SnHL l o 6 K SnH 2 L '°6 К 5 п Н з 1 . log K S n 2 L 
DCPDP 17.31(0.09) 12.09(0.05) 7.6(0.3) 5.7(0.1) 8.9(0.2) 
PDP 14.43(0.08) 8.1(0.2) 
Based on the stability constants from tables 5.2 and 5.3 the relative amounts 
of the various complex species and free metal ion present were calculated as 
a function of the pH. 
For the calcium complexes the results are represented in figures 5.3 till 5.8. 
For the stannous tin complexes the results are presented in figures 5.9 till 
5.14. ·/„ 
100 π 
8 0 
6 0 
ДО-
2 0 
θ 9 ЮрН 
Fig. 5.3. Relative amounts of the various calcium species present in a MDP 
containing medium (MDP: Ca = 2:1) at varying pH (0.1 M 
TMA-NO* 25° C). 
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5.4. 
10рН 
Relative amounts of the various calcium species present in a 
DCMDP containing medium (DCMDP : Ca = 2:1) at varying pH 
(0.1 M TMA-NOj, 25° C). 
Ю р Н 
5.5. Relative amounts of the various calcium species present in a 
pCPMDP containing medium (pCPMDP: Ca = 2:1) at varying 
pH(0.1 M TMA-NOj, 25° C). 
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10 pH 
5.6. Relative amounts of the various calcium species present in an 
EHDP containing medium (EHDP : Ca = 2:1) at varyingpH(0.1 
M TMA-NOr 25° C). 
10 pH 
5.7. Relative amounts of the various calcium species in a DCPDP 
containing medium (DCPDP: Ca = 2:1) at varying pH(0.1 M 
TM A-NO,, 25" C). 
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5.8. 
10 pH 
Relative amounts of the various calcium species present m a PDP 
containing medium (PDP: Ca =2:1) at varying pH (0.1 TMA-
NOj, 25° C). 
5.9. Relative amounts of the various stannous tin species present in a 
MDP containing medium (MDP: Sn = 8:1) at varying pH(0.1M 
TMA-NOj, 25° C). 
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Fig. 5.10. Relative amounts of the various stannous tin species present in a 
DCMDP containing medium (DCMDP: Sn = 4:1) at varying pH 
(0.1 M TMA-NOj, 25° C). 
10 pH 
Fig. 5.11. Relative amounts of the various stannous tin species present in a 
pCPMDP containing medium (pCPMDP: Sn = 4:1) at varying 
pH(0.1 M TMA-NOj 25° C). 
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"ІОрН 
Fig. 5.12. Relative amounts of the various stannous tin species present in an 
EHDΡ containing medium (EHDP: Sn = 4:1) at varyingpH(0.1 
M TMA-NOj, 25° C). 
Fig. 5.13. Relative amounts of the various stannous tin species present in a 
DCPDP containing medium (DCPDP: Sn = 4:1) at varying pH 
(0.1 M TMA-N03, 25° C). 
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Fig. 5.14. Relative amounts of the various stannous tin species present in a 
PDP containing medium (PDP: Sn = 4:1) at varying pH (0.1 M 
ΤΜΑ-Ν03, 25° С). 
5.5. DISCUSSION 
5.5.7. Acid dissociation constants. 
From table 5.1 it appears, that MDP, pCPMDP, and EHDP have almost 
equal acid strengths; DCMDP is, as expected, a stronger acid 
For DCPDP, K, and K, are supposed to represent dissociation constants 
for carboxylic protons. The values of these constants are in good agreement 
with the K. values of succinic acid, taking into account the negative charge 
on the molecule, originated from the dissociation of two diphosphonic acid 
protons. Because of the greater negative charge on the molecule, the two 
remaining diphosphonic acid protons ( H, and H6) are much less acidic than 
the corresponding protons in MDP, for example. 
For PDP, the 1С and K, values are slightly smaller than the corresponding 
constants for MDP, indicating a slightly greater acidity under the influence 
of the nitrogen atom in the pyrrolidone ring. The K4 belongs to the amido 
proton and its value is, as expected. The value of K5 indicates, that the last 
diphosphonic acid proton is even weaker acidic than in DCPDP. This is 
probably caused by hydrogen bridge formation between a phosphonic acid 
oxygen atom and the nitrogen atom in the ring. 
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5.5.2. Stability constants of calcium complexes. 
From table 5.2 it appears that the stability constants of the calcium 
complexes are much smaller than the formation constants of the correspon-
ding protonated diphosphonates. This means, that at equal concentrations 
of calcium and hydrogen ions the protonated species will preferably be 
formed. At a calcium concentration of 10~3 M below pH=4 no appreciable 
calcium complex formation may be expected. Only at higher pH values 
complex formation with calcium is of importance. 
Although the step stability constants of CaHL and CajL complexes are in 
the same range of magnitude, CaHL complexes prevail, as expected, at 
lower pH values (pH up to 7). 
The 1:1 calcium complexes ( CaL) have greater step stability constants than 
the binuclear calcium complexes (Cs^L). The second calcium ion is, as 
expected, less firmly bound than the first one. The formation of both the 
C&^L and the CaL complex requires the complete deprotonation of the 
diphosphonic acid molecule. Thus, the Ca^L complex will prevail at lower 
pH values than the CaL complex. The CaL complex will be the most 
important species at the highest pH values. 
Fromfigure5.3 till 5.8 it appears, thatatpH=7 DCMDP shows the highest 
level of complex formation and pCPMDP the lowest This is due to the 
stability of the CaH-DCMDP complex and to the presence of the Ca-
DCMDP complex, which gives a marked contribution atpH=7 (due to the 
greater acid strength of DCMDP in comparison with the other diphospho-
nic acids). 
Both DCPDP and PDP have one very weak acidic diphosphonic proton 
(pK— 12). This feature inhibits the formation of binuclear calcium comple-
xes with these two diphosphonates. Nevertheless a CajHL complex is 
found for DCPDP (fig.5.7). Probably one or two carboxylate groups are 
involved in the binding of the second calcium ion. 
In conclusion the following order of increasing stability of calcium 
diphosphonates was found (judged by the level of free calcium ions at 
pH=7) : pCPMDP < MDP < EHDP - DCPDP < PDP ~ DCMDP. 
5.5.3. Stability constants of tin complexes. 
Relatively few papers have been published, dealing with the complex 
formation of stannous tin in aqueous solutions [13,14,15,16]. Most of 
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these, however, did not give definite data on complex composition and 
stability constants. The limited number of studies on the complexing of 
stannous tin in aqueous solutions is probably due to the extensive hydrolysis 
and ease of oxidation of Sn (II), as well as to the extreme insolubility of the 
oxide. 
The step stability constants of the stannous tin complexes with diphospho­
nates show greater values than the formation constants of the protonated 
diphosphonates (table 5.3). Complex stannous tin species can thus exist 
even at low pH values. 
At lower pH values among the stannous tin species in diphosphonate 
containing media the Si^L and protonated tin complexes ( SnHL, SnH2L) 
prevail. At intermediate pH values the SnL complexes become more 
important, while at higher pH values all stannous tin species eventually are 
turned over into stannous hydroxide. 
The step stability constants of the stannous tin complexes are greater than 
the corresponding values for calcium complexes (compare tables 5.2 and 
5.3). This could be expected. The effective nuclear charge at the surface of 
the stannous tin ion(10.85) is greater than at the surface of the calcium ion 
(8.75) [ 171. This is illustrated by the fact that the radius of the stannous tin 
ion (0.93 A) is smaller than the radius of the calcium ion (0.99 A), although 
the number of electrons surrounding the tin nucleus is more than twice the 
number of electrons surrounding the calcium nucleus. d-Electrons, forming 
the outer shell of the stannous tin ion, are less effective in the shielding of the 
nuclear charge than the p-electrons, which form the outer shell of the 
calcium ion. The optimal shielding of the nuclear charge is achieved in the 
electronic configuration of an inert gas. The difference between the 
ionization potentials for calcium (6.11 and 11.87 eV) andtin(7.3 andl4.5 
eV) also illustrate the difference in the effective nuclear charge felt by the 
electrons in the 4s orbital of calcium and the 5 ρ orbital of tin. The greater 
effective nuclear charge at the surface of the stannous tin ion favours the 
complex formation of stannous tin. This is reflected by the differences in the 
stabilities of Ca(OH)2 and Sn(OH)2: calcium hydroxide easily dissociates 
in aqueous solutions and reacts as a strong base; stannous hydroxide is very 
stable and shows no basic reactions at all, but it forms stannates in strong 
яікаііпе solutions. 
A complicating feature of stannous tin is its readiness to hydrolyze. The 
stoichiometric stability constant of Sn (OH)? (see equation 5.28) is great, 
but the actual amount of stannous hydroxide formed, also depends on the 
hydroxide ion concentration. Above pH=7 stannous hydroxide becomes 
increasingly prevalent 
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Tobias described the presence of several hydrolyzed stannous tin species in 
aqueous solutions in the absence of complexing agents [18]. Among these 
were bi- and polynuclear stannous tin species. These species were also 
supposed to be present in diphosphonate containing stannous tin solutions 
at higher pH values. Mesmer and Irani showed from their calculations, that 
in acid solutions above pH=4 Sn (OH)+ is the predominant hydrolyzed 
stannous species [15]. Despite extensive trials, the only hydrolyzed 
stannous tin species, which could be identified in our computer calculations, 
had the formula: Sn (OH)2. 
Despite the fact that the calculations show extensive formation of Sn ( OH)2, 
no precipitation was observed in the presence of a sufficient amount of 
diphosphonate, although the solubility of stannous tin at pH=7 in the 
absence of complexing agents is very small [15]. This can be attributed to 
the inhibition of crystal growth under the influence of diphosphonates [19]. 
Diphosphonates stabilize supersaturated solutions in the concentration 
area of heterogeneous nucleation by inhibiting the growth of crystal nuclei. 
There are two indications that the titration solutions do not contain colloidal 
or greater particles: 
- after intravenous administration of these solutions to rabbits no appreci­
able amount of tin is found in liver, spleen or bone marrow, indicating the 
absence of colloidal particles (see chapter 4); 
- the solutions at pH=7.5 are able to pass over a 0.22 μπι filter without 
losses of stannous tin, as determined by jodometric titration. 
Particles of subcolloidal proportions (<100 A) might remain in solutioa 
However, the participation of polymers of hydrolyzed stannous tin in the 
complex equilibria was not confirmed by the computer calculations, which 
only indicated the presence of stannous hydroxide, Sn (OH)2. 
It is possible, that no polymers of hydrolyzed stannous tin were found, 
because the equilibration time in the titrations was too short. 
The polymerization of hydrolyzed stannous species is expected to be a slow 
reaction (for this reason Irani and Mesmer used incubation periods of at 
least 24 hr) [15]. Possibly, tin complexes are also slowly formed So, 
equilibrium might not be reached in reactions involving these substances 
under the rather arbitrarily chosen experimental conditions (section 
5.3.1). To test this supposition, titrations of diphosphonates and stannous 
tin with TMA hydroxide were immediately followed by a backtitration with 
sulphuric acid In the case of slow reactions, where no equilibrium is 
reached the backtitration curve will not match with the original titration 
curve. 
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Figure 5.15 shows the results of titrations of MDP-Sn (4:1 ) at 25° С with 
0.1 M TMA-OH and 0.1 N HjSO^ No matching, but instead hysteresis 
was found, indicating that indeed some sluggish reactions are involved 
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Fig. 5.15. Titration curves ofMDP-Sn(4:l)(MDP: 3.2 X 1(Г3 M) іп40 ml 
0.1 M TM A-nitrate. Titration with 0.1094 N TMA-hydroxide 
(9), reversed titration with 0.1207 N sulphuric acid(X) at25°C. 
Stannous sulphate was dissolved in 0.1207 N sulphuric acid 
before mixing with MDP solution. 
The previous experiment was repeated at 37° C. Two matching titration 
curves were found At 37° С equilibrium is more readily established than at 
25° С and each point of the first titration curve (with TMA-OH) appears to 
represent an equilibrium state. 
Figure 5.16 shows the results of titrations of MDP-Sn(8:l) at 25° С with 
0.1 N TMA-OH and0.1 N HjSO^ Two matching curves were found The 
curve recorded during titration with base, thus consists of points measured 
in equilibrium state. 
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A double titration experiment with pCPMDP- Sn (4:1 ) at room temperature 
(20° C) gave curves showing a significant hysteresis, while a similar 
experiment at 25° С gave matching curves (fig. 5.17) 
5 ml 
Fig. 5.16. Titration curves ofMDP-Sn(8:l) (MDR3.3 X КГ3 M) in 40 ml 
0.1 M TMA nitrate. Titration with 0.1094 N TMA hydroxide(9), 
reversed titration with 0.1207 N sulphuric acid (X) at 25° С 
Stannous sulphate was dissolved in 0.1207 N sulphuric acid 
before mixing with MDP solution. 
Titration experiments with DCMDP-Sn (4:1) and DCPDP-Sn (4:1) at 
25° С also gave matching curves. 
Only the titrations of MDP-Sn (4:1) at 25° С and the titrations of 
pCPMDP- Sn (4:1 ) at 20° С showed hysteresis. The data of the titrations of 
MDP-Sn (4:1 ) were abandoned in the calculations of the stability constants 
of MDP-tin complexes; only data from titrations of MDP-Sn (8:1) were 
used. For the calculations of stability constants of pCPMDP-tin complexes 
only data from titrations at 25° С were used 
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Fig. 5.17. Titration curves ofpCPMDP-Sn (4:l)(pCPMDP: 3.8 Χ 1(Г3 M) 
in 40 ml 0.1 M TM A nitrate. Titration with 0.1094 N TMA 
hydroxide (Ш), reversed titration with 0.1207 N sulphuric acid 
(X) at 25° C. Stannous sulphate was dissolved in 0.1207 N 
sulphuric acid before mixing with the pCPMDP solution. 
Because only for MDP, which forms the least stable tin complexes, non-
matching of titration and reversed titration was found at 25° C, it was 
assumed, that the titration results of EHDP and PDP in the presence of 
stannous tin also represented equilibrium states, just like the results of 
DCMDP, pCPMDP and DCPDP. 
The results of the reversed titrations experiments indicate, that no slow 
polymerization or complex formation reactions seem to influence the 
titration results and hence the constants, calculated with these results. It is 
however, still possible, that extremely slow polymerization reactions are 
involved, but these are not of importance for the underlying reactions, 
because skeletal scintigrams are made within a few hours after the 
preparation of the radiopharmaceutical. 
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Based on the experimental results it is most probable, that in those titration 
solutions where appreciable amounts of Sn (OH), were indicated by the 
computer calculations, the solutions were supersaturated with Sn(OH)2, at 
least below pH = 7 . 5 . 
Above pH = 7.5 an uncertainty remains however, the unknown solubility of 
Sn(OH)2 in the presence of diphosphonates. Because relevant data were not 
available a limited solubility of Sn (OH)2 was not taken into account in the 
computer calculations. Concentrations of Sn (OH)2 found in our calcula-
tions were as high as 3 X 10~4 M. Although no indications of precipitate or 
colloid formation were found at pH = 7.5, it is uncerte in, whether these high 
concentrations of Sn ( OH)2 are correct at higher pH values, because of the 
potentially limited solubility of Sn (OH)2. 
Due to unknown solubility of Sn (OH)2, the results of the equilibrium 
calculations above pH = 8, as shown in figures 5.9 till 5.14, should be 
looked upon with some scepticism. 
For the physiological pH range (around pH = 7) we feel, that a reliable 
conclusion is reached 
the order of increasing stability of the stannous tin diphosphonate 
(judged by the level of stannous hydroxide at pH = 7) is: 
MDP < DCPDP < PDP < DCMDP - EHDP < pCPMDP. 
This order of stability gives a firm basis for the hypothesis of the relation 
between bone seeking qualities and stability of a radiopharmaceutical. 
Comparison of the stability orders for calcium and tin show as the most 
interesting point the behaviour of pCPMDP. This gives the strongest 
complexation with tin and the weakest with calcium. The reason for this 
interesting phenomenon remains unclear for the moment 
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CHAPTER 6 
REDOX BEHAVIOUR OF STANNOUS TIN 
AND PERTECHNETATE IN 
DISPHOSPHONATE SOLUTIONS 
6.1. INTRODUCTION 
It is well known from common practice, that pertechnetate does not show 
bone seeking properties and in chapter 3 it has been described, that only 
reduced pertechnetate is adsorbed on hydroxyapatite. Stannous tin is 
mostly the preferred reducing agent The matter of the oxidation state of the 
reduced technetium and the stoichiometry of the reaction between pertech-
netate and stannous tin has not been settled yet 
As in the preceding chapters the influence of the nature of the diphosphonate 
on adsorption, biological behaviour and stability of diphosphonate comple-
xes was investigated, in this chapter the influence of diphosphonates on the 
oxidation of stannous tin and the reduction of pertechnetate will be studied. 
In section 6.2 oxidation and reduction potentials of stannous tin will be 
presented for five diphosphonates at several pH values. 
In section 6.3 reduction potentials of pertechnetate will be presented for 
MDP and DCMDP at several pH values. In this section also results will be 
described of coulometric reductions of pertechnetate in MDP or DCMDP 
solutions. 
The stoichiometry of the reaction of pertechnetate with stannous tin and its 
dependence on the nature of the diphosphonate and the pH was studied in 
titration experiments with Potentiometrie and amperometric endpoint 
detections. The results will be described in section6.4. The oxidation states 
of tin and the stoichiometry of the redox reactions were markedly elucidated 
by Sn-Mossbauer spectroscopy. These results will also be presented in 
section 6.4. 
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6.2. POLAROGRAPHY OF STANNOUS TIN SOLUTIONS 
6.2.7. Introduction. 
It is well known, that tin (II) solutions can be oxidized and reduced 
electrochemically at a dropping mercury electrode [ 5 ] and an overwhelming 
set of data for a great variety of media is available [ 1 ]. Some of these data are 
assembled in table 6.1. It appears, that at a dropping mercury electrode 
oxidation and reduction waves of stannous tin are found between +0.1 V 
and -1.2V (vs. SCE), depending on the pH and the presence of complexing 
agents. 
Table 6.1. 
Halfwave potentials (vs. SCE) for the oxidation and reduction ofSn(II) in various media. 
Medium 
0.1 M нею, 
4 
1 N HCl 
Citric acid 
(sat) pH=1.5-2 
Malonic acid 
(sat) pH= 1.5-2 
0.25 N Citrate 
buffer pH=3-4 
2 N Ammonium 
acetate pH=4-5 
0.1 N Ammonium 
citrate pH=6 
0.1 N Ammonia, 
0.1 N ammonium 
citrate pH=8.5 
1 N NaOH 
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Oxidation 
E
, 
(V) 
+0.136 
-0.1 
-0.05 
+0.15 
-0.21 
•0.16 
-0.406 
-0.47 
-0.-73 
Reduction 
E , 
(V) 
-0 43 
-0.47 
-0.40 
-0.397 
-0.54 
-0.62 
-0.662 
-0.752 
-1.22 
The redox behaviour of tin (II) diphosphonates in aqueous solutions 
however has not been studied in detail so far. Steigman [2] reported 
oxidation waves fortin (II) ini M sodium orthophosphate (pH=7) at-0.29 
V, in 0.2 M sodium pyrophosphate (pH=7) at -0.24 V, and in 0.01 M 
sodium polyphosphate at +0.02 V. Furthermore, he noted for 0.2 M 
EHDP (pH=5) ill-defined waves at +0.08 V and at-0.12 V. In a review 
article on the role of inorganic tin in nuclear medicine Francis [3] described 
the use of Polarographie methods for the determination of tin (II) in 
radiopharmaceuticals and for the estimation of the tin (II) diphosphonate 
complex stability. No details however were givea 
In this section the results will be described of a Polarographie study of five 
stannous tin diphosphonates at pH values between 2.5 and 8.5 and with 
molar tin diphosphonate ratios between 1:2 and 1:8. 
6.2.2. Experimental details. 
The polarograms to be shown in this chapter were made by means of a 
Princeton Applied Research model 264 Polarographie analyzer equiped 
with a model 175 dropping mercury electrode (DME) (EG&G, PAR). A 
platinum platelet (1X3 cm) was used as a counter electrode. All measure-
ments were done versus a saturated calomel electrode (SCE). The level of 
the mercury stock was kept at a fixed height (about 40 cm). 
Five diphosphonates were measured MDP, EHDP, DCMDP, DCPDP, 
and pCPMDP. MDP was purchased from Sigma Chemical Co., St Louis, 
USA. (M 9508). The other diphosphonates were kindly supplied by Henkel 
& Cie, Düsseldorf, G F R The diphosphonates were turned over into the 
acid form by means of a strong acid cation exchanger (Biorad, 50 W - X4, 
200 - 400 mesh). 
As supporting electrolyte 0.033 MTMA sulphate (Fluka, Buchs, Switzer-
land) was used. This salt was choosen instead of TMA nitrate (titration 
experiments chapter 5) because the sulphate is inert under the experimental 
conditions. The concentration of 0.033 M of TMA sulphate delivered a 
solution of the same ionic strength as used in the titration experiments 
(chapter 5 ). Because it is good practice in Polarographie experiments to use 
a hundredfold excess of supporting electrolyte and because the concentra-
tion of stannous tin in these experiments was 10"4 - 10"3 M, the 
concentration of 0.033 M TMA sulphate might be insufficient For Uvs 
reason two comparative experiments were performed: at pH=1.8 a 
polarogram was made of stannous sulphate in 0.1 M TMA sulphate and a 
second polarogram was made in 0.033 M TMA sulphate. Only small 
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differences were noted and in all further experiments 0.033 M TMA 
sulphate was used. 
As stannous tin source in all Polarographie (and titration) experiments 
SnSO, (Merck, Darmstadt, GFR.) was used. Stannous sulphate is 
preferred over stannous chloride because it is, in contrast with the latter, non 
hygroscopic and therefore in dry state less subject to hydrolysis and air 
oxidatioa Moreover, chloride ions might interfere with the tin diphospho-
nate complex formation and are for this reason not wanted in tin 
diphosphonate solutions. Stannous sulphate contained about 5% stannic 
tin, as was determined by jodometric titration. 
The solutions to be measured were prepared as follows: stannous sulphate 
(about 10 mg) was weighed directly into the polarography vessel. The 
diphosphonic acid solution (Vi-\ ml) was added under argon and the mixture 
was stirred until the stannous sulphate had been dissolved. The TMA 
sulphate solution (0.03 3 M) was added to bring the volume up to 40 ml. The 
pH was adjusted by addition of 1% TMA hydroxide (Merck, Darmstadt, 
GFR) or 0.1 N sulphuric acid. The prepared solutions were flushed with 
argon in the polarography stand for 15 minutes, before polarography was 
started. 
Several Polarographie techniques were employed; DC polarography (DC), 
normal pulse polarography (PP), and differential pulse polarography 
(DPP). Fundamentals on these techniques can be found in modem 
handbooks on electrochemistry [e.g. 4,5]. 
For each experiment using a pulse technique the starting potential was 
chosen at the point of zero current in the DC polarogram. In all PP and 
DPP polarograms the starting point is indicated From the starting point 
scans were performed in positive and negative direction over the desired 
potential area. 
A potential range between+0.1 V and -1.5V was used The upper value is 
set because of the oxidation of mercury at higher potentials and higher pH 
values. The lower border of the potential area is chosen because no tin 
reduction waves have been reported at lower potential values and because 
of the hydrogen ion reduction at lower pH values. 
For comparative reasons polarograms were made of stannous sulphate 
without addition of diphosphonate. In these experiments the pH was 
between 0.8 and 3, as at higher pH values massive precipitation of 
hydrolyzed tin occurs. For the other experiments the pH was between 2.5 
and 8.5. The diphosphonate tin ratios were between 2:1 and 8:1. 
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6.2.3. Results and discussion 
Table 6.2 gives the half-wave potentials and diffusion currents from normal 
pulse polarograms of stannous tin with two different concentrations of 
supporting electrolyte. 
Table 6.2. Half-wave potentials (Ey) vs. SCE and diffusion currents (ij of the 
oxidation and reduction of stannous tin in 0.033 M. and 0.1 M. TMA 
sulphate at pH= 1.9. 
TMA-S04 0.0033 M. 0.1 M 
pH 1.85 1.88 
Oxid Red Oxid Red 
Е
Й
( ) -0.05 -0.43 -0.04 -0.44 
i,/C(mA) 7.2 6.8 7.1 6.9 
Only minor differences are seen between the Polarographie results in 0.033 
M and in0.1 M TMA sulphate. In all further experiments 0.033 M TMA 
sulphate was used as supporting electrolyte. 
Table 6.3 gives the results of differential pulse polarograms of stannous 
sulphate solutions without addition of diphosphonate at several pH values. 
Above pH=2 the stannous sulphate solutions got a milky aspect as a 
consequence of the tin hydrolysis. 
Table 6.3 shows, that especially the oxidation peak shifts towards more 
negative potential values as the pH value increases. As a result the distance 
between the oxidation and the reduction peak (the potential region, where 
stannous tin is the stable species) becomes smaller at higher pH values. The 
potential shift of the stannous tin oxidation peak with increasing pH is in 
agreement with the general experience, that at higher oxidation states 
protons are expelled from and/or hydroxyl ions are bound to the coordina­
tion sphere surrounding a metal ioa The oxidation peak width increases 
with increasing pH value. The width of the reduction peak remains nearly 
constant For a reversible two electron transition on theoretical grounds a 
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Table 6.3. 
pH 
0.87 
1.19 
1.88 
3.08 
Peak potentials and peak widths at half peak height front DPP of stannous 
sulphate solutions (l(l·3 M) at various pH values; TMA sulphate.0.033 
M. 
EP(V) 
+0.04 
-0.06 
-0.07 
-0.19 
Oxidation 
*S(mV) 
66 
104 
114 
130 
Reduction 
EP(V) 
-0.42 
-0.43 
-0.42 
-0.45 
wh(mV) (vs. SCE) 
67 
68 
66 
67 
w1/4 value of 45 mV can be expected. The peak width data from table 6.3 
suggest, that the electron transfer rate for the oxidation of stannous tin 
becomes slower with increasing pH. 
Figure 6.1 shows two DC polarograms of MDP-tin (4:1). Only a small 
difference is seen between the limiting currents at pH=2.4 and pH=8.4. 
Fig. 6.1. DC. polarography of MDP-tin (4:1) at pH=2.43 (lower polaro-
gram) and pH=8.44 (upper polarogram). MDR 4.06. Ш3 M; 
SnSOf- 1.03 X m3 M; TMA sulphate: 0.033 M. Scan rate: 5 
m V/sec; drop tinte: 0.2 sec; filter 0.1 sec. The markings at-0.38 V 
and-0.70 V indicate the points of zero current, which were chosen 
as starting points for normal pulse or differential pulse polaro­
graphy. 
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τ 1 • , , 1-
αΟΟ -032 O i S Hi 150 V 
Fig. 6.2. Differential pulse polarography for MDP-tin (8:1) at pH values 
between2.46and8.42. MDP:8.0X 10~3M;SnSO.- 1.0X10-3M; 
TMA sulphate: 0.033 M. The vertical markings assign the star­
ting potentials. Oxidation peaks are found to the left and reduction 
peaks to the right of the starting point 
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Fig. 6.3. Differential pulse polarogram of EHDP-tin (4:1) at pH=2.77. 
EHDP: 4.5 X 10~3 M; SnSO¿ 1.1 X Ш3 M; TMA sulphate: 
0.033 M. Oxidation peaks to the left and reduction peaks to the 
right of the starting point 
π 1 1 1 1 1 1— 
005 026 042 071 Οθθ 1П 150 V 
Fig. 6.4. Differential pulse polarogram of EHDP-tin (4:1) at pH=6.46. 
EHDP: 4.5 X Ш3 M; SnSO¿ 1.2 X 10~3 M; TMA sulphate: 
0.033 M. Oxidation peaks to the left and reduction peaks to the 
right of the starting point 
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Fig. 6.5. Differential pulse polarogram ofDCPDP-tin (4:1) atpH=2.54. 
DCPDP: 3.9 X 10-3
 M; SnSO¿ 1.1 X 10-3 M; TMA sulphate: 
0.033 M. Oxidation peaks to the left and reduction peaks to the 
right of the starting point 
Fig. 6.6. Differential pulse polarogram ofDCPDP-tin (4:1) at pH=6.49. 
DCPDP: 3.8 X Ш3 M; SnSO¿ 1.1 X IO-3 M; TMA sulphate: 
0.033 M. Oxidation peaks to the left and reduction peaks to the 
right of the starting point 
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Apparently the loss of electroactive species at higher pH values as a result of 
tin hydrolysis is small. This supports the conclusion ( see chapter 5), that 
diphosphonates are able to stabilize supersaturated solutions of nonpoly-
merized stannous hydroxide. 
Figure 6.2 shows a series of differential pulse polarograms for MDP-tin 
(8:1) at pH values between 2.5 and8.5. The differential pulse polarogram 
shows, that at pH=8.4 only one species is present in solution plus a trace of 
another species. 
Based on the results of the titration experiments (chapter 5) it may be 
expected, that the last species, which remains in solution with increasing 
pH, is stannous hydroxide. For this reason the reduction peak at -1.1 V in 
the DPP at pH=8.40 іч ascribed to stannous hydroxide. 
Figures 6.3 till 6.6 show some typical examples of differential pulse 
polarograms of stannous tin diphosphonate solutions. 
Table 6.4 compiles the relevant results of the Polarographie experiments 
with stannous tin solutions. 
The polarograms of SnS04 without diphosphonate added show only single 
peaks for the oxidation as well as for the reduction. However, when 
diphosphonates were added, the polarograms became more complicated and 
mostly several peaks in the oxidation as well as in the reduction region were 
detected. The peaks are generally wider than expected for reversible 
reactions (cf. table 6.3). 
The following conclusions can be formulated: 
- The polarograms show, that in the presence of diphosphonates 
more than one electroactive species is present The titration 
experiments, described in chapter 5, revealed several tin diphos­
phonate complexes to be present, depending upon the pH of the 
solution. We think, that the various peaks in the polarograms 
correspond with reductions and oxidations of these complexes, 
assuming their interconversion to be slow as compared with the 
scan rate of the polarogram. Because these interconversion rates 
and their pH dependence are unknown, a more detailed analysis is 
impossible. So the Polarographie studies only qualitatively sup­
port the conclusion, that diphosphonates give various complexes 
with tin, depending upon the pH. 
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Table 6.4 Peak potentials in volt vs. SCE. for the oxidation and reduction of 
stannous tin with various diphosphonates and without diphosphonates at 
pH 2.5 and pH 6.5. The tin concentration was about Ш3 M: TMA 
sulphate: 0.033M. 
Tin, pH=1.88 
Tin, pH=3.08 
MDP-tin(8:l) 
pH=2.46 
DCMDP-tin(4:l) 
pH=2.42 
pCPMDP-tin(4:l) 
pH=2.51 
EHDP-tin(4:l) 
pH=2.77 
DCPDP-tin(4:l) 
pH=2.54 
MDP-tin(8:l) 
pH=6.23 
DCMDP-tin(4:l) 
pH=6.49 
pCPMDP-tin(4:l) 
pH=6.49 
EHDP-tin(4:l) 
pH=6.46 
DCPDP-tin(4:l) 
pH=6.49 
Oxidation 
-0.07 
-0.07 
-0.09 
-0.11 
-0.20 
-0.21 
-0.22 
-0.19 
-0.22 
-0.21 
-0.15 
-0.19 
-0.17 
-0.29 
-0.26 
-0.26 
-0.41 
-0.42 
-0.37 
-0.42 
-0.37 
Reduction 
-0.42 
-0.45 
-0.55 
-0.54 
-0.58 
-0.57 
-0.55 
-0.76 
-0.77 
-0.81 
-0.71 
-0.70 
-0.69 
-0.63 
-0.63 
-0.82 
-1.04 
-1.00 
-0.88 
-0.89 
-0.77 (?) 
-0.99 
-1.15 
-1.14 
-1.13 
-1.05 
The potentials of the Sn(II) -· Sn(IV) oxidations shift towards 
more negative values at increasing pH. Complex formation with 
the various diphosphonates has only a minor influence on the 
oxidation potential of stannous tin. Said in a rather vague, but 
popular way: the "reducing power" of Sn(II) is not greatly 
affected by any of the diphosphonates. 
The potentials for the Sn(II) — Sn(0) reduction also move 
towards more negative values as the pH increases. The influence 
of complex formation with diphosphonate is not insignificant, 
especially at pH=6.5. 
At pH=6.5, where a substantial amount of Sn(OH)2 is present 
(according to the results of chapter 5) no loss of electroactive 
material is seen, as the total peak area in the polarograms do not 
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show appreciable decreases as compared with pH=2.5. A D.C. 
polarogram of tin with MDP made at a pH as high as 8.4, does not 
show a great decrease in the limiting current. This supports the 
idea, suggested by the results of the titration experiments, that 
Sn(OH), is present as a supersaturated solution of a monomole-
cular species. 
- The peaks are wider than expected for reversible reactions. The 
electron transfer is apparently slow and the more so at higher pH. 
6.3. REDOX BEHAVIOUR OF PERTECHNETATE 
6.3. J. Introduction. 
As only reduced pertechnetate can be used to prepare radiopharmaceuti-
cals, a lot of work has been done to elucidate the fate of pertechnetate as it is 
reduced. For some years a lack of consent seemed to exist with respect to 
the question which oxidation states of technetium are formed after reduction 
of pertechnetate. Nowadays however, more agreement is found between 
most authors on the headlines of pertechnetate reduction. 
In acid media two or three reduction waves are seen [6,7,8,9]. Both the first 
and the second wave are irreversible. Sometimes a third wave is seen, which 
is however, related to catalytic reduction of hydrogen. The half-wave 
potential for the first wave is linearly related to the pH and can be described 
approximately by the relationship: Ew=-0.1 OXpH over the pH range from 
0 to 7. The second wave seems to be independent of the pH and its half-wave 
potential is about -0.9 to -1.0 V depending on the medium. 
The overall reaction, describing the first reduction wave of pertechnetate in 
acid media, can be written as: 
Tc04" + 5H+ + 4e" - TcO(OH) + 21^0 
Four electrons are involved in this reaction, so Tc (III) is formed. This 
reaction is totally irreversible. 
For the second reduction wave in acid media, some authors claim a three 
electron transition [6,7,10] (Tc (III)/Tc (0)), but others claim a seven 
electron transition (Tc( VII)/Tc(0)) [8]. Most authors agree however, on the 
formation of metallic technetium in the second reduction wave in acid 
media. 
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In alkaline media a three electron transition takes place, which can be 
described by the following reaction [9] : 
Tc04" + 2H 2 0 + 3e" - Tc0 2 + 40H 
The half-wave potential of this reduction wave is independent of the pH and 
has a value of about -0.8 V. Under some conditions this wave seems to be 
splitted into a two electron wave at-0.8 V and a one electron wave at-1.1 V 
[8,9]. Grassi showed, that this phenomenon should be attributed to 
adsorption of pertechnetate on the mercury drop [9]. The fact that the half-
wave potential of the pertechnetate reduction wave in alkaline media is pH-
independent may be linked to the total irreversibility of the system [9]. 
In unbuffered neutral media the reduction wave is found at -0.8 V, as in 
alkaline media. This probably reflects the alkalinization of the solution 
adjacent to the electrode as hydrogen ions are consumed in the reduction of 
pertechnetate. Russell reported the presence of a small prewave in some 
media at low pertechnetate concentrations [8]. This prewave could be 
mimicked by adding traces of acid and was proportional to the amount of 
acid added. It is more probable however, that this prewave is a residue of the 
first reduction wave in acid solutions. Salaria and coworkers showed for 
unbuffered chloride and sulphate solutions, that the disappearance of the 
acid pertechnetate reduction wave and the appearance of the alkaline 
pertechnetate reduction wave gradually take place between pH=3 and 
pH= 5 [6]. At pH = 4 both waves are present with equal intensities. These 
authors also reported, that the first acid reduction wave could shift down to 
-0.75 VatpH=9.8, provided that the right buffers were present in solution. 
Our own results will show also, that the coexistence of acid and alkaline 
reduction waves at a certain pH is governed by the capacity of the buffer 
present 
The common opinion in literature with respect to the four electron transition 
during the reduction of pertechnetate in acid and buffered neutral media 
does not mean however, that also a common opinion exists concerning the 
reduction product Grassi claimed, that a part of the Tc (III), which was 
formed during the course of coulometry, was transformed by an unknown 
reaction to a nonelectroactive species, which could not be identified [9]. The 
main part of the Tc (III) formed could easily be oxidized by either 
coulometric or chemical means (air oxygen) to Tc (IV). In sulphate 
solutions the presence of [Tc (OH)2(S04)2]2~ was indicated by αν. 
spectroscopy. This species is nonelectroactive. The presence of a three 
electron reduction wave at -1 V in the polarogram after coulometric 
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reduction of a pertechnetate solution (pH=2) at-0.5 V suggests however, 
that Tc(III) can survive in the deaerated reduction medium for at least 
several hours. After oxidation of Tc ( III) to Tc ( IV) in sulphate solution no 
wave was left in the polarogram, confirming the formation of a nonelectro-
active species. 
Most authors however believe, that as a product of the first reduction step of 
pertechnetate in acid and buffered neutral solutions hydrolyzed Tc(III) is 
formed in the absence of complexing agents, probably with the formula 
TcO (OH). 
The purpose of our study was limited to an investigation of the influence of 
diphosphonates on the reduction behaviour of pertechnetate. This was 
studied with Polarographie and coulometric methods. The products of the 
coulometric reductions were subjected to an acidimétrie titration, as 
described in chapter 5, in order to determine the stability constants of 
formed complexes between technetium and diphosphonate. 
6.3.2. Experimental details. 
6.3.2.1. Polarography. 
To solutions of 3X10"3 M MDP or DCMDP in 0.033 M TMA sulphate 
Tc-99- pertechnetate was added. Molar ratios of metal and diphosphonate 
were 1:2, 1:4, and 1:8. The pH was adjusted with 10% TMA hydroxide to 
values between 2.5 and 8.5. These solutions(40 ml) were purged with argon 
for 15 minutes before starting the Polarographie measurements. 
Tc-99-NH4Tc04 was purchased from the radiochemical centre at Amers-
ham, U. K. (36 mg Tc/ml, 5 mCi Tc-99 dissolved in 8.2 ml 0.1 NNH4OH). 
Polarograms (PP and DPP) were made between +0.1 and -2.0 V, scanning 
in negative direction. 
Further details for the Polarographie experiments were the same as for tin 
polarography (see section 6.2.2). 
6.3.2.2. Coulometric reductions. 
Solutions of 3X10 M diphosphonic acid with pertechnetate in 0.033 M 
TMA sulphate (40 ml) were purged with argon for 15 minutes and then 
electrolyzed at constant potential till the current had gone down to 3% of its 
initial value. 
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Three coulometric runs were carried out 
MDP + pertechnetate(4:l) pH=6.5 -0.75 V. 
M D P + pertechnetate (8:1) pH=2.8 -0.5 V. 
D C M D P + pertechnetate (5:1) pH=2.7 -0.5 V. 
Controlled potential electrolyses were carried out with a Wenking LB 75 M 
potentiostat and a Birtley electronic integrator. 
As cathode a mercury pool was used in combination with a platinum anode. 
The anodic compartment was connected to the cathodic compartment by an 
inverted U-type salt bridge, filled with silica gel and saturated potassium 
chloride. 
Before and after each coulometric experiment a differential pulse polaro-
gram was made and the pH was measured The amount of acid consumed in 
the course of the coulometric run was determined by restoring the pH, which 
existed before the experiment, by addition of 0.1 N sulphuric acid 
One of the objectives of the reduction experiments was, to dispose of 
technetium solutions, in which the complex stability with diphosphonate 
could be determined So, after completion of the reduction and restoring the 
initial pH, the solutions were titrated with TMA hydroxide, according to the 
procedures, described in chapter 5. From the obtained results the complex 
stability constants were calculated with the SCOGS programme ( see chap-
ter 5). 
6.3.3. Results. 
6.3.3.1. Polarography. 
Figure 6.7 shows a normal pulse polarogram of pertechnetate with MDP 
(1:4) at pH=2.75. Three waves are seen at potentials, which are in 
agreement with literature data (see section 6.3.1). At the first wave a 
maximum is seen. Spitsyn and coworkers [11] described maxima in 
association with catalytic waves (-1.3 V) in polarograms of pertechnetate 
solutions, whether these were neutral, acid or alkaline. The maximum in 
figure 6.7 is probably not related to a catalytic phenomenon, as the height of 
the maximum is rather small. The maximum in figure 6.7 is possibly caused 
by streaming of mercury in the drop relative to the solution. 
The ratio between the limiting currents of the first and second wave in figure 
6.7 is estimated to be 0.7 ± 0.1, which is in agreement with a four electron 
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Fig. 6.7. Normal pulse polarogram of pertechnetate (0.8X10~3 M) and 
MDP(3X10~3 M) in 0.033 M TM A sulphate. pH=2.75. 
transition for the first and a three electron transition for the second wave, as 
reported in literature [9]. At this low pH MDP shows no influence on the 
aspect of the polarogram. 
The results of the Polarographie study of the pertechnetate reduction with 
and without diphosphonate at various pH values, are presented in table 6.5. 
Figures 6.8 till 6.10 show a set of three differential pulse polarograms of 
pertechnetate and MDP ( 1:4) to illustrate the influence of the pH on the 
aspect of the polarogram in more or less neutral media. The peak at-0.75 V 
disappears with increasing pH. This peak presumably corresponds to the 
four electron transition peak in acid media. The peak at-0.83 V is related to 
the three electron transition in alkaline and unbuffered neutral media (see 
section 6.3.1). When the buffer capacity of MDP(pK,=7.1) is reduced to 
minimal values (at pH=8.5) the four electron peak disappears. For 
DCMDP, which has a smallerpK3 value than MDP (DCMDP: pK3=5.97) 
the four electron peak already disappears at pH=7.4. This had to be 
expected in the light of the literature data on the influence of the presence of 
buffers on the four electron reduction wave. 
The potentials of the pertechnetate reduction peaks seem only to be 
influenced by the pH and not by the presence of diphosphonates as could be 
expected for irreversible reduction reactions. 
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Fig. 6.8. Differential pulse polarogram ofpertechnetate(Q.8X10-} M) and 
MDP(3X10-3 M) in 0.033 M TMA sulphate. pH=6.45. Drop 
time: 0.2 sec, scan rate 5 mV/sec 
001 μΑ 
Fig. 6.9. See legend figure 6.8; pH=7.29. 
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Fig. 6.10. See legend figure 6.8; pH=8.49. 
The splitting of the four electron reduction wave in a three and a one electron 
transition (see table 6.5 for pertechnetate, pH=4.01) has been reported 
before [6]. 
The results of these Polarographie experiments are in agreement with 
literature data A reduction wave at-0.83 V is seen at pH=4 or above and 
in the acid and neutral regions a reduction wave is present at-0.3 - -0.75 V. A 
second reduction wave is seen only at pH=2.5. The influence of diphos-
phonate is marginal and seems to be limited to its buffering actioa 
6.3.3.2. Coulometric reductions. 
The results of the three coulometric reductions are presented in table 6.6. 
The results, shown in table 6.6, are in reasonable agreement with literature 
data of pertechnetate reductions, involving three or four electrons, depen­
ding on the pH. There seems to be no detectable influence of the 
diphosphonate. 
After each reduction a brown-black precipitate was seen and the solution 
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Table 6.5. Half-wave reduction potentials of pertechnetate (in V vs. SCE) with and 
without diphosphonate at various pH values. 
T c 0 4 
pH=4.01 -0.41 -0.58 -0.83 (3:1:20) 
pH=6.7 -0.84 
pH=8.33 -0.84 
Tc0 4 + MDP(1:4) 
pH=2.5 -0.32 -1.03 -1.24 (4:3:i) 
pH=6.5 -0.75 -0.84 (3:2) 
pH=7.3 -0.75 -0.84 (1:1) 
pH=8.5 -0.84 
TcQ, + D C M D P ( 1 : 2 ) 
-0.32 -1.03 -1.24 (4:3:i) 
-0.72 -0.83 (1:7:1) 
-0.75 -0.84 (2:5) 
-0.84 
-0.84 
pH= 
pH= 
pH= 
pH= 
pH= 
=2.5 
=4.99 
=6.5 
= 7.4 
= 8.5 
The values between parentheses represent ratios between the limiting 
currents of the waves mentioned. The third wave at pH=2.5 was ill-defined 
(i), because it was close to the hydrogen reduction wave. 
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Table 6.6. Number of electrons (η) and number of prolons (H+) involved in the 
reduction of one molecule pertechnetate. 
MDP+ Tc0 4 (4 : l ) 
MDP+ Tc0 4 (8 : l ) 
DCMDP+ Tc0 4 (5: l ) 
pH=6.5-9.1; 
pH=2.8-3.0; 
pH=2.7-3.2; 
-0.75 V: 
-0.5 V: 
-0.5 V: 
η 
3.2 
4.3 
4.4 
Η* 
3.6 
4 
6 
was brown coloured, but not completely clear. After the reductions in acid 
solutions, in the polarograms a small peak was seen at-1 V. This probably is 
a residue of the three electron wave (Tc (III) — Tc (0)). 
The titration results, which were in fact the main objective of the 
coulometric reduction experiments, show that in none of the solutions, 
containing reduced pertechnetate (Tc( III) orTc(IV)), a complex is formed 
with MDP, for DCMDP however, a Tc-(DCMDP) 2 complex could be 
identified with an overall stability constant 
log/3 = 6.9 ±0.15 
The amount of complex present as function of the pH is shown in figure 
6.11. 
80 
% Tc 
60 
40 
20 
D C M D P - Tc 5 : 1 
9 
pH 
10 
Fig. 6.11. Percentage of the total amount of technetium present in solution in 
the form of Tc-(DCMDP)2 at various pH values. 
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The titration results show, that DCMDP forms more stable complexes with 
technetium than MDP. The same result was obtained for complexes of 
these diphosphonates with calcium and stannous tin (see chapter 5). 
Because of the obvious difference between Tc (III)/Tc(IV) and Ca(II) and 
Sn (II) and because the complex chemistry of technetium is only poorly 
known, no further comment seems possible at this moment 
In conclusion: 
- Diphosphonates have no basic influence on the electrochemical 
reduction of pertechnetate, neither on the half-wave potentials nor 
on the number of electrons, involved in the reductioa The 
influence of the diphosphonates seems to be limited to their 
buffering action, which may affect the number of protons avail-
able in the direct neighbourhood of the dropping mercury elec-
trode. 
- A Tc-(DCMDP)2 complex has been found. 
- The difference between the half-wave potentials from table 6.5 
and the standard redox potentials for technetium seems remark-
able. 
6.3.4. Discussion. 
Cobble determined in 1953 the standard redox potential for theTc04" 
/ T c 0 2 couple using a technetium dioxide pertechnetate electrode [12]. The 
redox potential of this electrode has been measured in both acid and basic 
solutions to prove that the electrodes are reversible. The result was revised 
in 1955 [13] and is now sunn^sed to be: 
Tc047Tc02 
From the results of calorimetrie measurements the standard redox potential 
for the couple Tc04"/Tc was calculated 
E
°TcO4/Tc = 0 - 4 7 2 V · 
From the two preceding EQ values, the standard redox potential for the 
couple Tc0 2 /Tc was calculated 
E° T _ ._ = 0.272 V. Tc02/Tc 
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For reversible electrode processes the standard redox potential and the half-
wave potential are simply related 
RT - D > 
E
*
 = E
o +
 n F ''"i в, ) < б Л> 
where D and D represent the diffusion coefficients for the oxidized and 
reduced agent respectively. 
Assuming that D and D are nearly equal, one obtains for the half-wave 
potential: 
E* = E 0 (6.2) 
Thus for a reversible process at a dropping mercury electrode the half-wave 
potential has thermodynamic significance. 
The half-wave potentials, shown in table 6.5, which are in agreement with 
literature data, are however much smaller (more negative) than the reported 
value of E . 
о 
Two factors are supposed to be responsible for this result 
- the irreversibility of the technetium reduction process at the 
dropping mercury electrode, as was stated by several authors 
[6,14,9]. 
- the involvement of protons in the reduction process. 
For an irreversible electrode process the Nemst equation is no longer valid 
and rate theory must be used. 
For an irreversible reduction at a dropping mercury electrode the following 
expression holds: 
RT 
E, = E + ^ ° anF 
In[0.0886 · k°( β ) ] (6.3) 
where α is a transfer coefficient with a value between 0 and 1, к ° is the 
' e 
heterogeneous rate constant of the electrode process at the standard 
potential E , t is the drop time of the electrode, and D is the diffusion 
coefficient of the reacting species (D=D = D ). 
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This equation shows clearly, that the half-wave potential for an irreversible 
reaction is dependent on the drop time and the heterogeneous charge 
transfer rate constant and that position and shape of such a Polarographie 
wave is determined by the kinetics of the electron transfer step. 
For the reaction: 
Tc04" + 211,0 + 3e~ - Tc0 2 + 40H" 
the negative shift of E^ due to the irreversibility of the electrode reaction is 
(fort= 0.2 sec, estimating k° tobe IO"4 cm/ sec, D to be 10"5 cmVsec and a 
to be 0.5, in accord with literature data for similar systems): 
E
u
 = E - 0.08 V. 
Vi о 
When protons are involved in an irreversible electrode process, the 
following term must be added to equation 6.3: 
P R T _l. 
- _ In [ H i 
anF 
where ρ represents the number of protons involved. 
This means, that E^ shifts towards more negative potential values, as the 
pH increases. 
For the reaction mentioned above, at pH=8, assuming α = 0.5, a potential 
shift of 1.25 V relative to E may be expected in negative direction due to 
the involvement of protons in the irreversible reduction reaction. 
Because of the contribution of the factor a to the pH shift, the influence of 
the pH on the value of E¡A is thus nearly equal to the influence of the 
irreversibility of the electrode reactioa 
When we calculate E^ for the Tc04" — Tc02 reaction at pH=8 from EQ, 
taking into account the corrections because of the irreversibility of the 
electrode reaction, and expressing the result relative to the saturated 
calomel electrode, we obtain: 
E^ =-0.834 V(SCE). 
This is in agreement with the results of table 6.5. 
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In conclusion: 
the half-wave potentials of the reduction of pertechnetate do not have 
thermodynamic significance and can thus not be used to predict the 
possibility of a homogeneous chemical reactioa For this reason one 
should not be surprised that stannous tin reacts with pertechnetate, 
although the half-wave potentials of the stannous tin oxidation are 
greater than the half-wave potentials of the pertechnetate reduction. 
6.4. THE REACTION OF Sn (II)-DIPHOSPHONATES WITH 
PERTECHNETATE 
6.4.1. Introduction. 
Several studies have been carried out in order to elucidate the identity of the 
products of the reaction of pertechnetate and stannous tin in the presence of 
complexing agents [15,16,2]. In these studies titrations were performed of 
pertechnetate with stannous tin with and without the presence of comple-
xing agents. A variety of endpoint detection methods was used potentio-
metry [16], polarography [2], amperometry [15], and jodometric back-
titration of excess tin [16,2]. The problems with the latter endpoint 
detection method were already discussed by Steigman [2], who stated, that 
this method can not be used to determine the excess of stannous tin 
quantitatively, because of potential side reactions. In our hands the 
Potentiometrie endpoint detection method with a combination platinum 
electrode was not very satisfying, because no stable electrode readings were 
achieved. Most appropriate seems the amperometric titration method, as 
described by Russell [15], who measured the current at a dropping mercury 
electrode at -0.2 V and -1.2 V (vs. SCE) as a function of the amount of 
Sn(II) added to a pertechnetate solution; at-0.2 V the tin oxidation and at 
-1.2 V the pertechnetate reduction was measured. 
The results of the Polarographie study of tin diphosphonates showed (see 
section 6.2.3), that several tin species are present in solutions with 
diphosphonates and preliminary experiments revealed, that some tin 
species are more sensitive to oxidizing agents than others. For this reason, 
instead of a two point amperometric titration (-0.2 V and -1.2 V) we 
decided to record a complete differential pulse polarogram between +0.05 
V and -1.5 V after each addition of titrant 
Because in radiopharmaceuticals always a large excess of stannous tin 
exists, we decided to titrate stannous tin diphosphonate solutions with 
pertechnetate instead of titrating in the opposite directioa The latter has 
already, been described in several papers [15,16,2]. 
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6.4.2. Experimental details. 
Stannous diphosphonate solutions (40 ml 0.033 M TMA sulphate; 
tin/diphosphonate molar ratio 1:4; stannous tin: 1X10"3 M ) were titrated 
with a 29.8 X 10"3 M solution of Тс-99-ammonium pertechnetate (see 
section 6.3.2.1) at pH=2.5 and at pH=6.5. Five diphosphonates were 
used MDP (Sigma Chemical Company, St. Louis, USA), DCMDP, 
EHDP, DCPDP, and pCPMDP (kindly supplied by Henkel & Cie, 
Dusseldorf, G.F.R.). Special care was taken to remove oxygen from the 
diphosphonate solution before addition of tin sulphate by passing a 
humidified stream of argon for 15 minutes. The pertechnetate solution was 
treated in the same way, and also the TMA hydroxide solution, used for pH 
adjustment 
The pertechnetate solution (kept under argon) was added to the stannous 
diphosphonate solution by means of an Eppendorf pipet In the first part of 
the titration portions of 100 microliter pertechnetate were added. By the 
approach of the calculated equivalence point however, (—750 μΐ 29.8X 10"3 
M pertechnetate for 10 mg stannous sulphate, molar ratio TcSn=l:2) 25 
μ.1 portions were added. This determines the accuracy of the endpoint In 
most cases the titration was continued beyond the equivalence point until a 
distinct excess of pertechnetate was detected. 
After each addition of pertechnetate the solution was stirred for two minutes 
with argon and a differential pulse polarogram was prepared between +0.05 
V and -1.5 V with a dropping mercury electrode. See for further details 
section 6.2.2. 
Peak surfaces were used as a parameter for the concentration of the species 
present in solution. The peak surfaces of stannous tin peaks before the start 
of the titration were setto 100%. For the tin peaks the relative peak surface 
in percentage of the surface before titration was plotted against the volume 
of pertechnetate added. For pertechnetate the peak surface it self was 
plotted with a correction for the current range setting on the Polarographie 
analyzer. 
In order to find out, whether stannic tin reduction peaks had to be expected 
in the polarograms of the titration with pertechnetate, a set of polarograms 
was prepared of a titration of stannous DCMDP (1:8) with hydrogen 
peroxide at pH= 1.8. The titration conditions were the same as for titrations 
with pertechnetate. 
In the titrations with pertechnetate the possible occurrence of slow reactions 
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was tested by repeating each Polarographie run twenty minutes later, 
immediately before the addition of a next portion of pertechnetate. The 
possible occurrence of a time effect was also tested by addition of the 
experimentally determined equivalent amount of pertechnetate in one 
charge to a tin diphosphonate solution, followed by repeated recording of 
polarograms for one hour. 
Because coloured solutions were obtained (yellow in acid, pink in neutral 
solutions) as products of the reaction of pertechnetate with stannous 
diphosphonate, the titration of stannous diphosphonate (MDP,DCMDP, 
and pCPMDP) with pertechnetate was also followed with u.V.-vis. spectro­
photometry. Spectra of pertechnetate, stannous tin diphosphonate and their 
reaction product were measured between 500 and 200 nm. 
Pertechnetate shows an adsorbance maximum at 244-248 nm (doublet). 
Stannous MDP and stannous DCMDP show only a strong adsorbance 
below210 nm, pCPMDP shows adsorbance maxima at260, 267, and276 
nm, which are characteristic for the aromatic ring. The product of the 
reaction of pertechnetate with stannous diphosphonate shows adsorbance 
maxima at 326 nm and 400 nm. The first peak is especially well developed 
with DCMDP. 
To three milliliter portions of a stannous diphosphonate solution (Sn (II): 
1X10"3 M; Sn:DP=l:4;DP is MDP, DCMDP, or pCPMDP), which was 
kept under argon, in a quartz cuvet varying volumes (10-100 μΐ) of a 
deaerated pertechnetate solution (29.8 X10 M) were added. The cuvet 
was closed and its contents were mixed. Starting one minute after the 
addition of pertechnetate, the adsorbance at 326 and 400 nm was measured 
with one minute intervals until the adsorbance reached a constant level. 
This constant adsorbance value was plotted against the volume of pertech­
netate added. 
In one titration experiment the endpoint was determined by Sn-119-
Mössbauer spectroscopy. This technique is by far the most elegant one to 
determine the amounts of stannous and stannic tin present in solutioa The 
isomere shifts for stannous and stannic EHDP are such, that the relative 
amounts of stannous and stannic tin present in solution can be determined 
beyond doubt, giving direct evidence of the oxidation of stannous tin during 
the titration with pertechnetate. 
A solution was prepared containing 0.632 mM Sn (II) and 2.52 mM 
EHDP in 14 ml water, pH=4.7. Care was taken to prevent stannous tin 
oxidation before addition of pertechnetate. Two milliliter portions of this 
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solution were brought into five penicilline vials. The following volumes of 
pertechnetate (29.8 Χ ΙΟ"3 M ) were added to the stannous EHDP portions 
in the five vials: 0,0.3, 0.9, 1.5, and 1.9 ml. The contents of the vials were 
carefully mixed and were then immediately frozen in liquid nitrogen. Next, 
the vials were decapsulated and the contents were lyophilized overnight 
The lyophilized samples were well suited for Mössbauer spectroscopy. To 
establish, that the presence of reduced pertechnetate does not influence the 
tin peaks in the Mössbauer spectrum to an important extent, one stannous 
EHDP sample was completely oxidized by means of hydrogen peroxide 
before it was lyophilized; no pertechnetate was added. The relative amount 
of stannic tin present in the samples was plotted against the amount of 
pertechnetate added. 
6.4.3. Results. 
Figure 6.12 shows a typical example of a set of differential pulse 
polarograms prepared after addition of increasing volumes of a pertechne-
tate solutioa As can be seen in this figure, the peak heights diminish by 
addition of pertechnetate. The equivalence point is characterized by the 
disappearance of the stannous tin peaks and the concomitant appearance of 
pertechnetate peaks. At 725 μ\ the endpoint is reached. Continuing the 
pertechnetate addition, a pertechnetate peak appears at -0.76 V. The 
calculated endpoint for a molar reaction ratio of Tc:Sn=l:2 was: 752 μΐ 
pertechnetate solution. 
Figures 6.13 till 6.16 show four typical examples of titrations of stannous 
diphosphonates with pertechnetate with multiple amperometric endpoint 
detectioa Rather sharp endpoints are found at the disappearance of 
stannous tin peaks and the concomitant appearance of a pertechnetate peak. 
No stannic tin reduction peaks had to be expected in the differential pulse 
polarograms of the titrations with pertechnetate, because after oxidation of 
stannous DCMDP with hydrogen peroxide no peaks were left in the 
differential pulse polarogram between +0.05 V and -1.5 V. 
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Fig. 6.12. Differential pulse polarograms of MDP-tin (4:1), Sn(II): 1.12 
X10-3 M, pH=6.48, 0.033 M TMA sulphate after addition of 
increasing volumes of Тс-99-pertechnetate (29.8 ХШ3 M). 
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Fig. 6.13. Titration ofMDP-tin (4:1) (Sn(II): 1.12 X 70-* M, pH=6.48, 
0.033 Μ TMA sulphate, volume40ml) with pertechnetate(29.8'X 
Ш
3
 M). Curve "a" represents the stannous tin reduction peaks 
between-0.69 Vand-0.86 V; curve "b"represents the stannous tin 
oxidation peaks between-0.12 Vand-0.41 V; curve "c" represents 
the stannous tin reduction peak at -1.07 V and curve "d" 
represents the pertechnetate reduction peak at -0.76 V. The tin 
peaks are plotted as percentage of the peak surface before addition 
ofpertechnetate; the pertechnetate peak is plotted as peak surface 
with a correction for the current range setting on the Polarographie 
analyzer. 
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Fig. 6.14. Titration of EHDP-tin (4:1) (Sn(II): 1.12 ΧΙΟ-* M. pH=2.77, 
0.033 M TMA sulphate, volume 40 ml) with pertechnetate 
(29.8X10 3 M). Curve "a" represents the stannous tin reduction 
peak at -0.57 V; curve "b" represents the stannous tin oxidation 
peak at -0.20 V and curve "c" represents the pertechnetate 
reduction peak at-1.03 V. See further the legend of figure 6.13. 
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Fig. 6.15. Titration ofDCMDP-tin(4:l)(Sn(II): 1.12X10-3 м, pH= 2.33, 
0.033 M TM A sulphate, volume 40 ml) with pertechnetate 
(29.8X10-3 M). Curve "a" represents the stannous tin reduction 
peak at -0.53 V; curve "b" represents the stannous tin oxidation 
peak at -0.21 V; curve "c" represents the stannous tin reduction 
peak at-0.68 V; curve "d" represents the stannous tin oxidation 
peak at -0.08 V and curve "e" represents the pertechnetate 
reduction peak at -0.24 V See further the legend of figure 6.13. 
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Fig. 6.16 Titration ofDCMDP-tin(4:l)(Sn(U): 1.15X10-3M,pH= 6.49, 
0.033 M TM A sulphate, volume 40 ml) with pertechnetate 
(29.8X10-3 M). Curve "a" represents the stannous tin reduction 
peak at -0.77 V; curve "b" represents the stannous tin oxidation 
peak at -0.21 V; curve "c" represents the stannous tin reduction 
peak at-1.15 V; curve "d" represents the stannous tin reduction 
peak at -1.04 V and curve "e" represents the pertechnetate 
reduction peak at -0.76 V. See further the legend of figure 6.13. 
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Table 6.7 comprises the results of the titrations with amperometric 
detection. 
Table 6.7. Endpoints (in μι) of the amperometric titrations of stannous diphospho-
nates with pertechnetate (29.8X10~3 M), molar ratios of tin and techne­
tium in the solutions at the endpoints of the titrations, and numbers of 
electrons involved in the reduction of pertechnetate, assuming that the 
oxidation of each stannous tin ion delivers two electrons. 
endpoint 
(Ml) 
750 
725 
750 
925 
950 
725 
725 
775 
825 
Sn/Tc 
( ± 0 . 1 ) 
2.0 
2.1 
2.1 
1.6 
1.6 
2.1 
2.1 
1.9 
1.8 
e 
( ± 0.2) 
4.0 
4.2 
4.1 
3.3 
3.3 
4.2 
4.2 
3.9 
3.6 
MDP 
MDP 
DCMDP 
pCPMDP 
pCPMDP 
EHDP 
EHDP 
DCPDP 
DCPDP 
pH=2.49 
pH=6.48 
pH=6.49 
pH=2.51 
pH=6.49 
pH=2.77 
pH=6.46 
pH=2.57 
pH=6.53 
Figure 6.17 shows the curve of the titration of EHDP-tin (4:1) with 
pertechnetate. The amounts of stannous and stannic tin present in solution 
were determined by Mossbauer spectroscopy. Only a slight difference was 
seen between the stannic tin peak after oxidation with hydrogen peroxide 
and after oxidation with pertechnetate. The stannous and stannic tin peaks 
in the Mossbauer spectrum could be discriminated beyond any doubt 
The estimated endpoints of the spectrophotometric titrations are tabulated 
in table 6.8, together with the results of the titration with Mossbauer 
detectioa Within the limits of the applied volume range, no endpoint was 
found for the titration of pCPMDP-tin (4:1 ) with pertechnetate. 
No time effect was found in the amperometric titrations: no difference was 
seen between polarograms at two and twenty minutes after addition of 
pertechnetate. Adding the equivalent amount of pertechnetate in one charge 
to the tin diphosphonate solution gave the same result as the titrations did It 
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Fig. 6.17. Titration curve ofEHDP-tin (4:1) (Sn(II): 45.1X10-3 M; pH=4.7; 
2 ml) withpertechnetate(29.8X10-3 M). Detection with Mossbauer 
spectroscopy. The percentage of stannic tin is plotted against the 
amount of pertechnetate (in μΜ) added. Endpoint: 47.5 μΜ(1.59 
ml) pertechnetate. 
Table 6.8. Endpoints of the titrations of stannous diphosphonates with pertechnetate 
with spectrophotometric (S) or Mossbauer (M) endpoint detection. The 
ratios of the amounts of tin and technetium present in solution at the 
endpoint and the number of electrons, involved in the reduction of one 
molecule pertechnetate, have also been tabulated 
MDP 
DCMDP 
pCPMDP 
EHDP 
pH=2.5 
pH=2.5 
pH=2.5 
pH=4.7 
Endpoint 
M) 
62 
56 
— 
1590 
Sn/Tc 
(± 0.2) 
1.8 
2.0 
— 
1.9 
e 
(± 0.4) 
3.6 (S) 
4.1 (S) 
- ( S ) 
3.8 (M) 
seems, that the consumption of stannous tin by pertechnetate occurs within 
a few minutes. 
To the contrary, the adsorbance reading did not reach a constant level 
within 15 minutes after the pertechnetate addition. The adsorbance at 400 
nm reached its maximum level faster than the adsorbance at 326 nm. The 
increase in adsorbance between 1 and 15 minutes after addition of 
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pertechnetate could be as great as 50%. This result suggests, that the 
reduction of pertechnetate requires more than one reaction step. These 
kinetic data have, however not further been analyzed yet 
6.4.4. Discussion. 
Comparing the data from tables 6.7 and 6.8, the agreement is reasonably 
well. Although no end point was found in the spectrophotometnc titration of 
pCPMDP, this titration still confirms, that for this diphosphonate with 
stannous tin more pertechnetate is needed to reach the end point, than for 
other diphosphonates. 
Based on the results from tables 6.7 and6.8 we come to the conclusion, that 
four electrons are involved in the reduction of pertechnetate by stannous tin 
in the presence of MDP, DCMDP, EHDP, and DCPDP. This means, that 
Tc (III) is formed. This is in agreement with Polarographie and coulometric 
data (see section 6.3). 
In the presence of pCPMDP only three electrons seem to be involved in the 
reduction of pertechnetate by stannous tia 
In several reports [15,16.2] the reduction of pertechnetate by stannous tin in 
various media has been described as a three electron transitioa In these 
reports pertechnetate solutions were titrated with stannous tia Steigman 
pointed out, that an excess of stannous tin is able to reduce Tc ( Г ) to Tc ( III) 
[2]. Taking this point into consideration, it is understandable, that in our 
experiments a four electron transition is found, although Russell claimed, 
that identical results had been found for both types of titrations [15]. 
The difference between the results of Russell and our results might be 
explained by a difference in the amount of tin bound to diphosphonate. 
Figures 6.12 till 6.16 show, that different stannous tin species react with 
pertechnetate with different ease. This was also found for the reaction of 
stannous diphosphonates with hydrogen peroxide. It is supposed, that less 
firmly bound stannous tin is more easily oxidized, than stannous tin in a 
stable complex. Russell used in his experiments a 700 fold excess of 
complexing agent, while in our experiments a fourfold excess was used. So 
in our experiments more free tin is expected, than in the experiments by 
Russell. In radiopharmaceuticals a 10 fold excess of diphosphonate is used. 
The three electron transition, found in the titration of stannous pCPMDP 
with pertechnetate, also supports the idea of the importance of the binding of 
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stannous tin for the ease of oxidation. In chapter 5 it was demonstrated, that 
pCPMDP forms much more stable complexes with stannous tin, than any of 
the other diphosphonates tested. 
In conclusion: 
In the presence of excess of stannous tin, four electrons are involved 
in the reduction of pertechnetate in solutions containing MDP, 
DCMDP, EHDP, and DCPDP. With pCPMDP-tin a three elec­
tron transition is found This might be related to the exceptional 
stability of the stannous pCPMDP complex. The formed Тс (ΙΠ) 
may be reoxidized to Tc (IV), as Grassi stated, but as long as an 
excess of stannous tin is available, Tc (TV) will be reduced to Tc (III). 
When all stannous tin is consumed by this process, Тс(Г ) will no 
longer be reduced, but instead it will be slowly oxidized to 
pertechnetate as is well known from common experience with 
technetium labeled radiopharmaceuticals. In radiopharmaceuticals 
always a huge excess of tin exists in relation to the amount of 
technetium present and the agents commonly used for skeletal 
scintigraphy do not form very stable complexes with tin. For these 
reasons it may be expected, that in Tc-99m-labeled diphosphonates 
for skeletal scintigraphy, technetium is present as Tc (III), as long as 
sufficient stannous tin is available. 
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SUMMARY 
The main intention of this thesis is to identify the factors, which determine 
the uptake in bone of Tc-99m-diphosphonates. Because the in vivo process 
is too complicated to study directly, it seemed more appropriate to perform 
several chemical in vitro investigations as abstractions of the in vivo 
situation. The conclusions from the in vitro experiments are compared with 
results of experimental work in vivo to reach a general conclusion. 
In chapter 1 an historical view of nuclear medicine is given, which leads to 
technetium-99m as the most suitable radioisotope for imaging to day. 
Thanks to the Mo-99/Tc-99m generator one can dispose of Tc-99m-
pertechnetate wherever one wishes. In the next section an introduction is 
given to technetium chemistry, as far as relevant for the radiopharmaceuti-
cal application. The preparation of most technetium labeled radiopharma-
ceuticals requires the reduction of pertechnetate. Stannous tin is the agent 
which is mostly applied for this purpose. However, other reducing agents 
have also been used successfully. 
Diphosphonates are compounds which are structurally related to pyrophos-
phate and show a marked affinity for bone tissue, especially for hydroxy-
apatite. The specific uptake in bone of technetium labeled diphosphonates is 
supposed to be the consequence of the affinity of diphosphonates for bone. 
Other factors of importance involved in the uptake process of technetium 
diphosphonates are blood supply and the metabolic activity of bone. 
In the last section of chapter 1 the conclusions of this study are summarized 
and a description is given of the fate of the technetium diphosphonate from 
the moment of preparation until the accumulation in bone. 
When stannous tin is used as reducing agent, diphosphonate prevents the 
precipitation of hydrolyzed tin partly through complex formation. Stannous 
tin reduces pertechnetate to Tc (III) and excess stannous tin stabilizes this 
oxidation state. Tc (HI) is presumably complexed by diphosphonate 
although the precise nature of this species is unknown yet 
The technetium labeled diphosphonate radiopharmaceutical thus contains 
free diphosphonate, stannous diphosphonate complexes, stannous hydro-
xide (stabilized by diphosphonate), and technetium diphosphonate com-
plexes. Presumably no technetium-tin-diphosphonate complexes are for-
med. 
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Instable tin diphosphonate complexes may dissociate after administration 
of the technetium labeled diphosphonate to the blood circulation (probably 
as a consequence of dilution). The result depends on the ratio of the tin 
diphosphonate dose and the blood volume. When a high dose is injected into 
a relatively small blood volume, a colloidal solution of hydrolyzed tin is 
formed A fraction of the administered technetium activity will be bound to 
these colloidal particles possibly through occlusion or adsorption. This 
technetium labeled colloid will accumulate in liver, spleen, and bone 
marrow. When a sufficiently low dose of tin diphosphonate is injected into a 
sufficient volume of blood a result is obtained with bone uptake and 
excretion through the kidneys but without RES uptake. Stable diphospho-
nates (like EHDP) show no colloid formation on dilutioa 
Binding to erythrocytes and plasma proteins is not of great importance for 
technetium in bone seeking radiopharmaceuticals. 
The noncolloidal technetium labeled radiopharmaceutical, not bound to 
cellular or macromolecular blood components easily diffuses from the 
blood into the extracellular fluid surrounding the bone tissue. This is a 
prerequisite for uptake in bone. 
The amorphous fraction of the hydroxyapatite is believed to be the phase, 
where the technetium diphosphonate accumulates. When the technetium 
labeled radiopharmaceutical arrives at the hydroxyapatite surface first the 
free diphosphonate is adsorbed Diphosphonate complexes as such are not 
adsorbed The complexes have to dissociate before technetium an tin can be 
taken up by the apatite. A competition arises for binding of technetium and 
tin between the diphosphonate and the hydroxyapatite surface. The 
diphosphonate complex stability plays a decisive role in the determination 
of the uptake of technetium and tin on hydroxyapatite. A strong diphospho-
nate complex inhibits the uptake of technetium in bone and a very weak 
[complex causes an elevated soft tissue uptake of technetium. An interme-
diate strength of complexation is required. 
The order of increasing tin complex stability 
MDP < EHDP < pCPMDP 
is in accord with the order of decreasing technetium and tin adsorption: 
MDP > EHDP > pCPMDP. 
This is the same order as found for the bone uptake of technetium-99m in 
rabbits. 
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Chapter 2 is dedicated to the choice of the experimental model. In the first 
section of this chapter an introduction is given to the structure and 
physiology of bone tissue. Special attention is payed to those components of 
bone which may play a decisive role in the mechanism of uptake of 
technetium diphosphonates. In the second section the main aspects are 
described of the interaction between diphosphonates and bone. Diphospho-
nates may interfere with the bone metabolism along three routes: 
- The physicochemical way 
(adsorption to, growth inhibition and peptization of hydroxy-
apatite). 
- The enzymatic way 
(competitive inhibition and complexation of cofactors of phos-
phatase enzymes). 
- The cellular way 
(direct influence of diphosphonates on the metabolism of bone 
cells). 
The adsorption of diphosphonates on hydroxyapatite is probably respon-
sible for the high concentration of diphosphonates in bone with respect to 
the diphosphonate concentration in soft tissues. This may explain why 
diphosphonates can exert a profound effect on the metabolism of bone tissue 
but not on the metabolism of other tissues. Whether direct influence on the 
cellular metabolism plays an important role can not yet be stated with 
certainty. 
In the last section of chapter 2 three possible models for the uptake of 
technetium diphosphonates in bone are compared 
- The hydroxyapatite model. 
- The collagen model. 
- The enzyme model. 
It is concluded that hydroxyapatite is the most probable target in bone for 
technetium diphosphonates. 
Based on this conclusion in adsorption experiments synthetic amorphous 
hydroxyapatite was chosen as a model for the hydroxyapatite in bone. 
Chapter 3 describes the results of adsorption experiments with synthetic 
hydroxyapatite. The adsorption of the diphosphonates MDP, E HDP, and 
pCPMDP can be described with the Langmuir equation. Per apatite unit 
cell exposed to the extracellular fluid, one molecule of diphosphonate may 
be adsorbed. So the amount of exposed apatite surface is one of the 
determinants of the adsorbed amount of diphosphonate. The albumin 
concentration ( 15-30 mg/ml) and the pH(6-8) of the incubation medium do 
not show much influence on the adsorption of diphosphonate and tin. The 
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affinity for hydroxyapatite of EHDP is greater than that of MDP and 
pCPMDP. The two latter diphosphonates have nearly equal affinities. 
The tin adsorption isotherms with EHDP, pCPMDP and MDP show a 
different aspect with EHDP and pCPMDP the tin isotherms show a sharp 
maximum. With MDP in the tin isotherms a plateau of maximal adsorption 
is seen. The maximum level of tin adsorption with MDP is approximately 
1 г times as high as with EHDP and approximately 3 times as high as with 
pCPMDP. Adsorption experiments with equimolar amounts of EHDP and 
tin strongly suggest that the EHDP-tin complex is not adsorbed as such and 
that the complex has to dissociate before adsorption of the components can 
occur. Adsorption of EHDP is preferred over tin adsorption. A competition 
seems to exist for binding of tin between the apatite surface and EHDP in 
solution. 
The adsorption pattern of technetium shows the same aspect as the tin 
adsorption, although technetium and tin are not adsorbed in a fixed 
molecular ratio. The maximal technetium adsorption is higher with MDP 
than with EHDP. Pertechnetate is not adsorbed to hydroxyapatite. 
Chapter 4 describes the results of tissue distribution experiments of 26 
technetium diphosphonates in rabbits. 
Tc-99m-DCPDP has a slightly higher bone to soft tissue ratio than Tc-
99m-HMDP. Tc-99m-pCPMDP has the lowest bone to soft tissue ratio, 
which is ten times lower as for DCPDP. The blood disappearance rates are 
highest for technetium labeled MDP, HMDP, and DCPDP and lowest for 
Tc-99m-pCPMDP. 
The pH of preparation has not much influence on the tissue distribution of 
the technetium diphosphonate as long as the pH is between 5 and 8. 
Autoradiography shows that technetium and phosphate compounds accu­
mulate in the same regions of bone. Tin reduced technetium without 
diphosphonate localizes in liver, spleen, and bone marrow. 
The interaction of technetium diphosphonates with plasma proteins and 
blood cells is not of great importance, except for the phenyl methane 
diphosphonates. These technetium diphosphonates show a markedly 
delayed blood disappearance, which may be due to binding to plasma 
proteins. 
Results from biological experiments confirm that diphosphonates, which 
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give the highest technetium uptake in bone, form relatively unstable 
complexes. 
Chapter 5 describes the results of the determination of the stability 
constants of complexes of six diphosphonates with calcium and stannous 
tin. A modern version of the Schwarzenbach method was used for this 
purpose. 
Acidimétrie titration data were processed with the SCOGS computer 
programme. 
In the group of four basic diphosphonic acids under investigation (MDP, 
DCMDP, pCPMDP, and EHDP), DCMDP is the strongest acid The acid 
dissociation constants of the other acids in this group have more or less 
corresponding values. DCPDP and PDP have different acid dissociation 
constants because of the additional carboxylic or amido protons. 
At pH = 7 most calcium is complexed by DCMDP and PDP. At this pH 
value least calcium is bound by pCPMDP. Several calcium complexes are 
formed by the diphosphonates. The relative amounts of these complexes 
present in solution vary with the pH. Below pH = 4 no calcium complexes 
were found 
Tin complexes are more stable than corresponding calcium complexes. At 
pH = 7 most stannous tin is complexed by pCPMDP. At this pH MDP and 
DCPDP bind relatively little tin. The relative amounts of the various tin 
species present in solution depend on the pH. Uncomplexed tin above pH = 
4 is present in the form of Sn(OH)2. Below pH = 8 no other hydrolyzed tin 
species were found. No precipitates or colloidal particles were present in 
any of the titration solutions below pH=8. Supersaturated solutions of 
Sn (OH)2 may be stabilized by inhibition of the growth of crystal nuclei 
under influence of diphosphonates. 
The order of the tin complex stability constants found is in agreement with 
the results of adsorption and tissue distribution experiments. Diphospho-
nates which form relatively unstable tin complexes give the highest tin and 
technetium adsorption results and the highest technetium uptake in bone. 
Chapter 6 describes the results of electrochemical experiments. Differential 
pulse polarograms of stannous diphosphonate solutions at varying pH 
values show a qualitative correspondence with the results described in 
chapter 5. Several tin species are present in solution and the peak intensities 
vary with the pH. One of the peaks in the differential pulse polarograms may 
be attributed to Sn (OH),. Complex formation with the various diphospho-
216 
nates has only a minor influence on the oxidation potential of stannous tia 
Up to pH = 8.4 no loss of electroactive species occurs. This confirms that 
no significant amounts of colloidal hydrolyzed tin species are present in the 
measured solutions. The oxidation of stannous tin at a mercury electrode is 
irreversible. 
Diphosphonates have no basic influence on the electrochemical reduction 
of pertechnetate, neither on the half-wave potentials nor on the number of 
electrons involved in the reduction. After electrochemical reduction of 
pertechnetate in a DCMDP solution the Tc-(DCMDP)2 complex is 
formed The irreversibility of the pertechnetate reduction at the mercury 
electrode and the great number of protons involved cause a shift of more 
than 1 V in negative direction in the value of E^ relative to EQ. 
In technetium labeled bone seeking radiopharmaceuticals pertechnetate is 
reduced to Tc (HI) by excess stannous tin, which also reduces Tc (IV) 
formed by reoxidation of Tc (III). 
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SAMENVATTING 
Het voornaamste doel van dit onderzoek was, helderheid te brengen in het 
opname mechanisme van Tc-99m-difosfonaat in bot Aangezien de proces-
sen die zich in vivo afspelen te ingewikkeld zijn om rechtstreeks te 
onderzoeken, leek het verstandiger, als model voor de situatie in vivo, een 
aantal chemische in vitro onderzoeken uit te voerea De conclusies van deze 
in vitro experimenten worden in dit proefschrift vergeleken met resultaten 
van in vivo experimenten om zo tot een algemene conclusie te komea 
In hoofdstuk 1 wordt eerst een historisch overzicht gegeven van de 
ontwikkeling van de nucleaire geneeskunde tot heden. Hieruit blijkt onder 
meer, dat technetium-99m op dit moment voor de meeste scintigrafische 
onderzoeken het meest geschikte radioisotoop is. De Mo-99/Tc-99 m 
generator maakt het mogelijk, overal ter wereld te beschikken over het kort 
levende Tc-99m-pertechnetaat (Tw = 6 u). In een tweede paragraaf wordt 
een inleiding in de chemie van technetium gegeven in zoverre dat relevant is 
voor de toepassing in radiofarmaka. Voor het bereiden van de meeste 
technetium radiofarmaka is het vereist, dat pertechnetaat wordt geredu-
ceerd. Voor dit doel is tin ( II) het meest toegepaste agens. Andere reductie 
middelen zijn echter ook met succes toegepast 
Difosfonaten zijn verbindingen die een structurele gelijkenis vertonen met 
pyrofosfaat. Ze hebben een opvallende affiniteit voor botweefsel, in het 
bijzonder voor hydroxyapatiet Algemeen wordt aangenomen, dat de 
specificiteit van de opname van technetium difosfonaten in het skelet te 
danken is aan de affiniteit van difosfonaten voor botweefsel. Andere 
faktoren die betrokken zijn bij het opname proces van technetium difosfona-
ten zijn: de bloedvoorziening en de metabole aktiviteit van bot 
In de laatste paragraaf van hoofdstuk 1 worden de conclusies van deze 
studie samengevat aan de hand van een beschrijving van het gedrag van de 
verschillende componenten van het radiofarmakon vanaf het moment van 
bereiding tot aan de opname van technetium difosfonaat in bot 
In het geval dat tin (II) als reductie middel voor pertechnetaat wordt 
gebruikt, voorkomt het difosfonaat, deels door de vorming van complexen 
met tin, het neerslaan van gehydrolyseerd tin. Tin (II) reduceert pertechne-
taat tot Tc (III) en deze oxidatietoestand wordt door een overmaat aan 
tin(II) gestabiliseerd. Tc(III) wordi waarschijnlijk door difosfonaat gecom-
plexeerd, maar de juiste samenstelling van deze verbinding is tot op heden 
onbekend. 
218 
Met technetium gemarkeerd difosfonaat bevat dus vrij difosfonaat, tin 
difosfonaat complexen, tin hydroxide dat door difosfonaat in oplossing 
wordt gehouden en technetium difosfonaat complexen. Voor het bestaan 
van technetium-tin-difosfonaat complexen zijn geen duidelijke aanwijzin-
gen gevonden. 
Instabiele tin difosfonaat complexen kunnen in de bloedbaan dissociëren, 
waarschijnlijk als gevolg van verdunning. Hierbij is de verhouding van de tin 
difosfonaat dosis en het bloedvolume van belang. Wanneer een te hoge 
dosis aan een te klein bloedvolume wordt toegediend kan er colloidaal 
gehydrolyseerd tin worden gevormd. Een deel van het toegediende techne-
tium wordt aan deze colloidale deeltjes gebonden, zodat deze technetium 
aktiviteit in lever, milt en beenmerg wordt teruggevonden. Wanneer een 
voldoende lage dosis tin difosfonaat wordt toegediend aan een voldoende 
groot bloedvolume doet zich dit probleem niet voor en wordt een normaal 
technetium beeld verkregen met botopname en uitscheiding via de nieren. 
Difosfonaten die betrekkelijk stabiele complexen met tin vormen, zoals 
EHDP, zijn veel beter bestand tegen verdunning in het bloed en hebben 
minder neiging tot colloidvorming. Technetium in radiofarmaka voor 
botscintigrafie vertoont slechts weinig binding aan erythrocyten en plasma 
eiwitten. Het niet-colloidale technetium difosfonaat, dat niet aan bloed-
cellen of plasma eiwitten gebonden is, kan gemakkelijk vanuit het bloed 
diffunderen naarde extracellulaire vloeistof die hetbotweefsel omgeeft. Dit 
vormt een voorwaarde voor de opname van technetium difosfonaat in bot. 
De amorfe fraktie van het hydroxyapatiet wordt beschouwd als het 
bindende agens voor technetium difosfonaat in bot Wanneer het met 
technetium gemarkeerde radiofarmakon bij het hydroxyapatiet oppervlak 
arriveert, wordt eerst het vrije difosfonaat geadsorbeerd. Difosfonaat 
complexen worden als zodanig niet geadsorbeerd. De complexen moeten 
eerst dissociëren voordat technetium en tin door het apatiet kunnen worden 
opgenomen. Difosfonaat en hydroxyapatiet concurreren met elkaar om de 
binding van technetium en tin. De stabiliteit van het difosfonaat complex 
speelt een doorslaggevende rol bij het bepalen van de mate van opname van 
technetium en tin aan hydroxyapatiet Te stabiele difosfonaat complexen 
verminderen de opname van technetium in bot en te instabiele complexen 
geven een te hoge weke delen stapeling. Tussen deze beide uitersten moet 
het meest geschikte difosfonaat worden gevonden. 
De volgorde van toenemende tin complex stabiliteit: 
MDP < EHDP < pCPMDP 
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is in overeenstemming met de volgorde van afnemende technetium en tin 
adsorptie: 
MDP > EHDP > pCPMDP. 
Dit is dezelfde volgorde als werd gevonden voorde opname van technetium 
in bot bij konijnea 
Hoofdstuk 2 is gewijd aan de keuze van het experimentele model In de 
eerste paragraaf van dit hoofdstuk wordt een inleiding gegeven in struktuur 
en fysiologie van botweefsel. Hierbij wordt bijzondere aandacht besteed 
aan die botcomponenten die een belangrijke rol zouden kunnen spelen bij de 
opname van technetium difosfonaat in bot 
Verder wordt in hoofdstuk 2 een beschrijving gegeven van de voornaamste 
aspecten van de wisselwerking tussen difosfonaten en bot Difosfonaten 
kunnen op drie manieren invloed uitoefenen op het botmetabolisme: 
- Fysisch-chemische effekten. 
(adsorptie aan en groei inhibitie en peptisatie van hydroxy-
apatiet). 
- Enzymatische effekten. 
(competitieve inhibitie en complexering van cofactoren van 
fosfatase enzymen). 
- Cellulaire effekten. 
(direkte invloed van difosfonaten op het metabolisme van botcel-
len). 
De adsorptie van difosfonaten aan hydroxyapatiet vormt waarschijnlijk de 
reden voor de hoge concentratie van difosfonaten in bot, vergeleken met 
andere weefsels. Dit verklaart ook waarom difosfonaten wel een sterke 
invloed uitoefenen op het metabolisme van botweefsel, maar niet op dat van 
andere weefsels. Of een direkte invloed op het metabolisme van botcellen 
daarbij een belangrijke rol speelt, is op dit moment niet met zekerheid 
bekend. 
In de laatste paragraaf van hoofdstuk 2 worden drie mogelijke modellen 
voor de opname van technetium difosfonaten in bot vergeleken op grond van 
literatuurgegevens. Dit zijn: 
- het hydroxyapatiet model. 
- het collageen model. 
- het enzym model. 
Op grond van deze vergelijking wordt geconcludeerd, dat het hydroxy-
apatiet in bot waarschijnlijk het bindende agens voor technetium difosfonaat 
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vormt De beide andere modellen komen daarvoor al met al minder in 
aanmerking. 
Om deze reden is synthetisch amorf hydroxyapatiet gekozen als model voor 
hydroxyapatiet in bot voor het doen van adsorptie experimentea 
Hoofdstuk 3 beschrijft de resultaten van deze adsorptie experimenten. De 
adsorptie van de difosfonaten MDP, EHDP en pCPMDP laat zich 
beschrijven met behulp van de Langmuir vergelijking. Per eenheids-cel aan 
het oppervlak van het hydroxyapatiet die in direkt contact staat met de 
extracellulaire vloeistof, kan een molecuul difosfonaat worden geadsor-
beerd. De hoeveelheid apatiet oppervlak in contact met de extracellulaire 
vloeistof is dus een van de faktoren die de te adsorberen hoeveelheid 
difosfonaat bepaalt De albumine concentratie ( 15-30 mg/ml) en de pH (6-
8) van het incubatiemedium vertonen slechts een geringe invloed op de 
adsorptie van difosfonaat en tin. 
De affiniteit voor hydroxyapatiet van EHDP is groter dan die van MDP en 
pCPMDP. Deze laatste twee difosfonaten hebben een ongeveer even grote 
affiniteit voor hydroxyapatiet 
De tin adsorptie isothermen met EHDP, pCPMDP en MDP zien er 
verschillend uit met EHDP en pCPMDP vertonen de tin isothermen een 
scherp maximum. Met MDP laat de tin adsorptie isotherm een plateau zien. 
Het maximale niveau van de tin adsorptie is met MDP ongeveer 1 Vi maal zo 
hoog als met EHDP en ongeveer 3 maal zo hoog als met pCPMDP. 
Adsorptie experimenten met equimolaire hoeveelheden EHDP en tin laten 
zien, dat het EHDP-tin complex als zodanig niet wordt geadsorbeerd. Het 
complex moet dissociëren voordat adsorptie van de componenten kan 
plaats vindea EHDP wordt daarbij in ruimere mate geadsorbeerd dan tin. 
Het EHDP in de oplossing en het apatiet-oppervlak concurreren met elkaar 
om de binding van het tia 
Het adsorptie gedrag van technetium vertoont hetzelfde patroon als dat van 
tin, ofschoon technetium en tin niet in een vaste moleculaire verhouding 
worden geadsorbeerd. De maximale technetium adsorptie is hoger met 
MDP dan met EHDP. 
Pertechnetaat wordt niet aan hydroxyapatiet geadsorbeerd. 
Hoofdstuk 4 beschrijft de resultaten van weefselverdelingsexperimenten 
van 26 technetium difosfonaten in konijnen. 
Tc-99m-DCPDP heeft een iets hogere bot-weke delen verhouding dan Tc-
99m-HMDP. Tc-99m-pCPMDP heeft de laagste bot-weke delen verhou-
ding en deze is tien maal lager dan voor DCPDP. De bloedverdwijning is 
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het snelst voor met technetium gemarkeerd MDP, HMDP en DCPDP en 
het traagst voor Tc-99m-pCPMDP. 
Zolang de pH bij de markering van difosfonaten met technetium tussen 5 en 
8 is, bestaat slechts een geringe invloed van de bereidings-pH op de 
resulterende weefselverdeling van technetium. 
Autoradiografie laat zien, dat technetium en fosfaat verbindigen een zelfde 
verdelingspatroon in bot hebben. Met tin gereduceerd technetium zonder 
poly/pyrofosfaat of difosfonaat wordt opgenomen in lever, milt en been-
merg. 
Technetium difosfonaten vertonen slechts weinig binding aan plasma 
eiwitten en bloedcellen. Een uitzondering vormen met technetium gemar-
keerde fenyl methaan difosfonzuren. Deze hebben een veel tragere ver-
dwijning uit de bloedcirkulatie dan andere technetium difosfonaten en dit 
zou veroorzaakt kunnen zijn door een verhoogde binding aan plasma 
eiwitten. 
De resultaten van de dierproeven bevestigen, dat difosfonaten die de 
hoogste technetium opname in bot geven, relatief instabiele complexen 
vormen. 
Hoofdstuk 5 beschrijft de resultaten van de bepaling van de stabiliteits 
constanten van complexen van zes difosfonaten met calcium en tin (II). 
Voor dit doel werd een moderne versie toegepast van de methode van 
Schwarzenbach. Resultaten van acidimetrische titraties werden verwerkt 
met het SCOGS computer programma. 
Van de vier-basische difosfonzuren die werden onderzocht (MDP, 
DCMDP, pCPMDP en EHDP) is DCMDP het sterkste zuur. Van de drie 
overige zuren in deze groep verschillen de overeenkomstige zuur dissociatie 
constanten slechts weinig. DCPDP en PDP hebben afwijkende zuur 
dissociatie constanten vanwege de extra zuurgroepen in deze moleculen. 
Bij pH=7 wordt calcium het best gecomplexeerd door DCMDP en PDP. 
Bij deze pH wordt calcium het minst gecomplexeerd door pCPMDP. 
Verschillende calcium complexen kunnen door de difosfonaten worden 
gevormd. De mate waarin de verschillende complexen in de oplossing 
aanwezig zijn, is voornamelijk afhankelijk van de pH. Onder pH=4 worden 
geen calcium complexen gevormd. 
Tin (II) difosfonaat complexen zijn stabieler dan overeenkomstige calcium 
complexen. Bij pH=7 wordt tin(II) het best gecomplexeerd door pCPMDP. 
Bij deze pH wordt tin relatief slecht gecomplexeerd door MDP en DCPDP. 
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Ongecomplexeerd tin (II) komt boven pH=4 in de onderzochte difosfonaat 
oplossingen voor als Sn (OH)-. De mate, waarin de verschillende tin 
verbindingen in de oplossing aanwezig zijn, wordt voornamelijk bepaald 
door de pH van de oplossing. 
Onder pH=8 werden geen andere gehydrolyseerde tin (II) verbindingen 
gevonden. Onder pH=8 werd ook in geen van de titratie oplossingen 
neerslag of colloid gevonden. 
Oververzadigde tin hydroxide oplossingen kunnen door difosfonaten wor-
den gestabiliseerd via de remming van de groei van kristallisatiekemen. 
De resultaten van de stabiliteitsbepalingen van tin difosfonaat complexen 
zijn in overeenstemming met de resultaten van adsorptie en weefsel-
verdelingsexperimenten. Difosfonaten die relatief instabiele tin complexen 
vormen, geven hoge adsorptieresultaten voor tin en technetium in vitro en 
een hoge technetiumopname in bot in vivo. 
Hoofdstuk 6 beschrijft de resultaten van electrochemische experimenten. 
Differentiële pulspolarogrammen van tin (II) difosfonaat oplossingen bij 
verschillende pH's bevestigen op kwalitatieve wijze de resultaten uit 
hoofdstuk 5. Aan de pieken in de polarogrammen is te zien, dat er 
verschillende tin (II) verbindingen in oplossing aanwezig zijn; de piek-
oppervlakken variëren met de pH. In de differentiële pulspolarogrammen 
komt een piek voor, die aan Sn (OH)2 kan worden toegeschreven. 
Complexvorming met de verschillende difosfonaten heeft slechts een 
beperkte invloed op de oxidatie potentiaal van tin (II). Tot pH=8.4 is er bij 
de polarografiache experimenten geen verlies aan electroactieve species 
gevonden. Dit bevestigt, dat er geen aanmerkelijke hoeveelheden colloidaal 
gehydrolyseerd tin in de gemeten oplossingen aanwezig was. De oxidatie 
van tin (II) aan een kwikelectrode is irreversibel. 
Difosfonaten heoben nauwelijks invloed op de electrochemische reductie 
van pertechnetaaL Dit geldt zowel voor de ligging van de halfwaarde 
potentialen, als voor het aantal electronen, dat bij de reductie betrokken is. 
Na electrochemische reductie van pertechnetaat in een oplossing van 
DCMDP, wordt het Tc-(DCMDP)2 complex gevormd. 
De irreversibiliteit van de reductie van pertechnetaat aan een kwikelectrode 
en het grote aantal protonen dat betrokken is bij deze reductie maken dat de 
halfwaarde potentiaal voor deze reaktie meer dan 1 V in negatieve richting 
verschoven is to.v. de standaard redox potentiaal. 
In radiofarmaka voor skeletscintigrafie is pertechnetaat gereduceerd tot 
Tc (III) door de toegepaste overmaat tin (II). Deze overmaat reduceert ook 
Tc (IV) weer, dat door oxidatie van Tc (III) onder invloed van water is 
gevormd. 
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